1
|
Gutiérrez-González E, Pastor-Barriuso R, Castelló A, Castaño-Vinyals G, Fernández de Larrea-Baz N, Dierssen-Sotos T, Jiménez-Moleón JJ, Molina-Barceló A, Fernández-Tardón G, Zumel-Marne Á, Moreno V, Gómez-Ariza JL, Sierra MÁ, García-Barrera T, Espinosa A, Plans-Beriso E, Gómez-Acebo I, Aragonés N, Kogevinas M, Pollán M, Pérez-Gómez B. Toenail zinc and risk of prostate cancer in the MCC-Spain case-control study. Environ Res 2024; 245:118065. [PMID: 38159663 DOI: 10.1016/j.envres.2023.118065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Revised: 12/08/2023] [Accepted: 12/26/2023] [Indexed: 01/03/2024]
Abstract
BACKGROUND Some researchers have suggested that zinc (Zn) could reduce the risk of prostate cancer (PC). However, research from observational studies on the relationship between PC risk and biomarkers of Zn exposure shows conflicting results. OBJECTIVES To evaluate the association between toenail Zn and PC, considering tumour extension and aggressiveness, along with a gene-environment approach, exploring the interaction of individual genetic susceptibility to PC in the relationship between toenail Zn and PC. METHODS In MCC-Spain study we invited all incident PC cases diagnosed in the study period (2008-2013) and recruited randomly selected general population controls. In this report we included 913 cases and 1198 controls with toenail Zn determined by inductively coupled plasma mass spectrometry. To measure individual genetic susceptibility, we constructed a polygenic risk score based on known PC-related single nucleotide polymorphisms. The association between toenail Zn and PC was explored with mixed logistic and multinomial regression models. RESULTS Men with higher toenail Zn had higher risk of PC (OR quartile 4 vs.1: 1.41; 95% CI: 1.07-1.85). This association was slightly higher in high-grade PC [(ISUP≤2 Relative risk ratio (RRR) quartile 4 vs.1: 1.36; 1.01-1.83) vs. (ISUP3-5 RRR quartile 4 vs.1: 1.64; 1.06-2.54)] and in advanced tumours [(cT1-cT2a RRR quartile 4 vs.1: 1.40; 95% CI: 1.05-1.89) vs. (cT2b-cT4 RRR quartile 4 vs.1: 1.59; 1.00-2.53)]. Men with lower genetic susceptibility to PC were those at higher risk of PC associated with high toenail Zn (OR quartile 4 vs.1: 2.18; 95% CI: 1.08-4.40). DISCUSSION High toenail Zn levels were related to a higher risk for PC, especially for more aggressive or advanced tumours. This effect was stronger among men with a lower genetic susceptibility to PC.
Collapse
Affiliation(s)
| | - Roberto Pastor-Barriuso
- Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029, Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain
| | - Adela Castelló
- Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029, Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain
| | - Gemma Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain; Barcelona Institute of Global Health (ISGlobal), Carrer Del Dr. Aiguader, 88, 08003, Barcelona, Spain; University Pompeu Fabra, Plaça de La Mercè, 10-12, 08002, Barcelona, Spain; Hospital Del Mar Medical Research Institute (IMIM), Carrer Del Dr. Aiguader, 88, 08003, Barcelona, Spain
| | - Nerea Fernández de Larrea-Baz
- Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029, Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain
| | - Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain; Department of Medical and Surgical Sciences, Faculty of Medicine, University of Cantabria-IDIVAL, Calle Cardenal Herrera Oria, 39011, Santander, Spain
| | - José Juan Jiménez-Moleón
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain; Department of Preventive Medicine and Public Health, University of Granada, Av. de La Investigación, 11, 18016, Granada, Spain; Institute of Health Research IBS., Granada, Spain
| | - Ana Molina-Barceló
- Cancer and Public Health Area, The Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Av. de Catalunya, 21, 46020, Valencia, Spain
| | - Guillermo Fernández-Tardón
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain; Health Research Institute of Asturias (ISPA), University of Oviedo, Av. Del Hospital Universitario, 33011, Oviedo, Spain
| | - Ángela Zumel-Marne
- Research Centre for Natural Resources, Health and the Environment, University of Huelva, C/ Menéndez Pelayo, 21002, Huelva, Spain; Servei Cirurgia Ortopèdica i Traumatologia. Althaia Xarxa Assistencial Universitària de Manresa, 08243 Manresa, España; Public Health Research Group, University of Alicante, Avda. San Vicente Del Raspeig, 03080, Alicante, Spain
| | - Víctor Moreno
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain; Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Avinguda de La Granvia de L'Hospitalet, 199-203, 08908, L'Hospitalet de Llobregat, Barcelona, Spain; Colorectal Cancer Group, ONCOBELL Program, Institut de Recerca Biomedica de Bellvitge (IDIBELL), Avinguda de La Granvia de L'Hospitalet, 199, 08908, L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Spain
| | - José Luis Gómez-Ariza
- Research Centre for Natural Resources, Health and the Environment, University of Huelva, C/ Menéndez Pelayo, 21002, Huelva, Spain; Department of Chemistry, Faculty of Experimental Sciences, Campus El Carmen, University of Huelva, C/ Menéndez Pelayo, 21002, Huelva, Spain
| | - M Ángeles Sierra
- Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029, Madrid, Spain
| | - Tamara García-Barrera
- Research Centre for Natural Resources, Health and the Environment, University of Huelva, C/ Menéndez Pelayo, 21002, Huelva, Spain; Department of Chemistry, Faculty of Experimental Sciences, Campus El Carmen, University of Huelva, C/ Menéndez Pelayo, 21002, Huelva, Spain
| | - Ana Espinosa
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain; Barcelona Institute of Global Health (ISGlobal), Carrer Del Dr. Aiguader, 88, 08003, Barcelona, Spain; University Pompeu Fabra, Plaça de La Mercè, 10-12, 08002, Barcelona, Spain
| | - Elena Plans-Beriso
- Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029, Madrid, Spain
| | - Inés Gómez-Acebo
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain; Department of Medical and Surgical Sciences, Faculty of Medicine, University of Cantabria-IDIVAL, Calle Cardenal Herrera Oria, 39011, Santander, Spain
| | - Nuria Aragonés
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain; Cancer Surveillance and Registry Unit, Division of Public Health, Department of Health, C. San Martín de Porres, 6, 28035, Madrid, Spain
| | - Manolis Kogevinas
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain; Barcelona Institute of Global Health (ISGlobal), Carrer Del Dr. Aiguader, 88, 08003, Barcelona, Spain; University Pompeu Fabra, Plaça de La Mercè, 10-12, 08002, Barcelona, Spain; Hospital Del Mar Medical Research Institute (IMIM), Carrer Del Dr. Aiguader, 88, 08003, Barcelona, Spain
| | - Marina Pollán
- Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029, Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain
| | - Beatriz Pérez-Gómez
- Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029, Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain.
| |
Collapse
|
2
|
Veiga-Alonso A, Dierssen-Sotos T, Morales-Angulo C. Comments on "Otolaryngological manifestations in monkeypox". Acta Otorrinolaringol Esp (Engl Ed) 2024; 75:134-135. [PMID: 38346490 DOI: 10.1016/j.otoeng.2023.10.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Accepted: 10/01/2023] [Indexed: 02/19/2024]
Affiliation(s)
- Aida Veiga-Alonso
- Servicio de Otorrinolaringología, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Trinidad Dierssen-Sotos
- Medicina Preventiva y Salud Pública. Departamento de Ciencias Médicas y Quirúrgicas, Facultad de medicina. Universidad de Cantabria; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; IDIVAL, Santander, Spain
| | - Carmelo Morales-Angulo
- Servicio de Otorrinolaringología, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
| |
Collapse
|
3
|
Cavero-Ibiricu A, Canelas-Fernández J, Gómez-Acebo I, Alonso-Molero J, Martínez-Jiménez D, Llorca J, Cabero-Perez MJ, Dierssen-Sotos T. Association Between Assisted Reproductive Technology and Cerebral Palsy: A Meta-Analysis. Pediatr Neurol 2024; 152:115-124. [PMID: 38244531 DOI: 10.1016/j.pediatrneurol.2023.12.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 10/28/2023] [Accepted: 12/23/2023] [Indexed: 01/22/2024]
Abstract
BACKGROUND Since 1978 many children are born thanks to assisted reproductive technology (ART). However, the long-term effects of these therapies are still not fully known. Our objective is to evaluate the risk of cerebral palsy (CP) after ART compared with that in those spontaneously conceived (SC) and to examine this risk in single, multiple, and preterm births and the evolution of the risk over the years. METHODS PubMed, Embase, and Web of Science databases were searched until December 2022. Studies were included if they studied CP cases in children born through ART. 16 studies were finally selected. Quality of studies was assessed using Newcastle Ottawa Scale. Pooled OR was estimated by weighting individual OR/RR by the inverse of their variance. A random-effect model was applied. To assess the causes of heterogeneity, we performed meta-regression analyses. RESULTS A significantly high risk of CP was found (OR = 1.27; 95% CI 1.12 to 1.43) in children born through ART compared with those SC. This risk increased in singletons (OR = 1.48; 95% CI 1.23 to 1.79) but disappeared in multiple (OR = 1.05; 95% CI 0.93 to 1.18) and preterm births (OR = 1.09; 95% CI 0.87 to 1.37). We found a higher risk of CP in children born before the year 2000 (OR = 3.40; 95% CI 2.49 to 4.63). CONCLUSIONS ARTs slightly increase the risk of CP once the effect of multiple gestation is controlled. Further studies are needed to clarify whether the techniques themselves, fertility problems, or associated maternal comorbidities are responsible for this risk.
Collapse
Affiliation(s)
| | | | - Inés Gómez-Acebo
- Grupo de Medicina Preventiva, Universidad de Cantabria, Santander, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; IDIVAL-Instituto de investigación sanitaria Valdecilla, Santander, Spain
| | - Jessica Alonso-Molero
- Grupo de Medicina Preventiva, Universidad de Cantabria, Santander, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; IDIVAL-Instituto de investigación sanitaria Valdecilla, Santander, Spain.
| | | | - Javier Llorca
- Grupo de Medicina Preventiva, Universidad de Cantabria, Santander, Spain; Retired Professor, Universidad de Cantabria, Santander, Spain
| | - María J Cabero-Perez
- IDIVAL-Instituto de investigación sanitaria Valdecilla, Santander, Spain; Servicio de Pediatría, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Trinidad Dierssen-Sotos
- Grupo de Medicina Preventiva, Universidad de Cantabria, Santander, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; IDIVAL-Instituto de investigación sanitaria Valdecilla, Santander, Spain
| |
Collapse
|
4
|
Sanlés-González I, Grimal-Abejez L, Serrat-Muñoz J, Robert-Boter N, Segura-Egea A, Carreres-Molas A, Alonso-Valle H, Alonso-Molero J, Dierssen-Sotos T, Gómez-Acebo I. Characteristics of patients who died in the hospital emergency service during the SARS-CoV-2 pandemic: a retrospective cohort study in a tertiary hospital in Spain. Intern Emerg Med 2024:10.1007/s11739-023-03519-x. [PMID: 38270773 DOI: 10.1007/s11739-023-03519-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Accepted: 12/17/2023] [Indexed: 01/26/2024]
Abstract
The objective of this study is to analyze the characteristics of patients who died in the Hospital Emergency Department (HED) of a Spanish third-level hospital, with a special focus on those who died due to SARS-CoV-2. A retrospective cohort study was conducted, including all patients over 18 years old who died in the Hospital Emergency Department (HED) of a Spanish third-level hospital located in Badalona, Spain, from Jun 2019 to Dec 2020. Various sociodemographic, clinical, and diagnostic variables of the patients were analyzed to identify potential risk factors associated with mortality. During the first wave of the COVID-19 pandemic, a total of 72 patients died in the HED, representing a 42% increase compared to the pre-pandemic period. Of the deceased patients, 11% were attributed to SARS-CoV-2. Furthermore, it was found that patients who died from SARS-CoV-2 during the first wave were significantly younger than those in the second wave, with an average age of 78.6 ± 3.1 years in the first wave and 91.8 ± 4.8 years in the second wave. No significant differences were found regarding gender or associated comorbidities. Overall, the mortality rate at the HED in relation to COVID-19 was low, and infected patients died at younger ages during the first wave compared to the second wave.
Collapse
Affiliation(s)
| | | | | | - Neus Robert-Boter
- Hospital Universitario Germans Trias I Pujol, 08916, Badalona, Spain
| | | | | | - Héctor Alonso-Valle
- Hospital Universitario Marqués de Valdecilla, 39008, Santander, Cantabria, Spain
| | - Jessica Alonso-Molero
- Facultad de Medicina, Universidad de Cantabria, 39011, Santander, Spain
- IDIVAL Instituto de Investigación Sanitaria Valdecilla, 39011, Santander, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain
| | - Trinidad Dierssen-Sotos
- Facultad de Medicina, Universidad de Cantabria, 39011, Santander, Spain
- IDIVAL Instituto de Investigación Sanitaria Valdecilla, 39011, Santander, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain
| | - Inés Gómez-Acebo
- Facultad de Medicina, Universidad de Cantabria, 39011, Santander, Spain
- IDIVAL Instituto de Investigación Sanitaria Valdecilla, 39011, Santander, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain
| |
Collapse
|
5
|
Wang A, Shen J, Rodriguez AA, Saunders EJ, Chen F, Janivara R, Darst BF, Sheng X, Xu Y, Chou AJ, Benlloch S, Dadaev T, Brook MN, Plym A, Sahimi A, Hoffman TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Laisk T, Figuerêdo J, Muir K, Ito S, Liu X, Uchio Y, Kubo M, Kamatani Y, Lophatananon A, Wan P, Andrews C, Lori A, Choudhury PP, Schleutker J, Tammela TL, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Rentsch CT, Cho K, Mcmahon BH, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder A, Stroomberg HV, Batra J, Chambers S, Horvath L, Clements JA, Tilly W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordstrom T, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein S, Cook MB, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM, Hamilton RJ, Fleshner NE, Finelli A, Parent MÉ, Stanford JL, Ostrander EA, Koutros S, Beane Freeman LE, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CM, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Stern MC, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein BS, Kerns SL, Ostrer H, Teixeira MR, Paulo P, Brandão A, Watya S, Lubwama A, Bensen JT, Butler EN, Mohler JL, Taylor JA, Kogevinas M, Dierssen-Sotos T, Castaño-Vinyals G, Cannon-Albright L, Teerlink CC, Huff CD, Pilie P, Yu Y, Bohlender RJ, Gu J, Strom SS, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach RJ, Brenner H, Chen X, Holleczek B, Schöttker B, Klein EA, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Kim J, Neuhausen SL, Steele L, Ding YC, Isaacs WB, Nemesure B, Hennis AJ, Carpten J, Pandha H, Michael A, Ruyck KD, Meerleer GD, Ost P, Xu J, Razack A, Lim J, Teo SH, Newcomb LF, Lin DW, Fowke JH, Neslund-Dudas CM, Rybicki BA, Gamulin M, Lessel D, Kulis T, Usmani N, Abraham A, Singhal S, Parliament M, Claessens F, Joniau S, den Broeck TV, Gago-Dominguez M, Castelao JE, Martinez ME, Larkin S, Townsend PA, Aukim-Hastie C, Bush WS, Aldrich MC, Crawford DC, Srivastava S, Cullen J, Petrovics G, Casey G, Wang Y, Tettey Y, Lachance J, Tang W, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Yamoah K, Govindasami K, Chokkalingam AP, Keaton JM, Hellwege JN, Clark PE, Jalloh M, Gueye SM, Niang L, Ogunbiyi O, Shittu O, Amodu O, Adebiyi AO, Aisuodionoe-Shadrach OI, Ajibola HO, Jamda MA, Oluwole OP, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Diop H, Gundell SM, Roobol MJ, Jenster G, van Schaik RH, Hu JJ, Sanderson M, Kachuri L, Varma R, McKean-Cowdin R, Torres M, Preuss MH, Loos RJ, Zawistowski M, Zöllner S, Lu Z, Van Den Eeden SK, Easton DF, Ambs S, Edwards TL, Mägi R, Rebbeck TR, Fritsche L, Chanock SJ, Berndt SI, Wiklund F, Nakagawa H, Witte JS, Gaziano JM, Justice AC, Mancuso N, Terao C, Eeles RA, Kote-Jarai Z, Madduri RK, Conti DV, Haiman CA. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nat Genet 2023; 55:2065-2074. [PMID: 37945903 PMCID: PMC10841479 DOI: 10.1038/s41588-023-01534-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2022] [Accepted: 09/15/2023] [Indexed: 11/12/2023]
Abstract
The transferability and clinical value of genetic risk scores (GRSs) across populations remain limited due to an imbalance in genetic studies across ancestrally diverse populations. Here we conducted a multi-ancestry genome-wide association study of 156,319 prostate cancer cases and 788,443 controls of European, African, Asian and Hispanic men, reflecting a 57% increase in the number of non-European cases over previous prostate cancer genome-wide association studies. We identified 187 novel risk variants for prostate cancer, increasing the total number of risk variants to 451. An externally replicated multi-ancestry GRS was associated with risk that ranged from 1.8 (per standard deviation) in African ancestry men to 2.2 in European ancestry men. The GRS was associated with a greater risk of aggressive versus non-aggressive disease in men of African ancestry (P = 0.03). Our study presents novel prostate cancer susceptibility loci and a GRS with effective risk stratification across ancestry groups.
Collapse
Affiliation(s)
- Anqi Wang
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Jiayi Shen
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | | | | | - Fei Chen
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Rohini Janivara
- School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA
| | - Burcu F. Darst
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Xin Sheng
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Yili Xu
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Alisha J. Chou
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Sara Benlloch
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology,University of Cambridge, Cambridge, UK
| | | | | | - Anna Plym
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
- Urology Division, Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Ali Sahimi
- Department of Population and Public Health Sciences, Keck School of Medicine,University of Southern California, Los Angeles, CA, USA
| | - Thomas J. Hoffman
- Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA
- Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA
| | - Atushi Takahashi
- Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
- Department of Genomic Medicine, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan
| | - Koichi Matsuda
- Department of Computational Biology and Medical Sciences, Laboratory of Clinical Genome Sequencing,Graduate school of Frontier Sciences,The University of Tokyo, Tokyo, Japan
| | - Yukihide Momozawa
- Laboratory for Genotyping Development, RIKEN Center of Integrative Medical Sciences, Yokohama, Japan
| | - Masashi Fujita
- Laboratory for Cancer Genomics, RIKEN Center of Integrative Medical Sciences, Yokohama, Japan
| | - Triin Laisk
- Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia
| | - Jéssica Figuerêdo
- Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia
| | - Kenneth Muir
- Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
- Warwick Medical School, University of Warwick, Coventry, UK
| | - Shuji Ito
- Department of Orthopaedics, Shimane University, Izumo, Shimane, Japan
- RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Xiaoxi Liu
- Laboratory for Statistical and Translational Genetics, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
| | - The Biobank Japan Project
- Corresponding Author: Christopher A. Haiman, Harlyne J. Norris Cancer Research Tower, USC Norris Comprehensive Cancer Center, 1450 Biggy Street, Rm 1504, Los Angeles, CA 90033 or
| | - Yuji Uchio
- Department of Orthopaedics, Shimane University, Izumo, Shimane, Japan
| | - Michiaki Kubo
- RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Yoichiro Kamatani
- Laboratory for Statistical and Translational Genetics, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
- Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
| | - Artitaya Lophatananon
- Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester, UK
| | - Peggy Wan
- Department of Population and Public Health Sciences, Keck School of Medicine,University of Southern California, Los Angeles, CA, USA
| | - Caroline Andrews
- Harvard TH Chan School of Public Health and Division of Population Sciences,Dana Farber Cancer Institute, Boston, MA, USA
| | - Adriana Lori
- Department of Population Science, American Cancer Society, Kennesaw, GA, USA
| | | | - Johanna Schleutker
- Institute of Biomedicine, University of Turku, Turku, Finland
- Department of Medical Genetics, Genomics, Laboratory Division, Turku University Hospital, Turku, Finland
| | | | - Csilla Sipeky
- Institute of Biomedicine, University of Turku, Turku, Finland
| | - Anssi Auvinen
- Unit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland
| | - Graham G. Giles
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health,The University of Melbourne, Victoria, Australia
- Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia
| | - Melissa C. Southey
- Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia
| | - Robert J. MacInnis
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health,The University of Melbourne, Victoria, Australia
| | - Cezary Cybulski
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Dominika Wokolorczyk
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Jan Lubinski
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Christopher T. Rentsch
- Yale School of Medicine, New Haven, CT, USA
- Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK
- VA Connecticut Healthcare System, West Haven, CT, USA
| | - Kelly Cho
- Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
- VA Boston Healthcare System, Boston, MA, USA
| | | | - David E. Neal
- Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
- University of Cambridge, Department of Oncology, Addenbrooke’s Hospital, Cambridge, UK
- Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Cambridge, UK
| | - Jenny L. Donovan
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Freddie C. Hamdy
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
- Faculty of Medical Science, University of Oxford, John Radcliffe Hospital, Oxford, UK
| | - Richard M. Martin
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- NIHR Bristol Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit, University of Bristol, Bristol, UK
| | - Borge G. Nordestgaard
- Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Copenhagen, Denmark
| | - Sune F. Nielsen
- Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Copenhagen, Denmark
| | - Maren Weischer
- Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Copenhagen, Denmark
| | - Stig E. Bojesen
- Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Copenhagen, Denmark
| | - Andreas Røder
- Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Hein V. Stroomberg
- Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Jyotsna Batra
- Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia
- Translational Research Institute, Brisbane, Queensland, Australia
| | | | - Lisa Horvath
- Chris O’Brien Lifehouse (COBLH), Camperdown, Sydney, NSW, Australia, Sydney, Australia
- Garvan Institute of Medical Research, Sydney, Australia
| | - Judith A. Clements
- Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia
- Translational Research Institute, Brisbane, Queensland, Australia
| | - Wayne Tilly
- Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide, Adelaide, Australia
| | - Gail P. Risbridger
- Department of Anatomy and Developmental Biology, Biomedicine Discovery Institute, Monash University, Melbourne, Victoria, Australia
- Prostate Cancer Translational Research Program, Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - Henrik Gronberg
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - Markus Aly
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
- Department of Molecular Medicine and Surgery, Karolinska Institutet, and Department of Urology, Karolinska University Hospital, Solna, Stockholm, Sweden
- Department of Urology, Karolinska University Hospital, Stockholm, Sweden
| | - Robert Szulkin
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
- SDS Life Sciences, Stockholm, Sweden
| | - Martin Eklund
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - Tobias Nordstrom
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
- Department of Clinical Sciences at Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden
| | - Nora Pashayan
- University College London, Department of Applied Health Research, London, UK
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Laboratory, Cambridge, UK
- Department of Applied Health Research, University College London, London, UK
| | - Alison M. Dunning
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Laboratory, Cambridge, UK
| | - Maya Ghoussaini
- Open Targets, Wellcome Sanger Institute, Hinxton, Saffron Walden, Hinxton, UK
| | - Ruth C. Travis
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Tim J. Key
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Elio Riboli
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
| | - Jong Y. Park
- Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA
| | - Thomas A. Sellers
- Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA
| | - Hui-Yi Lin
- School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA, USA
| | - Demetrius Albanes
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Stephanie Weinstein
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Michael B. Cook
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH,, Bethesda, MD, USA
| | - Lorelei A. Mucci
- Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA
| | - Edward Giovannucci
- Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA
| | - Sara Lindstrom
- Department of Epidemiology, University of Washington, Seattle, WA, USA
| | - Peter Kraft
- Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA
| | - David J. Hunter
- Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Kathryn L. Penney
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, USA
| | - Constance Turman
- Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA
| | - Catherine M. Tangen
- SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Phyllis J. Goodman
- SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Ian M. Thompson
- CHRISTUS Santa Rosa Hospital – Medical Center, San Antonio, TX, USA
| | - Robert J. Hamilton
- Dept. of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
- Dept. of Surgery (Urology), University of Toronto, Toronto, Canada
| | - Neil E. Fleshner
- Dept. of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
| | - Antonio Finelli
- Division of Urology, Princess Margaret Cancer Centre, Toronto, Canada
| | - Marie-Élise Parent
- Epidemiology and Biostatistics Unit, Centre Armand-Frappier Santé Biotechnologie, Laval, QC, Canada
| | - Janet L. Stanford
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Elaine A. Ostrander
- National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Stella Koutros
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Laura E. Beane Freeman
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Meir Stampfer
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, USA
| | - Alicja Wolk
- Division of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
- Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
| | - Niclas Håkansson
- Division of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Gerald L. Andriole
- Brady Urological Institute in National Capital Region, Johns Hopkins University, Baltimore, MD, USA
| | - Robert N. Hoover
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Mitchell J. Machiela
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Karina Dalsgaard Sørensen
- Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
| | - Michael Borre
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
- Department of Urology, Aarhus University Hospital, Aarhus, Denmark
| | - William J. Blot
- Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
- International Epidemiology Institute, Rockville, MD, USA
| | - Wei Zheng
- Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | | | - James E. Mensah
- University of Ghana Medical School, Accra, Ghana
- Korle Bu Teaching Hospital, Accra, Ghana
| | - Yong-Jie Lu
- Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK
| | | | - Ninghan Feng
- Wuxi Second Hospital, Nanjing Medical University, Wuxi, Jiangzhu Province, China
| | - Xueying Mao
- Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK
| | - Yudong Wu
- Department of Urology, First Affiliated Hospital, The Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China
| | - Shan-Chao Zhao
- Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Zan Sun
- The People’s Hospital of Liaoning Proviouce, The People’s Hospital of China Medical University, Shenyang, China, Shenyang, China
| | - Stephen N. Thibodeau
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | | | - Daniel J. Schaid
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA
| | - Catharine M.L. West
- Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Radiotherapy Related Research, The Christie Hospital NHS Foundation Trust, Manchester, UK
| | - Gill Barnett
- University of Cambridge Department of Oncology, Oncology Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | | | | | | | - Adam S. Kibel
- Division of Urologic Surgery, Brigham and Womens Hospital, Boston, MA, USA
| | | | - Olivier Cussenot
- GRC 5 Predictive Onco-Urology, Sorbonne Université, Paris, France
- CeRePP, Paris, France
| | | | - Florence Menegaux
- Exposome and Heredity, CESP (UMR 1018), Paris-Saclay Medical School, Paris-Saclay University, Inserm, Gustave Roussy, Villejuif, France
| | - Thérèse Truong
- Exposome and Heredity, CESP (UMR 1018), Paris-Saclay Medical School, Paris-Saclay University, Inserm, Gustave Roussy, Villejuif, France
| | - Yves Akoli Koudou
- Cancer & Environment Group, Center for Research in Epidemiology and Population Health (CESP), INSERM, University Paris-Sud, University Paris-Saclay, Villejuif Cédex, France
| | - Esther M. John
- Department of Medicine, Stanford Cancer Institute,Stanford University School of Medicine, Stanford, CA, USA
| | | | - Lovise Maehle
- Department of Medical Genetics, Oslo University Hospital, Oslo, Norway
| | - Kay-Tee Khaw
- Clinical Gerontology Unit, University of Cambridge, Cambridge, UK
| | - Sue A. Ingles
- Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA
| | - Mariana C Stern
- Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA
| | - Ana Vega
- Fundación Pública Galega Medicina Xenómica, Santiago De Compostela, Spain
- Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago De Compostela, Spain
- Centro de Investigación en Red de Enfermedades Raras (CIBERER), Spain
| | - Antonio Gómez-Caamaño
- Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain
| | - Laura Fachal
- Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago De Compostela, Spain
- Centro de Investigación en Red de Enfermedades Raras (CIBERER), Spain
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK
- Fundación Pública Galega Medicina Xenómica, Santiago de Compostela, Spain
| | - Barry S. Rosenstein
- Department of Radiation Oncology and Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Sarah L. Kerns
- Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Harry Ostrer
- Professor of Pathology and Pediatrics, Albert Einstein College of Medicine, Bronx, NY, USA
| | - Manuel R. Teixeira
- Department of Laboratory Genetics, Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center, Porto, Portugal
- Cancer Genetics Group, IPO Porto Research Center (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center, Porto, Portugal
- School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal
| | - Paula Paulo
- Cancer Genetics Group, IPO Porto Research Center (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center, Porto, Portugal
| | - Andreia Brandão
- Cancer Genetics Group, IPO Porto Research Center (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center, Porto, Portugal
| | | | | | - Jeannette T. Bensen
- Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Ebonee N. Butler
- Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - James L. Mohler
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | - Jack A. Taylor
- Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
- Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
| | - Manolis Kogevinas
- ISGlobal, Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Trinidad Dierssen-Sotos
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- University of Cantabria-IDIVAL, Santander, Spain
| | - Gemma Castaño-Vinyals
- ISGlobal, Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Lisa Cannon-Albright
- Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, USA
| | - Craig C. Teerlink
- Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, USA
| | - Chad D. Huff
- Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
| | - Patrick Pilie
- Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
| | - Yao Yu
- Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
| | - Ryan J. Bohlender
- Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
| | - Jian Gu
- Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
| | - Sara S. Strom
- The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
| | - Luc Multigner
- Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), Rennes, France
| | - Pascal Blanchet
- CHU de Pointe-à-Pitre, Univ Antilles, Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), Pointe-à-Pitre, France
| | - Laurent Brureau
- CHU de Pointe-à-Pitre, Univ Antilles, Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), Pointe-à-Pitre, France
| | - Radka Kaneva
- Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, Sofia, Bulgaria
| | - Chavdar Slavov
- Department of Urology and Alexandrovska University Hospital, Medical University of Sofia, Sofia, Bulgaria
| | - Vanio Mitev
- Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, Sofia, Bulgaria
| | - Robin J. Leach
- Department of Cell Systems and Anatomy and Mays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
| | - Hermann Brenner
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
- Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany
| | - Xuechen Chen
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | | | - Ben Schöttker
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Eric A. Klein
- Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA
- Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Ann W. Hsing
- Department of Medicine and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA
| | | | - Adam B. Murphy
- Department of Urology, Northwestern University, Chicago, IL, USA
| | - Christopher J. Logothetis
- The University of Texas M. D. Anderson Cancer Center, Department of Genitourinary Medical Oncology, Houston, TX, USA
| | - Jeri Kim
- The University of Texas M. D. Anderson Cancer Center, Department of Genitourinary Medical Oncology, Houston, TX, USA
| | - Susan L. Neuhausen
- Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA, USA
| | - Linda Steele
- Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA, USA
| | - Yuan Chun Ding
- Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA, USA
| | - William B. Isaacs
- James Buchanan Brady Urological Institute, Johns Hopkins Hospital and Medical Institution, Baltimore, MD, USA
| | - Barbara Nemesure
- Department of Family, Population and Preventive Medicine, Stony Brook University, Stony Brook, NY, USA
| | - Anselm J.M. Hennis
- Department of Family, Population and Preventive Medicine, Stony Brook University, Stony Brook, NY, USA
- Chronic Disease Research Centre and Faculty of Medical Sciences, University of the West Indies, Bridgetown, Barbados
| | - John Carpten
- Department of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | | | | | - Kim De Ruyck
- Ghent University, Faculty of Medicine and Health Sciences, Basic Medical Sciences, Ghent, Belgium
| | - Gert De Meerleer
- Ghent University Hospital, Department of Radiotherapy, Ghent, Belgium
| | - Piet Ost
- Ghent University Hospital, Department of Radiotherapy, Ghent, Belgium
| | - Jianfeng Xu
- Program for Personalized Cancer Care and Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA
| | - Azad Razack
- Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - Jasmine Lim
- Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - Soo-Hwang Teo
- Cancer Research Malaysia (CRM), Outpatient Centre, Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia
| | - Lisa F. Newcomb
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- Department of Urology, University of Washington, Seattle, WA, USA
| | - Daniel W. Lin
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- Department of Urology, University of Washington, Seattle, WA, USA
| | - Jay H. Fowke
- Department of Preventive Medicine, Division of Epidemiology,The University of Tennessee Health Science Center, Memphis, TN, USA
| | | | - Benjamin A. Rybicki
- Department of Public Health Sciences, Henry Ford Hospital, Detroit, Detroit, MI, USA
| | - Marija Gamulin
- Division of Medical Oncology, Urogenital Unit, Department of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia
| | - Davor Lessel
- Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Tomislav Kulis
- Department of Urology, University Hospital Center Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia
| | - Nawaid Usmani
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
- Division of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada
| | - Aswin Abraham
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
- Division of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada
| | - Sandeep Singhal
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
| | - Matthew Parliament
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
- Division of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada
| | - Frank Claessens
- Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, Leuven, Belgium
| | - Steven Joniau
- Department of Urology, University Hospitals Leuven, Leuven, Belgium
| | - Thomas Van den Broeck
- Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, Leuven, Belgium
- Department of Urology, University Hospitals Leuven, Leuven, Belgium
| | - Manuela Gago-Dominguez
- Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, Servicio Galego de Saúde, SERGAS, Santiago de Compostela, Spain
- University of California San Diego, Moores Cancer Center, La Jolla, CA, USA
| | - Jose Esteban Castelao
- Genetic Oncology Unit, CHUVI Hospital, Complexo Hospitalario Universitario de Vigo, Instituto de Investigación Biomédica Galicia Sur (IISGS), Vigo (Pontevedra), Spain
| | - Maria Elena Martinez
- University of California San Diego, Moores Cancer Center, Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, USA
| | - Samantha Larkin
- Scientific Education Support, Thames Ditton, Surrey, Formerly Cancer Sciences, University of Southampton, Southampton, UK
| | - Paul A. Townsend
- School of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Surrey, UK
| | | | - William S. Bush
- Department of Population and Quantitative Health Sciences, Cleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, OH, USA
| | - Melinda C. Aldrich
- Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Dana C. Crawford
- Department of Population and Quantitative Health Sciences, Cleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, OH, USA
| | - Shiv Srivastava
- Department of Biochemistry and Molecular & Cellular Biology, Georgetown University Medical Center, Washington, DC, USA
| | - Jennifer Cullen
- Department of Population and Quantitative Health Sciences, Cleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, OH, USA
- Department of Surgery, Center for Prostate Disease Research,Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - Gyorgy Petrovics
- Department of Surgery, Center for Prostate Disease Research,Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - Graham Casey
- Department of Public Health Science, Center for Public Health Genomics,University of Virginia, Charlottesville, VA, USA
| | - Ying Wang
- Department of Population Science, American Cancer Society, Kennesaw, GA, USA
| | - Yao Tettey
- Korle Bu Teaching Hospital, Accra, Ghana
- Department of Pathology, University of Ghana, Accra, Ghana
| | - Joseph Lachance
- School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA
| | - Wei Tang
- Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | | | - Andrew A. Adjei
- Department of Pathology, University of Ghana Medical School, Accra, Ghana
| | - Evelyn Tay
- Korle Bu Teaching Hospital, Accra, Ghana
| | | | | | - Kosj Yamoah
- Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA
- Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | | | | | - Jacob M. Keaton
- Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
- Center for Precision Health Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Jacklyn N. Hellwege
- Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
- Division of Genetic Medicine, Department of Medicine, Vanderbilt Genetics Institute, Nashville, TN, USA
| | - Peter E. Clark
- Atrium Health/Levine Cancer Institute, Charlotte, NC, USA
| | | | | | | | - Olufemi Ogunbiyi
- Department of Pathology, College of Medicine, University of Ibadan, Ibadan, Nigeria
| | - Olayiwola Shittu
- Department of Surgery, College of Medicine, University of Ibadan and Univerity College Hospital, Ibadan, Nigeria
| | - Olukemi Amodu
- Institute of Child Health, College of Medicine, University of Ibadan and University College Hospital, Ibadan, Nigeria
| | - Akindele O. Adebiyi
- Clinical Epidemiology Unit, Department of Community Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria
| | - Oseremen I. Aisuodionoe-Shadrach
- College of Health Sciences, University of Abuja, University of Abuja Teaching Hospital and Cancer Science Center, Abuja, Nigeria
| | - Hafees O. Ajibola
- College of Health Sciences, University of Abuja, University of Abuja Teaching Hospital and Cancer Science Center, Abuja, Nigeria
| | - Mustapha A. Jamda
- College of Health Sciences, University of Abuja, University of Abuja Teaching Hospital and Cancer Science Center, Abuja, Nigeria
| | - Olabode P. Oluwole
- College of Health Sciences, University of Abuja, University of Abuja Teaching Hospital and Cancer Science Center, Abuja, Nigeria
| | - Maxwell Nwegbu
- College of Health Sciences, University of Abuja, University of Abuja Teaching Hospital and Cancer Science Center, Abuja, Nigeria
| | | | | | | | - Halimatou Diop
- Laboratoires Bacteriologie et Virologie, Hôpital Aristide Le Dantec, Dakar, Senegal
| | - Susan M. Gundell
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Monique J. Roobol
- Department of Urology, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Guido Jenster
- Department of Urology, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Ron H.N. van Schaik
- Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Jennifer J. Hu
- The University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA
| | - Maureen Sanderson
- Department of Family and Community Medicine, Meharry Medical College, Nashville, TN, USA
| | - Linda Kachuri
- Department of Epidemiology and Population Health, Stanford Cancer Institute, Stanford, CA, USA
| | - Rohit Varma
- Southern California Eye Institute, CHA Hollywood Presbyterian Medical Center, Los Angeles, CA, USA
| | - Roberta McKean-Cowdin
- Department of Population and Public Health Sciences, Keck School of Medicine,University of Southern California, Los Angeles, CA, USA
| | - Mina Torres
- Southern California Eye Institute, CHA Hollywood Presbyterian Medical Center, Los Angeles, CA, USA
| | - Michael H. Preuss
- The Charles Bronfman Institute for Personalized Medicine,Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Ruth J.F. Loos
- The Charles Bronfman Institute for Personalized Medicine,Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Matthew Zawistowski
- Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA
- Center for Statistical Genetics, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | - Sebastian Zöllner
- Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA
- Center for Statistical Genetics, University of Michigan School of Public Health, Ann Arbor, MI, USA
- Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA
| | - Zeyun Lu
- Department of Population and Public Health Sciences, Keck School of Medicine,University of Southern California, Los Angeles, CA, USA
| | | | - Douglas F. Easton
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology,, Cambridge, UK
| | - Stefan Ambs
- Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | - Todd L. Edwards
- Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Reedik Mägi
- Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia
| | - Timothy R. Rebbeck
- Harvard TH Chan School of Public Health and Division of Population Sciences, Dana Farber Cancer Institute, Boston, MA, USA
| | - Lars Fritsche
- Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, USA
| | - Stephen J. Chanock
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Sonja I. Berndt
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Fredrik Wiklund
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - Hidewaki Nakagawa
- Laboratory for Cancer Genomics, RIKEN Center of Integrative Medical Sciences, Yokohama, Japan
| | - John S. Witte
- Department of Epidemiology and Population Health, Stanford Cancer Institute, Stanford, CA, USA
- Departments of Biomedical Data Science, Stanford University, Stanford, CA, USA
| | - J. Michael Gaziano
- Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
- VA Boston Healthcare System, Boston, MA, USA
| | | | - Nick Mancuso
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Chikashi Terao
- Laboratory for Statistical and Translational Genetics, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
- Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan
- The Department of Applied Genetics, School of Pharmaceutical Sciences, Shizuoka, Japan
| | - Rosalind A. Eeles
- The Institute of Cancer Research, London, UK
- Royal Marsden NHS Foundation Trust, London, UK
| | | | | | - David V. Conti
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Christopher A. Haiman
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| |
Collapse
|
6
|
Peñalver-Argüeso B, García-Esquinas E, Castelló A, de Larrea-Baz NF, Castaño-Vinyals G, Amiano P, Fernández-Villa T, Guevara M, Fernández-Tardón G, Alguacil J, Obón-Santacana M, Gómez-Acebo I, Pinto-Carbó M, Marcos-Gragera R, Aragonés N, Aizpurua A, Martín-Sánchez V, Ardanaz E, Dierssen-Sotos T, Jiménez-Moleón JJ, Kogevinas M, Pollán M, Pérez-Gómez B. Smoking history and breast cancer risk by pathological subtype: MCC-Spain study. Tob Induc Dis 2023; 21:157. [PMID: 38034128 PMCID: PMC10688255 DOI: 10.18332/tid/174132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2023] [Revised: 10/07/2023] [Accepted: 10/13/2023] [Indexed: 12/02/2023] Open
Abstract
INTRODUCTION The role of cigarette smoking on breast cancer risk remains controversial, due to its dual carcinogenic-antiestrogenic action. METHODS In the population-based multi-case-control study (MCC-Spain), we collected epidemiological and clinical information for 1733 breast cancer cases and 1903 controls, including smoking exposure. The association with breast cancer, overall, by pathological subtype and menopausal status, was assessed using logistic and multinomial regression models. RESULTS Smokers had higher risk of premenopausal breast cancer, particularly if they had smoked ≥30 years (AOR=1.75; 95% CI: 1.04-2.94), although most estimates did not achieve statistical significance. In contrast, among postmenopausal women, smoking was associated with lower risk of breast cancer, mainly in overweight and obese women. The strongest risk reductions were observed among postmenopausal women who had stopped smoking ≥10 years before cancer diagnosis, particularly for HER2+ tumors (AOR=0.28; 95% CI: 0.11-0.68); p for heterogeneity = 0.040). Also, those who had smoked <10 pack-years (AOR=0.68; 95% CI: 0.47-0.98) or 10-25 pack-years (AOR=0.62; 95% CI: 0.42-0.92) during their lifetime were at a reduced risk of all breast cancer subtypes (p for heterogeneity: 0.405 and 0.475, respectively); however, women who had smoked more than 25 pack-years showed no reduced risk. CONCLUSIONS Menopausal status plays a key role in the relationship between tobacco and breast cancer for all cancer subtypes. While smoking seems to increase the risk in premenopausal woman, it might be associated to lower risk of breast cancer among postmenopausal women with excess weight.
Collapse
Affiliation(s)
- Belén Peñalver-Argüeso
- Public Health and Preventive Medicine Teaching Unit, National School of Public Health, Carlos III Institute of Health, Madrid, Spain
- Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Esther García-Esquinas
- Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
- Department of Preventive Medicine, Public Health and Microbiology, School of Medicine, Autonomous University of Madrid, Madrid, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
| | - Adela Castelló
- Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
| | - Nerea Fernández de Larrea-Baz
- Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
| | - Gemma Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
- Barcelona Institute for Global Health, Barcelona, Spain
- Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain
- Hospital del Mar Medical Research Institute, Barcelona, Spain
| | - Pilar Amiano
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
- Ministry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastián, Spain
- Epidemiology of Chronic and Communicable Diseases Group, Biodonostia Health Research Institute, San Sebastián, Spain
| | - Tania Fernández-Villa
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
- Research Group on Gene-Environment Interactions and Health, Institute of Biomedicine, Universidad de León, León, Spain
| | - Marcela Guevara
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
- Public Health Institute of Navarra, Pamplona, Spain
- Navarra Institute for Health Research, Pamplona, Spain
| | - Guillermo Fernández-Tardón
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
- Health Research Institute of Asturias, Oviedo, Spain
- University Institute of Oncology of Asturias, Oviedo, Spain
| | - Juan Alguacil
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
- Natural Resources, Health and Environment Research Center, University of Huelva, Huelva, Spain
| | - Mireia Obón-Santacana
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
- Biomarkers and Susceptibility Unit, Oncology Data Analytics Program, Catalan Institute of Oncology, Barcelona, Spain
- ONCOBELL Program, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Inés Gómez-Acebo
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
- Instituto de Investigación Marqués de Valdecilla, Santander, Spain
- Faculty of Medicine, University of Cantabria, Santander, Spain
| | - Marina Pinto-Carbó
- Cancer and Public Health Research Area, Foundation for the Promotion of Health and Biomedical Research, Valencia, Spain
| | - Rafael Marcos-Gragera
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
- Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona, Spain
- Descriptive Epidemiology, Genetics and Cancer Prevention Group, Girona Biomedical Research Institute, Girona, Spain
| | - Nuria Aragonés
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
- Epidemiology Section, Public Health Division, Department of Health of Madrid, Madrid, Spain
| | - Amaia Aizpurua
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
- Ministry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastián, Spain
- Epidemiology of Chronic and Communicable Diseases Group, Biodonostia Health Research Institute, San Sebastián, Spain
| | - Vicente Martín-Sánchez
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
- Research Group on Gene-Environment Interactions and Health, Institute of Biomedicine, Universidad de León, León, Spain
| | - Eva Ardanaz
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
- Public Health Institute of Navarra, Pamplona, Spain
- Navarra Institute for Health Research, Pamplona, Spain
| | - Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
- Instituto de Investigación Marqués de Valdecilla, Santander, Spain
- Faculty of Medicine, University of Cantabria, Santander, Spain
| | - Jose Juan Jiménez-Moleón
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
- Instituto de Investigación Biosanitaria de Granada, Hospitales Universitarios de Granada, Universidad de Granada, Granada, Spain
| | - Manolis Kogevinas
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
- Barcelona Institute for Global Health, Barcelona, Spain
- Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain
- Hospital del Mar Medical Research Institute, Barcelona, Spain
| | - Marina Pollán
- Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
| | - Beatriz Pérez-Gómez
- Public Health and Preventive Medicine Teaching Unit, National School of Public Health, Carlos III Institute of Health, Madrid, Spain
- Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
| |
Collapse
|
7
|
Gómez-Acebo I, Llorca J, Alonso-Molero J, Díaz-Martínez M, Pérez-Gómez B, Amiano P, Belmonte T, Molina AJ, Burgui R, Castaño-Vinyals G, Moreno V, Molina-Barceló A, Marcos-Gragera R, Kogevinas M, Pollán M, Dierssen-Sotos T. Circulating miRNAs signature on breast cancer: the MCC-Spain project. Eur J Med Res 2023; 28:480. [PMID: 37925534 PMCID: PMC10625260 DOI: 10.1186/s40001-023-01471-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Accepted: 10/23/2023] [Indexed: 11/06/2023] Open
Abstract
PURPOSE To build models combining circulating microRNAs (miRNAs) able to identify women with breast cancer as well as different types of breast cancer, when comparing with controls without breast cancer. METHOD miRNAs analysis was performed in two phases: screening phase, with a total n = 40 (10 controls and 30 BC cases) analyzed by Next Generation Sequencing, and validation phase, which included 131 controls and 269 cases. For this second phase, the miRNAs were selected combining the screening phase results and a revision of the literature. They were quantified using RT-PCR. Models were built using logistic regression with LASSO penalization. RESULTS The model for all cases included seven miRNAs (miR-423-3p, miR-139-5p, miR-324-5p, miR-1299, miR-101-3p, miR-186-5p and miR-29a-3p); which had an area under the ROC curve of 0.73. The model for cases diagnosed via screening only took in one miRNA (miR-101-3p); the area under the ROC curve was 0.63. The model for disease-free cases in the follow-up had five miRNAs (miR-101-3p, miR-186-5p, miR-423-3p, miR-142-3p and miR-1299) and the area under the ROC curve was 0.73. Finally, the model for cases with active disease in the follow-up contained six miRNAs (miR-101-3p, miR-423-3p, miR-139-5p, miR-1307-3p, miR-331-3p and miR-21-3p) and its area under the ROC curve was 0.82. CONCLUSION We present four models involving eleven miRNAs to differentiate healthy controls from different types of BC cases. Our models scarcely overlap with those previously reported.
Collapse
Affiliation(s)
- Inés Gómez-Acebo
- Department of Preventive Medicine and Public Health, University of Cantabria, Santander, Spain.
- IDIVAL, Santander, Spain.
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
| | - Javier Llorca
- Department of Preventive Medicine and Public Health, University of Cantabria, Santander, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
| | - Jessica Alonso-Molero
- Department of Preventive Medicine and Public Health, University of Cantabria, Santander, Spain
- IDIVAL, Santander, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
| | - Marta Díaz-Martínez
- Department of Preventive Medicine and Public Health, University of Cantabria, Santander, Spain
| | - Beatriz Pérez-Gómez
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Pilar Amiano
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Sub Directorate for Public Health and Addictions of Gipuzkoa, Ministry of Health of the Basque Government, San Sebastian, Spain
- Epidemiology of Chronic and Communicable Diseases Group, Biodonostia Health Research Institute, San Sebastián, Spain
| | - Thalía Belmonte
- IUOPA, University of Oviedo and ISPA (Health Research Institute of Asturias), Oviedo, Spain
| | - Antonio J Molina
- Grupo de Investigación en Interacción, Gen-Ambiente-Salud (GIIGAS), Instituto de Biomedicina (IBIOMED), Universidad de León, León, Spain
| | - Rosana Burgui
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Institute of Public and Occupational Health of Navarre (ISPLN), 31003, Pamplona, Spain
| | - Gemma Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain
- Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain
| | - Víctor Moreno
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Colorectal Cancer Group, ONCOBELL Program, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
- Oncology Data Analytics Program, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain
- Department of Clinical Sciences, Faculty of Medicine and health Sciences and Universitat de Barcelona Institute of Complex Systems (UBICS), University of Barcelona, Barcelona, Spain
| | - Ana Molina-Barceló
- Cancer and Public Health UnitFoundation for the Promotion of Health and Biomedical Research (FISABIO-Salud Pública) in the Valencia Region, Valencia, Spain
| | - Rafael Marcos-Gragera
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology (ICO), Girona Biomedical Research Institute (IdiBGi), Girona, Spain
| | - Manolis Kogevinas
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain
- Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain
| | - Marina Pollán
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Trinidad Dierssen-Sotos
- Department of Preventive Medicine and Public Health, University of Cantabria, Santander, Spain
- IDIVAL, Santander, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
| |
Collapse
|
8
|
González IS, Valle HA, Abejez LG, Molas AC, Alonso-Molero J, Dierssen-Sotos T, Gómez-Acebo I. Impact of the COVID-19 pandemic on visits to the hospital emergency service in two hospitals in Spain, from March 14, 2020 to June 21, 2020. Intern Emerg Med 2023; 18:2093-2103. [PMID: 37308693 PMCID: PMC10259810 DOI: 10.1007/s11739-023-03328-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Accepted: 05/25/2023] [Indexed: 06/14/2023]
Abstract
This study will describe trends in the use of emergency departments before and after the Spanish State of Alarm, especially in pathologies not directly related to this infection. A cross-sectional study was conducted of all visits to the emergency departments in two third-level hospitals in two Spanish communities during the Spanish State of Alarm, compared with the same period of the previous year. The variables collected included the day of the week, the time of the visit, the duration of the visit, the final destination of the patients (home, admission to a conventional hospitalization ward, admission to the intensive care unit, and death), and the diagnosis at discharge according to the International Classification of Diseases 10th Revision. During the Spanish State of Alarm period, an overall decrease in care demand of 48% was observed, which reached 69.5% in pediatric emergency departments. We also saw a drop of between 20 and 30% in time-dependent pathologies (heart attack, stroke, sepsis, poisoning). The decrease in overall attendance in the emergency departments and absence of serious pathologies, such as time-dependent diseases, observed during the Spanish State of Alarm compared to the previous year highlights the need to strengthen the messages addressed to the population to encourage them to seek care without delay in case of alarming symptoms and reduce the high morbidity and mortality rate if the diagnosis is delayed.
Collapse
Affiliation(s)
- Iria Sanlés González
- Department of Emergency Medicine, Germans Trias i Pujol University Hospital, c/ Canyet, 08916 Badalona, Spain
| | - Héctor Alonso Valle
- Department of Emergency Medicine, Marqués de Valdecilla University Hospital, Santander, Spain
| | - Laura Grimal Abejez
- Department of Emergency Medicine, Germans Trias i Pujol University Hospital, c/ Canyet, 08916 Badalona, Spain
| | - Anna Carreres Molas
- Department of Emergency Medicine, Germans Trias i Pujol University Hospital, c/ Canyet, 08916 Badalona, Spain
| | - Jéssica Alonso-Molero
- Medicine School, Cantabria University, Santander, Spain
- IDIVAL Valdecilla Health Research Institute, Santander, Spain
| | - Trinidad Dierssen-Sotos
- Medicine School, Cantabria University, Santander, Spain
- IDIVAL Valdecilla Health Research Institute, Santander, Spain
- CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain
| | - Inés Gómez-Acebo
- Medicine School, Cantabria University, Santander, Spain
- IDIVAL Valdecilla Health Research Institute, Santander, Spain
- CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain
| |
Collapse
|
9
|
Llorca J, Gómez-Acebo I, Alonso-Molero J, Dierssen-Sotos T. Instantaneous reproduction number and epidemic growth rate for predicting COVID-19 waves: the first 2 years of the pandemic in Spain. Front Public Health 2023; 11:1233043. [PMID: 37780431 PMCID: PMC10540620 DOI: 10.3389/fpubh.2023.1233043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Accepted: 08/23/2023] [Indexed: 10/03/2023] Open
Abstract
Introduction Several indicators were employed to manage the COVID-19 pandemic. In this study, our objective was to compare the instantaneous reproductive number and the epidemic growth rate in the Spanish population. Methods Data on daily numbers of cases, admissions into hospitals, admissions into ICUs, and deaths due to COVID-19 in Spain from March 2020 to March 2022 were obtained. The four "pandemic state indicators", which are daily numbers of cases, admissions into hospitals, admissions into ICUs, and deaths due to COVID-19 in Spain from March 2020 to March 2022 were obtained from the Instituto de Salud Carlos III. The epidemic growth rate was estimated as the derivative of the natural logarithm of daily cases with respect to time. Both the reproductive number and the growth rate, as "pandemic trend indicators," were evaluated according to their capacity to anticipate waves as "pandemic state indicators." Results Using both the reproductive number and the epidemic growth rate, we were able to anticipate most COVID-19 waves. In most waves, the more severe the presentation of COVID-19, the more effective the pandemic trend indicators would be. Conclusion Besides daily number of cases or other measures of disease frequency, the epidemic growth rate and the reproductive number have different roles in measuring the trend of an epidemic. Naïve interpretations and the use of any indicator as a unique value to make decisions should be discouraged.
Collapse
Affiliation(s)
- Javier Llorca
- Department of Preventive Medicine and Public Health, University of Cantabria, Santander, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
| | - Inés Gómez-Acebo
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Cantabria-Instituto de Investigación Sanitaria de Valdecilla (IDIVAL), Santander, Spain
| | - Jessica Alonso-Molero
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Cantabria-Instituto de Investigación Sanitaria de Valdecilla (IDIVAL), Santander, Spain
| | - Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Cantabria-Instituto de Investigación Sanitaria de Valdecilla (IDIVAL), Santander, Spain
| |
Collapse
|
10
|
López-Herreros J, Martínez-González MA, Gea A, Sánchez-Villegas A, Dierssen-Sotos T, Jiménez-Moleón JJ, Ruiz-Canela M, Toledo E. Health-related quality of life and mortality in the 'Seguimiento Universidad de Navarra' prospective cohort study. Exp Gerontol 2023; 178:112224. [PMID: 37244372 DOI: 10.1016/j.exger.2023.112224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2022] [Revised: 05/03/2023] [Accepted: 05/24/2023] [Indexed: 05/29/2023]
Abstract
OBJECTIVE To study the association between health-related quality of life (HRQoL) and all-cause mortality in a healthy middle-aged Mediterranean cohort. METHODS We included 15,390 participants -mean age 42.8 years at first HRQoL ascertainment, all university graduates-. HRQoL was assessed with the self-administered Medical Outcomes Study Short Form-36 (SF-36) twice, with a 4-year gap. We used multivariable-adjusted Cox regression models to address the relation between self-reported health and Physical or Mental Component Summary (PCS-36 or MCS-36) and mortality, and their interaction with prior comorbidities or adherence to the Mediterranean diet (MedDiet). RESULTS Over 8.7 years of median follow-up time, 266 deaths were identified. Hazard ratio (HR) for the excellent vs. poor/fair category in self-reported health was 0.30 (95 % confidence interval (CI), 0.16-0.57) in the model with repeated measurements of HRQoL. Both the PCS-36 (HRquartile4(Q4)vs.Q1 0.57 [95%CI, 0.36-0.90], ptrend < 0.001; HRper+10points: 0.64 [95%CI, 0.54-0.75]) and the MCS-36 (HRQ4vs.Q1 0.67 [95%CI, 0.46-0.97], ptrend = 0.025; HRper+10points: 0.86 [95%CI, 0.74-0.99]) were inversely associated with mortality in the model with repeated measurements of HRQoL. Previous comorbidities or adherence to the MedDiet did not modify these associations. CONCLUSIONS Self-reported HRQoL -assessed as self-reported health, PCS-36 and MCS-36- obtained with the Spanish version of the SF-36 were inversely associated with mortality risk, regardless of the presence of previous comorbidities or adherence to the MedDiet.
Collapse
Affiliation(s)
- J López-Herreros
- Universidad de Navarra, Department of Preventive Medicine and Public Health, Pamplona, Spain
| | - M A Martínez-González
- Universidad de Navarra, Department of Preventive Medicine and Public Health, Pamplona, Spain; Biomedical Research Network Centre for Pathophysiology of Obesity and Nutrition (CIBEROBN), Carlos III Health Institute, Madrid, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; Department of Nutrition, Harvard T. H Chan School, Boston, MA 02115, USA
| | - A Gea
- Universidad de Navarra, Department of Preventive Medicine and Public Health, Pamplona, Spain; Biomedical Research Network Centre for Pathophysiology of Obesity and Nutrition (CIBEROBN), Carlos III Health Institute, Madrid, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - A Sánchez-Villegas
- Biomedical Research Network Centre for Pathophysiology of Obesity and Nutrition (CIBEROBN), Carlos III Health Institute, Madrid, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; ISFOOD - Institute for Innovation & Sustainable Development in Food Chain, Universidad Pública de Navarra (UPNA), Pamplona, Spain
| | - T Dierssen-Sotos
- Biomedical Research Network Centre for Pathophysiology of Epidemiology and Public Health (CIBERESP), Carlos III Health Institute, Madrid, Spain; IDIVAL Santander, 39011 Santander, Spain; Faculty of Medicine, University of Cantabria, 39011 Santander, Spain
| | - J J Jiménez-Moleón
- Biomedical Research Network Centre for Pathophysiology of Epidemiology and Public Health (CIBERESP), Carlos III Health Institute, Madrid, Spain; Universidad de Granada, Department of Preventive Medicine and Public Health, Granada, Spain; Instituto de Investigación Biosanitaria ibs. GRANADA, Granada, Spain
| | - M Ruiz-Canela
- Universidad de Navarra, Department of Preventive Medicine and Public Health, Pamplona, Spain; Biomedical Research Network Centre for Pathophysiology of Obesity and Nutrition (CIBEROBN), Carlos III Health Institute, Madrid, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - E Toledo
- Universidad de Navarra, Department of Preventive Medicine and Public Health, Pamplona, Spain; Biomedical Research Network Centre for Pathophysiology of Obesity and Nutrition (CIBEROBN), Carlos III Health Institute, Madrid, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
| |
Collapse
|
11
|
Palomar-Cros A, Straif K, Romaguera D, Aragonés N, Castaño-Vinyals G, Martin V, Moreno V, Gómez-Acebo I, Guevara M, Aizpurua A, Molina-Barceló A, Jiménez-Moleón JJ, Tardón A, Contreras-Llanes M, Marcos-Gragera R, Huerta JM, Pérez-Gómez B, Espinosa A, Hernández-Segura N, Obón-Santacana M, Alonso-Molero J, Burgui R, Amiano P, Pinto-Carbó M, Olmedo-Requena R, Fernández-Tardón G, Santos-Sánchez V, Fernández de Larrea-Baz N, Fernández-Villa T, Casabonne D, Dierssen-Sotos T, Ardanaz E, Dorronsoro A, Pollán M, Kogevinas M, Lassale C. Consumption of aspartame and other artificial sweeteners and risk of cancer in the Spanish multicase-control study (MCC-Spain). Int J Cancer 2023. [PMID: 37323037 DOI: 10.1002/ijc.34577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Revised: 05/03/2023] [Accepted: 05/04/2023] [Indexed: 06/17/2023]
Abstract
Use of artificial sweeteners (AS) such as aspartame, cyclamate, saccharin and sucralose is widespread. We evaluated the association of use of aspartame and other AS with cancer. In total 1881 colorectal, 1510 breast, 972 prostate and 351 stomach cancer and 109 chronic lymphocytic leukaemia (CLL) cases and 3629 population controls from the Spanish Multicase-Control (MCC-Spain) study were recruited (2008-2013). The consumption of AS, from table-top sweeteners and artificially sweetened beverages, was assessed through a self-administered and validated food frequency questionnaire (FFQ). Sex-specific quartiles among controls were determined to compare moderate consumers (<third quartile) and high consumers (≥ third quartile) vs non consumers (reference category), distinguishing aspartame-containing products and other AS. Unconditional logistic regression models were used to estimate adjusted OR and 95%CI, and results were stratified by diabetes status. Overall, we found no associations between the consumption of aspartame or other AS and cancer. Among participants with diabetes, high consumption of other AS was associated with colorectal cancer (OR = 1.58, 95% CI 1.05-2.41, P trend = .03) and stomach cancer (OR = 2.27 [0.99-5.44], P trend = .06). High consumption of aspartame, was associated with stomach cancer (OR = 2.04 [0.7-5.4], P trend = .05), while a lower risk was observed for breast cancer (OR = 0.28 [0.08-0.83], P trend = .03). In some cancers, the number of cases in participants with diabetes were small and results should be interpreted cautiously. We did not find associations between use of AS and cancer, but found associations between high consumption of aspartame and other AS and different cancer types among participants with diabetes.
Collapse
Affiliation(s)
- Anna Palomar-Cros
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
| | - Kurt Straif
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Boston College, Boston, Massachusetts, USA
| | - Dora Romaguera
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain
- CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Madrid, Spain
| | - Nuria Aragonés
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Public Health Division, Department of Health, Madrid, Spain
| | - Gemma Castaño-Vinyals
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Vicente Martin
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- The Research Group in Gene-Environment and Health Interactions (GIIGAS)/Institute of Biomedicine (IBIOMED), Universidad de León, León, Spain
| | - Victor Moreno
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Cancer Epidemiology Research Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
- Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain
- Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | - Inés Gómez-Acebo
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Faculty of Medicine, University of Cantabria, Santander, Spain
- IDIVAL-Instituto de investigación sanitaria Valdecilla, Santander, Spain
| | - Marcela Guevara
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Institute of Public and Occupational Health of Navarre (ISPLN), Pamplona, Spain
- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - Amaia Aizpurua
- Ministry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastian, Spain
- Biodonostia Health Research Institute, Epidemiology of Chronic and Communicable Diseases Group, San Sebastián, Spain
| | - Ana Molina-Barceló
- Cancer and Public Health Research Unit, Foundation for the Promotion of Health and Biomedical Research, (FISABIO-Public Health), Valencia, Spain
| | - José-Juan Jiménez-Moleón
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Instituto de Investigación Biosanitaria ibs.GRANADA, Complejo Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain
- Departamento de Medicina Preventiva y Salud Pública, Universidad de Granada, Granada, Spain
| | - Adonina Tardón
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- University of Oviedo, Health Research Institute of Asturias (ISPA), Asturias, Spain
| | - Manuel Contreras-Llanes
- Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, Huelva, Spain
- Grupo de investigación en Epidemiología Clínica, Ambiental y Transformación Social (EPICAS), Departamento de Sociología, Trabajo Social y Salud Pública, Universidad de Huelva, Huelva, Spain
| | - Rafael Marcos-Gragera
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology (ICO), Girona Biomedical Research Institute (IdiBGi), Girona, Spain
| | - José Mª Huerta
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Department of Epidemiology, Murcia Regional Health Council-IMIB, Murcia, Spain
| | - Beatriz Pérez-Gómez
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Ana Espinosa
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Natalia Hernández-Segura
- The Research Group in Gene-Environment and Health Interactions (GIIGAS)/Institute of Biomedicine (IBIOMED), Universidad de León, León, Spain
| | - Mireia Obón-Santacana
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Cancer Epidemiology Research Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
- Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain
- Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | - Jessica Alonso-Molero
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Faculty of Medicine, University of Cantabria, Santander, Spain
- IDIVAL-Instituto de investigación sanitaria Valdecilla, Santander, Spain
| | - Rosana Burgui
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Institute of Public and Occupational Health of Navarre (ISPLN), Pamplona, Spain
- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - Pilar Amiano
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Ministry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastian, Spain
- Biodonostia Health Research Institute, Epidemiology of Chronic and Communicable Diseases Group, San Sebastián, Spain
| | - Marina Pinto-Carbó
- Cancer and Public Health Research Unit, Foundation for the Promotion of Health and Biomedical Research, (FISABIO-Public Health), Valencia, Spain
| | - Rocio Olmedo-Requena
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Instituto de Investigación Biosanitaria ibs.GRANADA, Complejo Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain
- Departamento de Medicina Preventiva y Salud Pública, Universidad de Granada, Granada, Spain
| | - Guillermo Fernández-Tardón
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- University of Oviedo, Health Research Institute of Asturias (ISPA), Asturias, Spain
| | - Vanessa Santos-Sánchez
- Grupo de investigación en Epidemiología Clínica, Ambiental y Transformación Social (EPICAS), Departamento de Sociología, Trabajo Social y Salud Pública, Universidad de Huelva, Huelva, Spain
| | - Nerea Fernández de Larrea-Baz
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Tania Fernández-Villa
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- The Research Group in Gene-Environment and Health Interactions (GIIGAS)/Institute of Biomedicine (IBIOMED), Universidad de León, León, Spain
| | - Delphine Casabonne
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Cancer Epidemiology Research Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
- Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain
| | - Trinidad Dierssen-Sotos
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Faculty of Medicine, University of Cantabria, Santander, Spain
- IDIVAL-Instituto de investigación sanitaria Valdecilla, Santander, Spain
| | - Eva Ardanaz
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- Institute of Public and Occupational Health of Navarre (ISPLN), Pamplona, Spain
- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - Ane Dorronsoro
- Ministry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastian, Spain
- Biodonostia Health Research Institute, Epidemiology of Chronic and Communicable Diseases Group, San Sebastián, Spain
| | - Marina Pollán
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Manolis Kogevinas
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- CIBER Epidemiology and Public Health CIBERESP ISCIII, Madrid, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Camille Lassale
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Madrid, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| |
Collapse
|
12
|
Cabrera-Serrano AJ, Sánchez-Maldonado JM, ter Horst R, Macauda A, García-Martín P, Benavente Y, Landi S, Clay-Gilmour A, Niazi Y, Espinet B, Rodríguez-Sevilla JJ, Pérez EM, Maffei R, Blanco G, Giaccherini M, Cerhan JR, Marasca R, López-Nevot MÁ, Chen-Liang T, Thomsen H, Gámez I, Campa D, Moreno V, de Sanjosé S, Marcos-Gragera R, García-Álvarez M, Dierssen-Sotos T, Jerez A, Butrym A, Norman AD, Luppi M, Slager SL, Hemminki K, Li Y, Berndt SI, Casabonne D, Alcoceba M, Puiggros A, Netea MG, Försti A, Canzian F, Sainz J. Do GWAS-Identified Risk Variants for Chronic Lymphocytic Leukemia Influence Overall Patient Survival and Disease Progression? Int J Mol Sci 2023; 24:8005. [PMID: 37175717 PMCID: PMC10178669 DOI: 10.3390/ijms24098005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2023] [Revised: 04/14/2023] [Accepted: 04/23/2023] [Indexed: 05/15/2023] Open
Abstract
Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults worldwide. Although genome-wide association studies (GWAS) have uncovered the germline genetic component underlying CLL susceptibility, the potential use of GWAS-identified risk variants to predict disease progression and patient survival remains unexplored. Here, we evaluated whether 41 GWAS-identified risk variants for CLL could influence overall survival (OS) and disease progression, defined as time to first treatment (TTFT) in a cohort of 1039 CLL cases ascertained through the CRuCIAL consortium. Although this is the largest study assessing the effect of GWAS-identified susceptibility variants for CLL on OS, we only found a weak association of ten single nucleotide polymorphisms (SNPs) with OS (p < 0.05) that did not remain significant after correction for multiple testing. In line with these results, polygenic risk scores (PRSs) built with these SNPs in the CRuCIAL cohort showed a modest association with OS and a low capacity to predict patient survival, with an area under the receiver operating characteristic curve (AUROC) of 0.57. Similarly, seven SNPs were associated with TTFT (p < 0.05); however, these did not reach the multiple testing significance threshold, and the meta-analysis with previous published data did not confirm any of the associations. As expected, PRSs built with these SNPs showed reduced accuracy in prediction of disease progression (AUROC = 0.62). These results suggest that susceptibility variants for CLL do not impact overall survival and disease progression in CLL patients.
Collapse
Affiliation(s)
- Antonio José Cabrera-Serrano
- Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, 18016 Granada, Spain; (A.J.C.-S.); (J.M.S.-M.)
- Instituto de Investigación Biosanitaria IBs.Granada, 18012 Granada, Spain
| | - José Manuel Sánchez-Maldonado
- Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, 18016 Granada, Spain; (A.J.C.-S.); (J.M.S.-M.)
- Instituto de Investigación Biosanitaria IBs.Granada, 18012 Granada, Spain
| | - Rob ter Horst
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria;
| | - Angelica Macauda
- Genomic Epidemiology Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; (A.M.); (F.C.)
| | | | - Yolanda Benavente
- Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), 08908 Barcelona, Spain; (Y.B.); (V.M.); (S.d.S.); (D.C.)
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), University of Barcelona, 08908 Barcelona, Spain; (R.M.-G.); (T.D.-S.)
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
| | - Stefano Landi
- Department of Biology, University of Pisa, 56126 Pisa, Italy; (S.L.); (M.G.); (D.C.)
| | - Alyssa Clay-Gilmour
- Department of Epidemiology & Biostatistics, Arnold School of Public Health, University of South Carolina, Greenville, SC 29208, USA;
| | - Yasmeen Niazi
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany; (Y.N.); (A.F.)
- Hopp Children’s Cancer Center (KiTZ), 69120 Heidelberg, Germany
| | - Blanca Espinet
- Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain; (B.E.); (G.B.); (A.P.)
- Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain
| | | | - Eva María Pérez
- Hospital Campus de la Salud, PTS, 18016 Granada, Spain; (P.G.-M.); (E.M.P.)
| | - Rossana Maffei
- Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy; (R.M.); (R.M.); (M.L.)
| | - Gonzalo Blanco
- Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain; (B.E.); (G.B.); (A.P.)
- Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain
| | - Matteo Giaccherini
- Department of Biology, University of Pisa, 56126 Pisa, Italy; (S.L.); (M.G.); (D.C.)
| | - James R. Cerhan
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA; (J.R.C.); (A.D.N.)
| | - Roberto Marasca
- Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy; (R.M.); (R.M.); (M.L.)
| | | | - Tzu Chen-Liang
- Hematology Department, Morales Meseguer University Hospital, 30008 Murcia, Spain; (T.C.-L.); (I.G.)
| | | | - Irene Gámez
- Hematology Department, Morales Meseguer University Hospital, 30008 Murcia, Spain; (T.C.-L.); (I.G.)
| | - Daniele Campa
- Department of Biology, University of Pisa, 56126 Pisa, Italy; (S.L.); (M.G.); (D.C.)
| | - Víctor Moreno
- Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), 08908 Barcelona, Spain; (Y.B.); (V.M.); (S.d.S.); (D.C.)
- Cancer Prevention and Control Program, Unit of Biomarkers and Susceptibility, Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology, 08907 Barcelona, Spain
- Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, 08907 Barcelona, Spain
| | - Silvia de Sanjosé
- Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), 08908 Barcelona, Spain; (Y.B.); (V.M.); (S.d.S.); (D.C.)
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), University of Barcelona, 08908 Barcelona, Spain; (R.M.-G.); (T.D.-S.)
| | - Rafael Marcos-Gragera
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), University of Barcelona, 08908 Barcelona, Spain; (R.M.-G.); (T.D.-S.)
- Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona Biomedical Research Institute (IdiBGi), 17190 Girona, Spain
- Department of Nursing, Universitat de Girona, 17007 Girona, Spain
- Josep Carreras Leukemia Research Institute, 08916 Girona, Spain
| | - María García-Álvarez
- Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), 37007 Salamanca, Spain; (M.G.-Á.); (M.A.)
| | - Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), University of Barcelona, 08908 Barcelona, Spain; (R.M.-G.); (T.D.-S.)
- Faculty of Medicine, University of Cantabria, 39011 Santander, Spain
| | - Andrés Jerez
- Department of Hematology, Experimental Hematology Unit, Vall d’Hebron Institute of Oncology (VHIO), University Hospital Vall d’Hebron, 08035 Barcelona, Spain;
| | - Aleksandra Butrym
- Department of Cancer Prevention and Therapy, Medical University of Wrocław, 50-556 Wrocław, Poland;
| | - Aaron D. Norman
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA; (J.R.C.); (A.D.N.)
| | - Mario Luppi
- Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy; (R.M.); (R.M.); (M.L.)
| | - Susan L. Slager
- Division of Computational Genomics, Mayo Clinic, Rochester, MN 85054, USA;
- Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
| | - Kari Hemminki
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany;
- Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, 30605 Pilsen, Czech Republic
| | - Yang Li
- Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands; (Y.L.); (M.G.N.)
- Centre for Individualised Infection Medicine (CiiM) & TWINCORE, Joint Ventures between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), 30625 Hannover, Germany
| | - Sonja I. Berndt
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA;
| | - Delphine Casabonne
- Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), 08908 Barcelona, Spain; (Y.B.); (V.M.); (S.d.S.); (D.C.)
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), University of Barcelona, 08908 Barcelona, Spain; (R.M.-G.); (T.D.-S.)
| | - Miguel Alcoceba
- Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), 37007 Salamanca, Spain; (M.G.-Á.); (M.A.)
| | - Anna Puiggros
- Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain; (B.E.); (G.B.); (A.P.)
- Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain
| | - Mihai G. Netea
- Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands; (Y.L.); (M.G.N.)
- Department for Immunology & Metabolism, Life and Medical Sciences Institute (LIMES), University of Bonn, 53115 Bonn, Germany
| | - Asta Försti
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany; (Y.N.); (A.F.)
- Hopp Children’s Cancer Center (KiTZ), 69120 Heidelberg, Germany
| | - Federico Canzian
- Genomic Epidemiology Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; (A.M.); (F.C.)
| | - Juan Sainz
- Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, 18016 Granada, Spain; (A.J.C.-S.); (J.M.S.-M.)
- Instituto de Investigación Biosanitaria IBs.Granada, 18012 Granada, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), University of Barcelona, 08908 Barcelona, Spain; (R.M.-G.); (T.D.-S.)
- Department of Biochemistry and Molecular Biology I, Faculty of Sciences, University of Granada (UGR), 18012 Granada, Spain
| |
Collapse
|
13
|
Collatuzzo G, Negri E, Pelucchi C, Bonzi R, Turati F, Rabkin CS, Liao LM, Sinha R, Palli D, Ferraroni M, López-Carrillo L, Lunet N, Morais S, Albanes D, Weinstein SJ, Parisi D, Zaridze D, Maximovitch D, Dierssen-Sotos T, Jiménez-Moleón JJ, Vioque J, Garcia de la Hera M, Curado MP, Dias-Neto E, Hernández-Ramírez RU, López-Cervantes M, Ward MH, Tsugane S, Hidaka A, Lagiou A, Lagiou P, Zhang ZF, Trichopoulou A, Karakatsani A, Camargo MC, La Vecchia C, Boffetta P. Yoghurt Intake and Gastric Cancer: A Pooled Analysis of 16 Studies of the StoP Consortium. Nutrients 2023; 15:nu15081877. [PMID: 37111097 PMCID: PMC10147010 DOI: 10.3390/nu15081877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Revised: 03/13/2023] [Accepted: 03/21/2023] [Indexed: 04/29/2023] Open
Abstract
BACKGROUND Yoghurt can modify gastrointestinal disease risk, possibly acting on gut microbiota. Our study aimed at exploring the under-investigated association between yoghurt and gastric cancer (GC). METHODS We pooled data from 16 studies from the Stomach Cancer Pooling (StoP) Project. Total yoghurt intake was derived from food frequency questionnaires. We calculated study-specific odds ratios (ORs) of GC and the corresponding 95% confidence intervals (CIs) for increasing categories of yoghurt consumption using univariate and multivariable unconditional logistic regression models. A two-stage analysis, with a meta-analysis of the pooled adjusted data, was conducted. RESULTS The analysis included 6278 GC cases and 14,181 controls, including 1179 cardia and 3463 non-cardia, 1191 diffuse and 1717 intestinal cases. The overall meta-analysis revealed no association between increasing portions of yoghurt intake (continuous) and GC (OR = 0.98, 95% CI = 0.94-1.02). When restricting to cohort studies, a borderline inverse relationship was found (OR = 0.93, 95% CI = 0.88-0.99). The adjusted and unadjusted OR were 0.92 (95% CI = 0.85-0.99) and 0.78 (95% CI = 0.73-0.84) for any vs. no yoghurt consumption and GC risk. The OR for 1 category of increase in yoghurt intake was 0.96 (95% CI = 0.91-1.02) for cardia, 1.03 (95% CI = 1.00-1.07) for non-cardia, 1.12 (95% CI = 1.07-1.19) for diffuse and 1.02 (95% CI = 0.97-1.06) for intestinal GC. No effect was seen within hospital-based and population-based studies, nor in men or women. CONCLUSIONS We found no association between yoghurt and GC in the main adjusted models, despite sensitivity analyses suggesting a protective effect. Additional studies should further address this association.
Collapse
Affiliation(s)
- Giulia Collatuzzo
- Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy
| | - Eva Negri
- Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy
| | - Claudio Pelucchi
- Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy
| | - Rossella Bonzi
- Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy
| | - Federica Turati
- Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy
| | - Charles S Rabkin
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA
| | - Linda M Liao
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA
| | - Rashmi Sinha
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA
| | - Domenico Palli
- Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network, ISPRO, 50139 Florence, Italy
| | - Monica Ferraroni
- Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy
| | | | - Nuno Lunet
- EPIUnit-Instituto de Saúde Pública da Universidade do Porto, 4050-600 Porto, Portugal
- Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), 4050-600 Porto, Portugal
- Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Faculdade de Medicina da Universidade do Porto, 4200-450 Porto, Portugal
| | - Samantha Morais
- EPIUnit-Instituto de Saúde Pública da Universidade do Porto, 4050-600 Porto, Portugal
- Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), 4050-600 Porto, Portugal
- Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Faculdade de Medicina da Universidade do Porto, 4200-450 Porto, Portugal
| | - Demetrius Albanes
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA
| | - Stephanie J Weinstein
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA
| | - Dominick Parisi
- Information management Services, Inc., Silver Spring, MD 20904, USA
| | - David Zaridze
- Department of Clinical Epidemiology, N.N. Blokhin National Medical Research Center for Oncology, 115478 Moscow, Russia
| | - Dmitry Maximovitch
- Department of Clinical Epidemiology, N.N. Blokhin National Medical Research Center for Oncology, 115478 Moscow, Russia
| | - Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Cantabria-IDIVAL, 39005 Santander, Spain
| | - José Juan Jiménez-Moleón
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain
- Departamento de Medicina Preventiva y Salud Pública, Universidad de Granada, 18010 Granada, Spain
- Instituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain
| | - Jesus Vioque
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain
- Instituto de Investigación Sanitaria y Biomédica de Alicante, Universidad Miguel Hernandez (ISABIAL-UMH), 03202 Alicante, Spain
| | - Manoli Garcia de la Hera
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain
- Instituto de Investigación Sanitaria y Biomédica de Alicante, Universidad Miguel Hernandez (ISABIAL-UMH), 03202 Alicante, Spain
| | - Maria Paula Curado
- Centro Internacional de Pesquisa, A. C. Camargo Cancer Center, São Paulo 01508-010, Brazil
| | - Emmanuel Dias-Neto
- Centro Internacional de Pesquisa, A. C. Camargo Cancer Center, São Paulo 01508-010, Brazil
| | | | | | - Mary H Ward
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA
| | - Shoichiro Tsugane
- Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo 104-0045, Japan
- National Institute of Health and Nutrition, National Institutes of Biomedical Innovation, Health and Nutrition, Tokyo 162-8636, Japan
| | - Akihisa Hidaka
- Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo 104-0045, Japan
| | - Areti Lagiou
- Department of Public and Community Health, School of Public Health, University of West Attica, 11521 Athens, Greece
| | - Pagona Lagiou
- Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
| | - Zuo-Feng Zhang
- Department of Epidemiology, UCLA Fielding School of Public Health, Jonsson Comprehensive Cancer Center, Los Angeles, CA 10833, USA
| | | | - Anna Karakatsani
- Hellenic Health Foundation, 11527 Athens, Greece
- 2nd Pulmonary Medicine Department, Medical School, "ATTIKON" University Hospital, National and Kapodistrian University of Athens, 11527 Haidari, Greece
| | - Maria Constanza Camargo
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA
| | - Carlo La Vecchia
- Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy
| | - Paolo Boffetta
- Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy
- Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY 11794, USA
| |
Collapse
|
14
|
Llorca J, Dierssen-Sotos T, Carrasco-Marín E, Guerra-Díez JL, Lechosa-Muñiz C, Paz-Zulueta M, Gómez-Acebo I, Cabero-Perez MJ. Time of leaving work pregnancy results during COVID-19 pandemic. The MOACC-19 cohort from Spain. BMC Public Health 2023; 23:441. [PMID: 36882824 PMCID: PMC9990053 DOI: 10.1186/s12889-023-15357-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2022] [Accepted: 03/01/2023] [Indexed: 03/09/2023] Open
Abstract
BACKGROUND COVID-19 pandemic has changed the way pregnancies have been controlled as well as working conditions. In countries with paid leave of work, leaving earlier has been a relevant measure for controlling the pandemic. No study has been published on factors associated with earlier leaving work in pregnancy and the consequences it could have on pregnancy outcomes. OBJECTIVE We aimed to identify woman and pregnancy characteristics associated with leaving work earlier and its consequences on pregnancy results. METHOD A cohort study was carried out in Cantabria, Northern Spain, including 760 women who were pregnant in 2020 and were working at the beginning of their pregnancy. Data on pregnancy characteristics and results were obtained from medical records and gestational age at leaving work was self-reported. In a logistic regression analysis, leaving work before 26th week of pregnancy was the main effect variable. RESULTS Several factors were associated with lower probability of leaving work before 26th week, including university studies (OR = 0.49, 95% CI: 0.36, 0.68), having presential work (OR = 0.57, 95% CI: 0.40, 0.81), women born in non-European countries (OR = 0.55, 95% CI: 0.30, 1.01) and non-smokers (OR for smokers = 1.79, 95% CI: 1.12, 2.87). Neither type of delivery, gestational age at delivery nor other pregnancy results were associated with the gestational age of leaving work. CONCLUSION Several pregnancy and women characteristics were associated with leaving work earlier in the COVID-19 pandemic, although it was not associated with any pregnancy outcome.
Collapse
Affiliation(s)
- Javier Llorca
- Universidad de Cantabria- CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain
| | - Trinidad Dierssen-Sotos
- Universidad de Cantabria-IDIVAL-CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain. .,Facultad de Medicina, Universidad de Cantabria, Santander, 39792, Spain.
| | | | | | | | | | - Inés Gómez-Acebo
- Universidad de Cantabria-IDIVAL-CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain
| | - María J Cabero-Perez
- Hospital Universitario Marqués de Valdecilla-Universidad de Cantabria, Santander, Spain
| | | |
Collapse
|
15
|
Terán AÁ, Palazuelos C, Dierssen-Sotos T, Alonso-Molero J, Llorca J, Gómez-Acebo I. Evolution of Medical Students' Perception of the Patient's Right to Privacy. Int J Environ Res Public Health 2022; 19:11067. [PMID: 36078783 PMCID: PMC9517786 DOI: 10.3390/ijerph191711067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 07/21/2022] [Revised: 08/26/2022] [Accepted: 08/31/2022] [Indexed: 06/15/2023]
Abstract
During clinical rotations, medical students experience situations in which the patients' right to privacy may be violated. The aim of this study is to analyze medical students' perception of clinical situations that affect patients' right to privacy, and to look for the influential factors that may contribute to the infringement on their rights, such as the students' age, sex, academic year or parents' educational level. A cross-sectional study was conducted with a survey via "Google Drive". It consisted of 16 questions about personal information, 24 questions about their experience when rotating and 21 questions about their opinion concerning several situations related to the right to privacy. A total of 129 medical students from various Spanish medical schools participated. Only 31% of 3rd-6th year students declared having signed a confidentiality agreement when starting their clinical practice, and most students (52%) reported that doctors "sometimes", "rarely" or "never" introduce themselves and the students when entering the patients' rooms. Additionally, about 50% of all students reported that they would take a picture of a patient's hospitalization report without his/her (consent), which would be useful for an assignment. Important mistakes during medical students' rotations have been observed, as well as a general lack of knowledge regarding patient's right to privacy among Spanish medical students. Men and older students showed better knowledge of current legislation, as well as those whose parents were both university-educated and those in higher academic years.
Collapse
Affiliation(s)
| | - Camilo Palazuelos
- Faculty of Medicine, Universidad de Cantabria, 39011 Santander, Spain
| | - Trinidad Dierssen-Sotos
- Faculty of Medicine, Universidad de Cantabria, 39011 Santander, Spain
- IDIVAL Instituto de Investigación Sanitaria Valdecilla, 39011 Santander, Spain
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
| | - Jessica Alonso-Molero
- Faculty of Medicine, Universidad de Cantabria, 39011 Santander, Spain
- IDIVAL Instituto de Investigación Sanitaria Valdecilla, 39011 Santander, Spain
| | - Javier Llorca
- Faculty of Medicine, Universidad de Cantabria, 39011 Santander, Spain
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
| | - Inés Gómez-Acebo
- Faculty of Medicine, Universidad de Cantabria, 39011 Santander, Spain
- IDIVAL Instituto de Investigación Sanitaria Valdecilla, 39011 Santander, Spain
- Centro de Investigación Biomédica en Red Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
| |
Collapse
|
16
|
Blanco Muñoz J, Lope V, Fernández de Larrea-Baz N, Gómez-Ariza JL, Dierssen-Sotos T, Fernández-Tardón G, Aragonés N, Amiano P, Gómez-Acebo I, Tardón A, Grau-Pérez M, García-Barrera T, Kogevinas M, Pollán M, Pérez-Gómez B. Levels and determinants of urinary cadmium in general population in Spain: Metal-MCC-Spain study. Environ Res 2022; 210:112959. [PMID: 35189102 DOI: 10.1016/j.envres.2022.112959] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Revised: 01/17/2022] [Accepted: 02/12/2022] [Indexed: 06/14/2023]
Abstract
BACKGROUND Cadmium is a ubiquitous and persistent metal, associated with different harmful health effects and with increased morbidity and mortality. Understanding the main sources of exposure is essential to identify at risk populations and to design public health interventions. OBJECTIVE To evaluate cadmium exposure in a random-sample of general adult population from three regions of Spain, assessed by the urinary cadmium (U-Cd) concentration, and to identify its potential determinants and sex-specific differences, including sociodemographic, lifestyle and dietary factors. MATERIALS AND METHODS We measured U-Cd (μg/g creatinine) in single urine spot samples from 1282 controls enrolled in the multicase-control study in common tumors in Spain (MCC-Spain) with inductively coupling plasma-mass spectrometry equipped with an octopole reaction systems (ICP-ORS-MS). The association between sociodemographic, lifestyle, and dietary characteristics and U-Cd concentrations was evaluated using geometric mean ratios (GMR) estimated by multiple log-linear regression models. RESULTS Overall, geometric mean U-Cd concentration was 0.40 (95%CI: 0.38, 0.41) μg/g creatinine. Levels were higher in women than in men (GMR]: 1.19; 95%CI: 1.07, 1.32), and increased with age in males (ptrend< 0.001). Cigarette smoking was clearly associated to U-Cd levels (GMRformer vs non-smokers: 1.16; 95%CI: 1.05, 1.29; GMRcurrent vs non-smokers: 1.42; 95%CI: 1.26, 1.60); the relationship with secondhand tobacco exposure in non-smokers, was restricted to women (pinteraction = 0.02). Sampling season and region also seemed to influence U-Cd concentrations, with lower levels in summer (GMRsummer vs average: 0.79; 95%CI: 0.71, 0.88), and higher levels in North-Spain Asturias (GMRAsturias vs average: 1.13; 95%CI: 1.04, 1.23). Regarding diet, higher U-Cd concentration was associated with eggs consumption only in men (pinteraction = 0.04), just as rice intake was associated in women (pinteraction = 0.03). CONCLUSION These results confirmed that tobacco exposure is the main modifiable predictor of U-Cd concentrations, and remark that the role of dietary/sociodemographic factors on U-Cd levels may differ by sex.
Collapse
Affiliation(s)
- Julia Blanco Muñoz
- Department of Environmental Health. Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública. Cuernavaca, Morelos, Mexico
| | - Virginia Lope
- Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III, Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain.
| | - Nerea Fernández de Larrea-Baz
- Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III, Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain
| | - José Luis Gómez-Ariza
- Department of Chemistry, Faculty of Experimental Sciences, Campus El Carmen, University of Huelva. Research Center for Natural Resources, Health and the Environment, Campus El Carmen, University of Huelva, Av. del Tres de Marzo, 3, 21007, Huelva, Spain
| | - Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Universidad de Cantabria - IDIVAL, 39011, Santander, Spain
| | - Guillermo Fernández-Tardón
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Institute of Health Research of the Principality of Asturias (ISPA)/University of Oviedo, 03301, Oviedo, Spain
| | - Nuria Aragonés
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Epidemiology Section, Public Health Division, Department of Health of Madrid, Madrid, Spain. C/San Martín de Porres, 6, 28035, Madrid, Spain
| | - Pilar Amiano
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Sub-Directorate for Public Health and Addictions of Gipuzkoa, Ministry of Health of the Basque Government, 20013, San Sebastian, Spain; Epidemiology and Public Health Area, Biodonostia Health Research Institute, 20014, San Sebastian, Spain
| | - Inés Gómez-Acebo
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Universidad de Cantabria - IDIVAL, 39011, Santander, Spain
| | - Adonina Tardón
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Institute of Health Research of the Principality of Asturias (ISPA)/University of Oviedo, 03301, Oviedo, Spain
| | - María Grau-Pérez
- Department of Preventive Medicine and Public Health, Universidad Autónoma de Madrid/ IdiPAZ, 28049, Madrid, Spain; Cardiometabolic and Renal Risk Unit, Biomedical Research Institute INCLIVA, Valencia, Spain
| | - Tamara García-Barrera
- Department of Chemistry, Faculty of Experimental Sciences, Campus El Carmen, University of Huelva. Research Center for Natural Resources, Health and the Environment, Campus El Carmen, University of Huelva, Av. del Tres de Marzo, 3, 21007, Huelva, Spain
| | - Manolis Kogevinas
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Instituto de Salud Global de Barcelona (ISGlobal), 08003, Barcelona, Spain; Hospital del Mar Medical Research Institute (IMIM), 08003, Barcelona, Spain
| | - Marina Pollán
- Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III, Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain
| | - Beatriz Pérez-Gómez
- Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Instituto de Salud Carlos III, Av/Monforte de Lemos, 5, 28029, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III. Av/Monforte de Lemos, 5, 28029, Madrid, Spain
| |
Collapse
|
17
|
Domínguez-Casas LC, Rodriguez Cundin P, Dierssen-Sotos T, Vegas-Revenga N, Corrales A, González-Gay MA, Blanco R. AB0279 HERPES ZOSTER IN RHEUMATOID ARTHRITIS. PROSPECTIVE SINGLE UNIVERSITY CENTER STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundPatients with Rheumatoid arthritis (RA) have an increased risk of infections due to the disease itself, and/or immunosuppressive therapy. The risk of herpes zoster (HZ) including disseminated HZ is also increased(1)ObjectivesIn an unselected series of RA patientswe assessa)prevalence, b)general features and c) predictive factors of HZ.MethodsStudy of 393 RA patients included in the prospective vaccination program of the Preventive Medicine and Rheumatology department of a University hospital, from October 2011 to October 2016. The minimum follow-up was of 12 months; therefore, it was made until December 2020. HZ vaccination is not included in our vaccination program.RA was diagnosed according to the ACR/EULAR 2010 criteria. HZ was diagnosed if presented: characteristic skin rash and blisters, paresthesia and local pain, in one (localized) or more dermatomes (generalized).Information on patients and HZ characteristics was retrieved from the hospital and general physician records.ResultsWe studied 393 patients (310 women), mean age 61.5±11.9 years. They were followed-up during a mean period of 82.6±15.2 months(range; 50 months-9 years).HZ infection was observed in 31 of 393 patients (7.9%) (26 women); mean age 67.5±11.6ys. Prevalence of HZ in this period (122months) was 7.88% with an annual incidence rate of 0.73/100 patients/year. A comparison between patients with and without HZ was performed (Table 1).Table 1.Main features of different groupsVariablesRA patientsN= 393RA with HZN=31RA without HZN=362PHZ vs noHZVariables (continued)RA patientsN= 393RA with HZN=31RA without HZN=362PHZ vs noHZAge (years) (men±SD)59.4±12.964.7±11.859.1±12.90.02MTX365 (92.87)29 (93.54)336 (92.81)0.87Sex (women)(%)309(78.62)25 (80.6)284 (78.5)0.95LFN127 (32.31)12 (38.70)115 (31.76)0.42RA Evolution(months) (mean±SD)136.9±109.8155.3±117.0135.30±109.20.33SSZ94 (23.91)7 (22.58)87 (24.03)0.78Hypertension, n(%)165 (42.0)19 (61.3)146 (40.3)0.04Anti-TNFa, n (%)Diabetes Mellitus, n(%)55 (14.0)7 (22.6)48 (13.3)0.24ADA144 (36.6)15 (48.4)129 (35.6)0.22Dislypidemia, n(%)149 (37.9)15 (48.4)134 (37.0)0.29ETN139(35.4)16 (51.6)123 (33.9)0.05RAfeatures, n(%)IFX40 (10.1)5 (16.1)35 (9.7)0.25PositiveRF224 (57.0)17 (54.8)207 (57.2)0.95GLM33 (8.4)3 (9.7)30 (8.3)0.74PositiveACPA207 (52.7)13 (41.9)194 (53.6)0.29CZP13 (3.3)1 (3.2)12 (3.3)0.97Erosions145 (36.9)10 (32.3)135 (37.3)0.71Non anti-TNFa n (%)Subcutaneousnodules22 (5.6)1 (4.6)21 (5.8)0.85TCZ134 (34.1)16 (51.6)118 (32.6)0.05Pulmonary fibrosis20 (5.1)3 (9.7)17 (4.7)0.20RTX69 (17.5)9 (29.0)60 (16.7)0.13Associated Sjögren Syndrome20 (5.1)1 (3.2)19 (5.3)0.95ABA55 (13.9)6 (19.3)49 (13.5)0.41Vasculitis23 (5.9)2 (6.5)21 (5.8)0.7SARI2 (5.1)1 (3.2)1 (0.3)0.03RATreatment, n (%)JAK inhibitors n (%)Prednisone139 (35.4)19 (61.3)120 (33.1)0.04BARI32 (8.14)3 (9.67)29 (8.01)0.73Prednisona>5mg/d13 (3.30)5 (16.1)8 (2.20)0.001TOFA17 (4.32)3 (9.67)14 (3.87)0.14ConventionalDMARDsUPA4 (1.01)1 (3.22)3 (0.83)0.20HZ locations were intercostal (n=6), dorsal (5), abdominal (3), lumbar (3), facial (3), cervical (1), gluteus (1), submmamary fold (1), intermmamary fold (1) and upper extremity (1). Main HZ complications were post-herpetic neuralgia (n=7), visual alteration in facial HZ (n=1) and disseminated HZ(n=1).HZ treatment was anitiviral agents (n=23) (brivudine=7; acyclovir 6; famciclovir6; valaciclovir4), topic (n=2) and none (n=6).Predictive factors for HZ(Figure 1) were older age (>65 years), hypertension and treatment with high prednisone dose and antiTNF.Figure 1.Predictive factors for Herpes zosterConclusionHZ is a relative frequent complication of RA. In our series, although are usually localized, post-herpetic neuralgia is relatively frequent. Probably to include HZ vaccine in our vaccination program of RA may be useful.References[1]Robert Harrington et al., J Inflamm Res, 2020 14;13:519-531Disclosure of InterestsNone declared
Collapse
|
18
|
Domínguez-Casas LC, Rodriguez Cundin P, Dierssen-Sotos T, Vegas-Revenga N, Corrales A, González-Gay MA, Blanco R. AB0280 SERIOUS INFECTIONS-RELATED HOSPITALIZATION IN RHEUMATOID ARTHRITIS. OBSERVATIONAL STUDY OF 392 PATIENTS FROM A SINGLE UNIVERSITY CENTER. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundPatients with Rheumatoid Arthritis (RA) have an increased risk of infections. This may belinked to disease-related, the immunosuppressive therapy and the co-morbidities.Objectivesin an unselected group of RA patients, our aim was to assess the a)incidence b)features of disease and c)predictive factors of serious infections-related hospitalization.MethodsObservational study of all patients diagnosed with RA that were included in the vaccination program of our university hospital between October2011 and October 2016.The minimum follow-up was of 12 months; therefore, it was made until December 2020.Patients with serious infections-related hospitalization were a) compared with those not requiring hospital admission and, b)identified predictive factors (multivariate analysis adjusted by age and sex).Vaccination program in our hospital includes vaccination for Influenza, Streptococcus pneumoniae and Haemophilus influenzae.Information on patients, infections and hospitalizations was retrieved from the hospital and general physician records.ResultsWe studied 392RApatients (309women/83men); mean age 63.1±13.7 years.After a mean follow-up of 71.8±20.6 months, in 88 of 392patients (22.4%) (60 women) 187serious infections-related hospitalizations were required. The median [IQR] number of hospitalizations were 1.5 [1-2]. The main serious infections were respiratory (44 patients; 78 hospitalizations), urinary (33 patients; 48 hospitalization), cutaneous (19 patients; 28 hospitalizations), abdominal (17 patients, 20 hospitalizations), septic arthritis (7 patients; 8 hospitalizations), maxillofacial(2 patients, 2 hospitalizations), bacterial endocarditis (2 patients, 2 hospitalizations) and genital (1 patient, 1 hospitalization).Patients with serious infections-related hospitalization were older, with a longer RA, with more co-morbidities (hypertension, hypercholesterolemia diabetes mellitus, and Interstitial lung disease) and with more conventional and biological DMARDS (Table 1).Table 1.Comparative study of different groupsPatientswithserious infections-related hospitalization N=88Patients without serious infections-related hospitalization N=304pDemographic features and comorbiditiesAge (years),mean±SD69.7±11.259.2±12.60.005Women, n (%)60 (68.2)249 (81.9)0.33Active smokers, n (%)41 (46.6)114 (7.5)0.32Hypertension, n (%)56 (63.6)109 (35.8)0.004Hypercholesterolemia, n(%)47 (53.4)101 (33.2)0.02Diebetes Mellitus, n(%)25 (28.4)30 (9.9)0.0002RA featuresDuration of RA (months) mean±SD165.8±130.1128.6±102.60.005Positive RF, n (%)52(59.1)171(56.2)0.80Positive ACPA, n (%)48 (54.5)158 (52.6)0.81Erosive disease, n (%)32 (36.4)113 (51.9)0.89Associated Sjögren Syndrome, n (%)4 (4.5)16 (5.3)0.79Interstitial lung disease n (%)11 (12.5)9 (2.9)0.0008Subcutaneousnodules n (%)6 (6.8)16 (5.3)0.57Prednisone (or equivalent) dose mg/day, mean±SD5.3±4.53.3±3.80.001Number of convencional DMARDs, mean±SD1.9±1.41.5±1.30.05Number of biologic DMARDs, mean±SD0.1±0.20.1±0.40.03Number of JAK inhibitors, mean±SD69.7±11.259.2±12.60.1The predictive factors for hospitalization were hypertension and Diabetes Mellitus, RA related interstitial lung disease and treatment with biologic DMARDs. (Figure 1)Figure 1.Predictive factors for serious infections-related hospitalizationConclusionDespite to be included in a vaccination program up to 22% of patients required hospitalization due to serious infection. The main predictive factors were co-morbidities, interstitial lung disease and treatment with biologic DMARDs. Serious infections in RA remain to be an unmet need.Disclosure of InterestsNone declared
Collapse
|
19
|
Lozano-Lorca M, Salcedo-Bellido I, Olmedo-Requena R, Castaño-Vinyals G, Amiano P, Shivappa N, Hébert JR, Pérez-Gómez B, Gracia-Lavedan E, Gómez-Acebo I, Molina-Barceló A, Barrios-Rodríguez R, Alguacil J, Fernández-Tardón G, Aragonés N, Dierssen-Sotos T, Romaguera D, Pollán M, Kogevinas M, Jiménez-Moleón JJ. Dietary inflammatory index and prostate cancer risk: MCC-Spain study. Prostate Cancer Prostatic Dis 2022; 25:568-575. [PMID: 35418209 DOI: 10.1038/s41391-022-00532-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 03/02/2022] [Accepted: 03/24/2022] [Indexed: 11/09/2022]
Abstract
BACKGROUND The etiology of prostate cancer (PCa) is not well-known, and the role of diet is not well established. We aimed to evaluate the role of the inflammatory power of the diet, measured by the Dietary Inflammatory Index (DII®), on the risk of PCa. METHODOLOGY A population-based multicase-control (MCC-Spain) study was conducted. Information was collected on sociodemographic characteristics, personal and family antecedents, and lifestyles, including diet from a Food Frequency Questionnaire. The inflammatory potential of the diet was assessed using the energy-adjusted Dietary Inflammatory Index (E-DII) based on 30 parameters (a higher score indicates a higher inflammatory capacity of the diet). Tertiles of E-DII were created using the cut-off points from the control group. The International Society of Urology Pathology (ISUP) was grouped as ISUP 1, ISUP 2, or ISUP 3-5. Unconditional logistic regression models were used to estimate adjusted odds ratios (aOR) and 95% confidence intervals (CI) for the association between E-DII score and PCa risk. RESULTS A total of 928 PCa cases and 1278 population controls were included. Among PCa cases, the mean value of the E-DII score was 0.18 (SD: 1.9) vs. 0.07 (SD: 1.9) in the control group (p = 0.162). Cases with a more pro-inflammatory diet (3rd tertile) had the highest risk of PCa, aORT3vsT1 = 1.30 (95% CI 1.03-1.65) (p-trend = 0.026). When stratifying by ISUP, this risk association was observed only for ISUP 2 and ISUP 3-5, aORT3vsT1 = 1.46 (95% CI 1.02-2.10) and 1.60 (95% CI 1.10-2.34), respectively. CONCLUSION A positive association was observed between consuming a pro-inflammatory diet and PCa in the MCC-Spain population, specifically for an ISUP grade greater or equal than 2.
Collapse
Affiliation(s)
- Macarena Lozano-Lorca
- Universidad de Granada. Departamento de Medicina Preventiva y Salud Pública, Granada, Spain.,Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain
| | - Inmaculada Salcedo-Bellido
- Universidad de Granada. Departamento de Medicina Preventiva y Salud Pública, Granada, Spain. .,Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain. .,Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.
| | - Rocío Olmedo-Requena
- Universidad de Granada. Departamento de Medicina Preventiva y Salud Pública, Granada, Spain.,Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.,Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain
| | - Gemma Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.,Instituto de Salud Global de Barcelona (ISGlobal), Barcelona, Spain.,Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra (UPF), Barcelona, Spain.,IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Pilar Amiano
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.,Public Health Division of Gipuzkoa, Donostia-San Sebastian, Spain
| | - Nitin Shivappa
- Cancer Prevention and Control Program, University of South Carolina, Columbia, SC, USA.,Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA
| | - James R Hébert
- Cancer Prevention and Control Program, University of South Carolina, Columbia, SC, USA.,Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA
| | - Beatriz Pérez-Gómez
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.,Department of Epidemiology for Chronic Diseases, National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
| | - Esther Gracia-Lavedan
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.,Instituto de Salud Global de Barcelona (ISGlobal), Barcelona, Spain.,Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Inés Gómez-Acebo
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.,Department of Preventive Medicine and Public Health, University of Cantabria-IDIVAL, 39011, Santander, Spain
| | | | - Rocío Barrios-Rodríguez
- Universidad de Granada. Departamento de Medicina Preventiva y Salud Pública, Granada, Spain.,Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.,Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain
| | - Juan Alguacil
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.,Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, Huelva, Spain
| | - Guillermo Fernández-Tardón
- Health Research Institute of the Principality of Asturias (ISPA), Oncology Institute, University of Oviedo, Oviedo, Asturias, Spain.,Department of Medicine, University of Oviedo, Oviedo, Spain
| | - Nuria Aragonés
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.,Epidemiology Section, Division of Public Health, Department of Health, Madrid, Spain
| | - Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.,Department of Preventive Medicine and Public Health, University of Cantabria-IDIVAL, 39011, Santander, Spain
| | - Dora Romaguera
- Instituto de Salud Global de Barcelona (ISGlobal), Barcelona, Spain.,Instituto de Investigación Sanitaria Illes Balears (IdISBa), Palma de Mallorca, Spain.,Consortium for Biomedical Research in Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Madrid, Spain
| | - Marina Pollán
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.,Department of Epidemiology for Chronic Diseases, National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
| | - Manolis Kogevinas
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.,Instituto de Salud Global de Barcelona (ISGlobal), Barcelona, Spain.,IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - José-Juan Jiménez-Moleón
- Universidad de Granada. Departamento de Medicina Preventiva y Salud Pública, Granada, Spain. .,Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain. .,Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.
| | | |
Collapse
|
20
|
Álvarez-Álvarez L, Vitelli-Storelli F, Rubín-García M, Aragonés N, Ardanaz E, Castaño-Vinyals G, Obón-Santacana M, Dierssen-Sotos T, Salas-Trejo D, Tardón A, Moleón JJJ, Alguacil J, Chirlaque MD, Pérez-Gómez B, Pollán M, Kogevinas M, Martín V. Relationship between the Risk of Gastric Cancer and Adherence to the Mediterranean Diet According to Different Estimators. MCC-Spain Study. Cancers (Basel) 2021; 13:cancers13215281. [PMID: 34771444 PMCID: PMC8582518 DOI: 10.3390/cancers13215281] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2021] [Revised: 10/18/2021] [Accepted: 10/19/2021] [Indexed: 01/22/2023] Open
Abstract
Simple Summary Dietary habits are one of the factors that influence the development of gastric cancer and, although it has been seen that the Mediterranean diet has a protective effect on this type of cancer, there are different indexes to assess the degree of adherence to this dietary pattern; this implies differences in the results obtained in the reduction of risk. The aim of this work was to assess the effect of adherence to the Mediterranean diet, measured with five different indexes, on the risk of gastric cancer. Abstract The aim was to assess the effect of adherence to the Mediterranean Diet, measured with five different indexes, on the risk of gastric cancer. Data come from the multicase-control study MCC—Spain, which included 354 gastric cancer cases and 3040 controls with data on diet. We used five indexes to evaluate adherence to the Mediterranean diet and assess the association between each pattern with the risk of gastric cancer, using multivariate logistic regression. The analyses were performed for the whole set of gastric cancer cases, by anatomical location (cardia and non-cardia) and by histological type (intestinal and diffuse). According to the used index, a high adherence protects one from gastric cancer (between 48% (aOR = 0.52; CI 95% = 0.28–0.94) and 75% (aOR = 0.25; CI 95% = 0.12–0.52)), from non-cardia (between 48% (aOR = 0.52; CI 95% = 0.36–0.75) and 65% (aOR = 0.35; CI 95% = 0.23–0.52)), and from the intestinal type (between 41% (aOR = 0.59; CI 95% = 0.36–0.95) and 72% (aOR = 0.28; CI 95% = 0.16–0.50)), but not from the diffuse type. In conclusion, high adherence to a Mediterranean diet pattern is a protective factor for the risk of gastric cancer, with greater adherence leading to greater protection.
Collapse
Affiliation(s)
- Laura Álvarez-Álvarez
- Group of Investigation in Interactions Gene-Environment and Health (GIIGAS), Institute of Biomedicine (IBIOMED), University of León, 24071 León, Spain; (L.Á.-Á.); (F.V.-S.); (V.M.)
| | - Facundo Vitelli-Storelli
- Group of Investigation in Interactions Gene-Environment and Health (GIIGAS), Institute of Biomedicine (IBIOMED), University of León, 24071 León, Spain; (L.Á.-Á.); (F.V.-S.); (V.M.)
| | - María Rubín-García
- Group of Investigation in Interactions Gene-Environment and Health (GIIGAS), Institute of Biomedicine (IBIOMED), University of León, 24071 León, Spain; (L.Á.-Á.); (F.V.-S.); (V.M.)
- Correspondence: ; Tel.: +34-653252471
| | - Nuria Aragonés
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, 28029 Madrid, Spain; (N.A.); (E.A.); (G.C.-V.); (T.D.-S.); (D.S.-T.); (A.T.); (J.J.J.M.); (J.A.); (M.D.C.); (B.P.-G.); (M.P.); (M.K.)
- Cancer Epidemiology Section, Public Health Division, Department of Health of Madrid, 28035 Madrid, Spain
| | - Eva Ardanaz
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, 28029 Madrid, Spain; (N.A.); (E.A.); (G.C.-V.); (T.D.-S.); (D.S.-T.); (A.T.); (J.J.J.M.); (J.A.); (M.D.C.); (B.P.-G.); (M.P.); (M.K.)
- Navarra Institute for Health Research (IdiSNA) Navarra Public Health Institute, 31008 Pamplona, Spain
| | - Gemma Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, 28029 Madrid, Spain; (N.A.); (E.A.); (G.C.-V.); (T.D.-S.); (D.S.-T.); (A.T.); (J.J.J.M.); (J.A.); (M.D.C.); (B.P.-G.); (M.P.); (M.K.)
- ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), 08036 Barcelona, Spain
| | - Mireia Obón-Santacana
- Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L’Hospitalet Del Llobregat, 08908 Barcelona, Spain;
| | - Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, 28029 Madrid, Spain; (N.A.); (E.A.); (G.C.-V.); (T.D.-S.); (D.S.-T.); (A.T.); (J.J.J.M.); (J.A.); (M.D.C.); (B.P.-G.); (M.P.); (M.K.)
- Universidad de Cantabria—IDIVAL, 39005 Santander, Spain
| | - Dolores Salas-Trejo
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, 28029 Madrid, Spain; (N.A.); (E.A.); (G.C.-V.); (T.D.-S.); (D.S.-T.); (A.T.); (J.J.J.M.); (J.A.); (M.D.C.); (B.P.-G.); (M.P.); (M.K.)
- Valencian Breast Cancer Screening Program, General Directorate of Public Health, 46020 València, Spain
| | - Adonina Tardón
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, 28029 Madrid, Spain; (N.A.); (E.A.); (G.C.-V.); (T.D.-S.); (D.S.-T.); (A.T.); (J.J.J.M.); (J.A.); (M.D.C.); (B.P.-G.); (M.P.); (M.K.)
- Department of Medicine, University of Oviedo, 33003 Oviedo, Spain
| | - José Juan Jiménez Moleón
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, 28029 Madrid, Spain; (N.A.); (E.A.); (G.C.-V.); (T.D.-S.); (D.S.-T.); (A.T.); (J.J.J.M.); (J.A.); (M.D.C.); (B.P.-G.); (M.P.); (M.K.)
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Hospitales Universitarios de Granada, Universidad de Granada, 18012 Granada, Spain
| | - Juan Alguacil
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, 28029 Madrid, Spain; (N.A.); (E.A.); (G.C.-V.); (T.D.-S.); (D.S.-T.); (A.T.); (J.J.J.M.); (J.A.); (M.D.C.); (B.P.-G.); (M.P.); (M.K.)
- Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, Campus Universitario de El Carmen, 21004 Huelva, Spain
| | - María Dolores Chirlaque
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, 28029 Madrid, Spain; (N.A.); (E.A.); (G.C.-V.); (T.D.-S.); (D.S.-T.); (A.T.); (J.J.J.M.); (J.A.); (M.D.C.); (B.P.-G.); (M.P.); (M.K.)
- Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia University, 30008 Murcia, Spain
| | - Beatriz Pérez-Gómez
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, 28029 Madrid, Spain; (N.A.); (E.A.); (G.C.-V.); (T.D.-S.); (D.S.-T.); (A.T.); (J.J.J.M.); (J.A.); (M.D.C.); (B.P.-G.); (M.P.); (M.K.)
- Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, 28029 Madrid, Spain
| | - Marina Pollán
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, 28029 Madrid, Spain; (N.A.); (E.A.); (G.C.-V.); (T.D.-S.); (D.S.-T.); (A.T.); (J.J.J.M.); (J.A.); (M.D.C.); (B.P.-G.); (M.P.); (M.K.)
- Cancer and Environmental Epidemiology Unit, Department of Epidemiology and Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, 28029 Madrid, Spain
| | - Manolis Kogevinas
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, 28029 Madrid, Spain; (N.A.); (E.A.); (G.C.-V.); (T.D.-S.); (D.S.-T.); (A.T.); (J.J.J.M.); (J.A.); (M.D.C.); (B.P.-G.); (M.P.); (M.K.)
- Institute of Global Health (ISGlobal), 08036 Barcelona, Spain
| | - Vicente Martín
- Group of Investigation in Interactions Gene-Environment and Health (GIIGAS), Institute of Biomedicine (IBIOMED), University of León, 24071 León, Spain; (L.Á.-Á.); (F.V.-S.); (V.M.)
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, 28029 Madrid, Spain; (N.A.); (E.A.); (G.C.-V.); (T.D.-S.); (D.S.-T.); (A.T.); (J.J.J.M.); (J.A.); (M.D.C.); (B.P.-G.); (M.P.); (M.K.)
| |
Collapse
|
21
|
Rodríguez-Díaz M, Alonso-Molero J, Cabero-Perez MJ, Llorca J, Dierssen-Sotos T, Gómez-Acebo I. Pregnancy and Birth Outcomes during the Early Months of the COVID-19 Pandemic: The MOACC-19 Cohort. Int J Environ Res Public Health 2021; 18:10931. [PMID: 34682679 PMCID: PMC8535818 DOI: 10.3390/ijerph182010931] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Revised: 09/29/2021] [Accepted: 10/12/2021] [Indexed: 01/08/2023]
Abstract
The new coronavirus, SARS-CoV-2, is devastating for specific groups of patients, but currently there is not enough information concerning its effects on pregnant women. The purpose of this study is to identify the impact of SARS-CoV-2 infection on pregnancy and the consequences that it could cause. We studied a cohort of pregnant ladies who were tested for SARS-CoV-2 infection by RT-PCR and classified as infected or not infected. The recruitment was carried out in the HUMV hospital, a third-level hospital located in Santander, northern Spain. It started on 23 March 2020 and ended on 14 October 2020. Data from our cohort were compared to another cohort recruited in 2018 at the same hospital. We found that gestational hypertension, placental abruptio, and home exposure to an infected person, among other variables, could be associated with SARS-CoV-2 infection. In conclusion, we consider pregnant women a high-risk group of patients towards a possible SARS-CoV-2 infection, especially those who present with conditions such as gestational hypertension or obesity; moreover, we think that SARS-CoV-2 infection could increase the possibilities of having an abruptio placentae, although this result was found in only a few women, so it requires further confirmation.
Collapse
Affiliation(s)
- Marta Rodríguez-Díaz
- Faculty of Medicine, Universidad de Cantabria, 39011 Santander, Spain; (M.R.-D.); (J.A.-M.); (M.J.C.-P.); (J.L.)
| | - Jéssica Alonso-Molero
- Faculty of Medicine, Universidad de Cantabria, 39011 Santander, Spain; (M.R.-D.); (J.A.-M.); (M.J.C.-P.); (J.L.)
- IDIVAL Instituto de Investigación Sanitaria Valdecilla, 39011 Santander, Spain
| | - María J. Cabero-Perez
- Faculty of Medicine, Universidad de Cantabria, 39011 Santander, Spain; (M.R.-D.); (J.A.-M.); (M.J.C.-P.); (J.L.)
- IDIVAL Instituto de Investigación Sanitaria Valdecilla, 39011 Santander, Spain
- Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain
| | - Javier Llorca
- Faculty of Medicine, Universidad de Cantabria, 39011 Santander, Spain; (M.R.-D.); (J.A.-M.); (M.J.C.-P.); (J.L.)
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
| | - Trinidad Dierssen-Sotos
- Faculty of Medicine, Universidad de Cantabria, 39011 Santander, Spain; (M.R.-D.); (J.A.-M.); (M.J.C.-P.); (J.L.)
- IDIVAL Instituto de Investigación Sanitaria Valdecilla, 39011 Santander, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
| | - Inés Gómez-Acebo
- Faculty of Medicine, Universidad de Cantabria, 39011 Santander, Spain; (M.R.-D.); (J.A.-M.); (M.J.C.-P.); (J.L.)
- IDIVAL Instituto de Investigación Sanitaria Valdecilla, 39011 Santander, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
| | | |
Collapse
|
22
|
Rubín-García M, Martín V, Vitelli-Storelli F, Moreno V, Aragonés N, Ardanaz E, Alonso-Molero J, Jiménez-Moleón JJ, Amiano P, Fernández-Tardón G, Molina-Barceló A, Alguacil J, Dolores-Chirlaque M, Álvarez-Álvarez L, Pérez-Gómez B, Dierssen-Sotos T, Olmedo-Requena R, Guevara M, Fernández-Villa T, Pollán M, Benavente Y. [Family history of first degree as a risk factor for colorectal cancer]. Gac Sanit 2021; 36:345-352. [PMID: 34272081 DOI: 10.1016/j.gaceta.2021.04.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/27/2020] [Revised: 04/12/2021] [Accepted: 04/23/2021] [Indexed: 11/15/2022]
Abstract
OBJECTIVE To evaluate the association between first-degree family history and colorectal cancer (CRC). METHOD We analyzed data from 2857 controls and 1360 CRC cases, collected in the MCC-Spain project. The adjusted odds ratio (OR) and 95% confidence interval (95% CI) of association with the family history of CRC was estimated by non-conditional logistic regression. RESULTS First-degree relatives doubled the risk of CRC (OR: 2.19; 95% CI: 1.80-2.66), increasing in those with two or more (OR: 4.22; 95% CI: 2.29-7.78) and in those whose relatives were diagnosed before 50 years (OR: 3.24; 95% CI: 1.52-6.91). Regarding the association of the family history with the location, no significant differences were observed between colon and rectum, but there were in the relation of these with the age of diagnosis, having more relatives those diagnosed before 50 years (OR: 4.79; 95% CI: 2.65-8.65). CONCLUSIONS First-degree relatives of CRC increase the chances of developing this tumor, they also increase when the relative is diagnosed at an early age. Therefore, it must be a target population on which to carry out prevention measures.
Collapse
Affiliation(s)
- María Rubín-García
- Grupo de Investigación en Interacciones Gen-Ambiente y Salud, Instituto de Biomedicina (IBIOMED), Universidad de León, León, España
| | - Vicente Martín
- Grupo de Investigación en Interacciones Gen-Ambiente y Salud, Instituto de Biomedicina (IBIOMED), Universidad de León, León, España; CIBER de Epidemiología y Salud Pública (CIBERESP), España.
| | - Facundo Vitelli-Storelli
- Grupo de Investigación en Interacciones Gen-Ambiente y Salud, Instituto de Biomedicina (IBIOMED), Universidad de León, León, España
| | - Víctor Moreno
- CIBER de Epidemiología y Salud Pública (CIBERESP), España; Departamento de Ciencias Clínicas, Facultad de Medicina, Universidad de Barcelona, Barcelona, España; Programa de Analítica de Datos Oncológicos (PADO), Instituto Catalán de Oncología (ICO), L'Hospitalet del Llobregat, Barcelona, España; Programa ONCOBELL, Instituto de Investigación Biomédica de Bellvitge Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, España
| | - Nuria Aragonés
- CIBER de Epidemiología y Salud Pública (CIBERESP), España; Dirección General de Salud Pública, Madrid, España
| | - Eva Ardanaz
- CIBER de Epidemiología y Salud Pública (CIBERESP), España; Instituto de Salud Pública y Laboral de Navarra, Pamplona, España; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, España
| | - Jéssica Alonso-Molero
- CIBER de Epidemiología y Salud Pública (CIBERESP), España; Universidad de Cantabria - IDIVAL, Santander, España
| | - José J Jiménez-Moleón
- CIBER de Epidemiología y Salud Pública (CIBERESP), España; Instituto de Investigación Biosanitaria (ibs.GRANADA), Granada, España; Departamento de Medicina Preventiva y Salud Pública. Universidad de Granada, España
| | - Pilar Amiano
- CIBER de Epidemiología y Salud Pública (CIBERESP), España; Departamento de Salud del Gobierno Vasco, Subdirección de Salud Pública y Adicciones de Gipuzkoa, San Sebastián, España; Instituto de Investigaciones Sanitarias Biodonostia, Grupo de Epidemiología de Enfermedades Crónicas y Transmisibles, San Sebastián, España
| | - Guillermo Fernández-Tardón
- CIBER de Epidemiología y Salud Pública (CIBERESP), España; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), IUOPA, Universidad de Oviedo, Asturias, España
| | | | - Juan Alguacil
- CIBER de Epidemiología y Salud Pública (CIBERESP), España; Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, Campus Universitario de El Carmen, Huelva, España
| | - María Dolores-Chirlaque
- CIBER de Epidemiología y Salud Pública (CIBERESP), España; Departamento de Epidemiología, Consejería de Salud, IMIB-Arrixaca, Universidad de Murcia, El Palmar, Murcia, España
| | - Laura Álvarez-Álvarez
- Grupo de Investigación en Interacciones Gen-Ambiente y Salud, Instituto de Biomedicina (IBIOMED), Universidad de León, León, España
| | - Beatriz Pérez-Gómez
- CIBER de Epidemiología y Salud Pública (CIBERESP), España; Unidad de Cáncer y Epidemiología Ambiental, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, España; Grupo de Investigación en Epidemiología del Cáncer, Área de Oncología y Hematología, IIS Puerta de Hierro, Madrid, España
| | - Trinidad Dierssen-Sotos
- CIBER de Epidemiología y Salud Pública (CIBERESP), España; Universidad de Cantabria - IDIVAL, Santander, España
| | - Rocío Olmedo-Requena
- CIBER de Epidemiología y Salud Pública (CIBERESP), España; Instituto de Investigación Biosanitaria (ibs.GRANADA), Granada, España; Departamento de Medicina Preventiva y Salud Pública. Universidad de Granada, España
| | - Marcela Guevara
- CIBER de Epidemiología y Salud Pública (CIBERESP), España; Instituto de Salud Pública y Laboral de Navarra, Pamplona, España; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, España
| | - Tania Fernández-Villa
- Grupo de Investigación en Interacciones Gen-Ambiente y Salud, Instituto de Biomedicina (IBIOMED), Universidad de León, León, España
| | - Marina Pollán
- CIBER de Epidemiología y Salud Pública (CIBERESP), España; Unidad de Cáncer y Epidemiología Ambiental, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, España
| | - Yolanda Benavente
- CIBER de Epidemiología y Salud Pública (CIBERESP), España; Programa de Recerca en Epidemiologia del Càncer, Institut Català d'Oncologia (IDIBELL), L'Hospitalet de Llobregat, Barcelona, España
| |
Collapse
|
23
|
Domínguez L, Rodriguez Cundin P, Dierssen-Sotos T, Calvo-Río V, Vegas-Revenga N, Corrales A, Palmou-Fontana N, Prieto-Peña D, Calderón-Goercke M, González-Gay MA, Blanco R. POS1467-HPR SEVERE RESPIRATORY INFECTIONS IN RHEUMATOID ARTHRITIS PATIENTS WITH BIOLOGIC THERAPY. COMPARATIVE STUDY BETWEEN VACCINATED AND NON VACCINATED PATIENTS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Rheumatoid arthritis (RA) patients are at increased risk of severe infections due to the disease itself, and the immunosuppressive treatment. Vaccination programs are designed to decrease the risk of infections.Objectives:In patients with RA treated with biologic therapy (BT) our aim was to assess a) the incidence of severe respiratory infections and b) to compare the risk between vaccinated and non vaccinated patients.Methods:Observational study of 431 patients diagnosed with RA that iniciated BT. One group of patients participated in a vaccination program from October 2011 to October 2016 (Group 1). The other group was not included in the vaccination program (Group 2). The follow-up was made until June 2017 with a minimum follow-up period of 8 months and a maximum of 5.5 years.Information on severe respiratory infections, defined as those that required hospitalization or at least one dose of intravenous antibiotic treatment at the emergency room, was retrieved from the hospital medical records.Results:We studied 431 patients (335 women/96 men); mean age 63.4±13.7 years. In the vaccination program (group 1) were included 299 (69.37%) patients and in the group 2 132 patients (30.63%). The main features of both groups are summarized in Table 1.During the follow-up, we registered 299 hospital admissions due to severe respiratory infections in both groups (incidence density 9.9 (95% CI: 6.9-13.6).In group 1, vaccinated patients, this incidence density was reduced to 7.1 (95% CI: 4.1-11.6). Figure 1.The vaccination program reduced the general incidence of severe respiratory infection in 44%.Conclusion:RA patients with BT included in the vaccination program present a lower incidence of severe respiratory infections compared with non vaccinated patients.Table 1.Main general features at BT onsetGroup 1Vaccination programN=299Group 2Non vaccination programN=132pAge (years) mean±SD61.32±13.0467.97±14.170.32Women, n (%)231 (77.3%)105 (79.5%)0.59Duration of RA (months) mean±SD73.24±10.4112.62±60.2Positive RF/ Positive ACPA, n (%)177(59.2)/172 (57.52%)93(70.5%)98 (74.24%)0.02/0,01Erosive disease, n (%)116 (38.8%)70 (53%)0.06Vasculitis, n (%)15 (5%)2 (1.5%)0.08Interstitial lung disease n (%)12 (4%)7 (5.3%)0.54Subcutaneous nodules n (%)16 (5.4%)6 (4.5%)0.72Corticosteroids299 (100%)132 (100%)1Number of conventional DMARDs, mean±SD1.66±0.892.03±1.050.3Figure 1.Disclosure of Interests:None declared
Collapse
|
24
|
Pinto-Carbó M, Peiró-Pérez R, Molina-Barceló A, Vanaclocha-Espi M, Alguacil J, Castaño-Vinyals G, O’Callaghan-Gordo C, Gràcia-Lavedan E, Pérez-Gómez B, Lope V, Aragonés N, Molina AJ, Fernández-Villa T, Gil-Majuelo L, Amiano P, Dierssen-Sotos T, Gómez-Acebo I, Guevara M, Moreno-Iribas C, Obón-Santacana M, Rodríguez-Suárez MM, Salcedo-Bellido I, Delgado-Parrilla A, Marcos-Gragera R, Chirlaque MD, Kogevinas M, Pollán M, Salas D. Social mobility and healthy behaviours from a gender perspective in the Spanish multicase-control study (MCC-Spain). PLoS One 2021; 16:e0251447. [PMID: 33979362 PMCID: PMC8115806 DOI: 10.1371/journal.pone.0251447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Accepted: 04/26/2021] [Indexed: 11/19/2022] Open
Abstract
There is evidence for the influence of socioeconomic status (SES) on healthy behaviours but the effect of social mobility (SM) is not yet well known. This study aims to analyse the influence of origin and destination SES (O-SES and D-SES) and SM on healthy behaviours and co-occurrence, from an integrated gender and age perspective. Data were obtained from the controls of MCC-Spain between 2008-2013 (3,606 participants). Healthy behaviours considered: healthy diet, moderate alcohol consumption, non-smoking and physical activity. SM was categorized as stable high, upward, stable medium, downward or stable low. Binary and multinomial logistic regression models were adjusted. Those aged <65, with a low O-SES, D-SES and stable low SM are less likely to have healthy behaviours in the case of both women (physically active: OR = 0.65 CI = 0.45-0.94, OR = 0.71 CI = 0.52-0.98, OR = 0.61 CI = 0.41-0.91) and men (non-smokers: OR = 0.44 CI = 0.26-0.76, OR = 0.54 CI = 0.35-0.83, OR = 0.41 CI 0.24-0.72; physically active: OR = 0.57 CI = 0.35-0.92, OR = 0.64 CI = 0.44-0.95, OR = 0.53 CI = 0.23-0.87). However, for those aged ≥65, this probability is higher in women with a low O-SES and D-SES (non-smoker: OR = 8.09 CI = 4.18-15.67, OR = 4.14 CI = 2.28-7.52; moderate alcohol consumption: OR = 3.00 CI = 1.45-6.24, OR = 2.83 CI = 1.49-5.37) and in men with a stable low SM (physically active: OR = 1.52 CI = 1.02-1.26). In the case of men, the same behaviour pattern is observed in those with a low O-SES as those with upward mobility, with a higher probability of co-occurring behaviours (three-to-four behaviours: OR = 2.00 CI = 1.22-3.29; OR = 3.13 CI = 1.31-7.48). The relationship of O-SES, D-SES and SM with healthy behaviours is complex and differs according to age and gender.
Collapse
Affiliation(s)
- M. Pinto-Carbó
- Cancer and Public Health Area, Foundation for the Promotion of the Research in Healthcare and Biomedicine (FISABIO-Salud Pública), Valencia, Valencian Community, Spain
| | - R. Peiró-Pérez
- Inequalities Area, Foundation for the Promotion of the Research in Healthcare and Biomedicine (FISABIO-Salud Pública), Valencia, Valencian Community, Spain
- General Directorate of Public Health, Valencia, Valencian Community, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
| | - A. Molina-Barceló
- Cancer and Public Health Area, Foundation for the Promotion of the Research in Healthcare and Biomedicine (FISABIO-Salud Pública), Valencia, Valencian Community, Spain
| | - M. Vanaclocha-Espi
- Cancer and Public Health Area, Foundation for the Promotion of the Research in Healthcare and Biomedicine (FISABIO-Salud Pública), Valencia, Valencian Community, Spain
| | - J. Alguacil
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Centre for Health and Environmental Research, Huelva University, Huelva, Andalucia, Spain
| | - G. Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Catalonia, Spain
- Universitat Pompeu Fabra, Plaça de la Mercè, Barcelona, Catalonia, Spain
- Hospital del Mar Medical Research Institute, Barcelona, Catalonia, Spain
| | - C. O’Callaghan-Gordo
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Catalonia, Spain
- Universitat Pompeu Fabra, Plaça de la Mercè, Barcelona, Catalonia, Spain
- Faculty of Health Science,Universitat Oberta de Catalunya, Barcelona, Catalonia, Spain
| | - E. Gràcia-Lavedan
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Catalonia, Spain
- Hospital del Mar Medical Research Institute, Barcelona, Catalonia, Spain
| | - B. Pérez-Gómez
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - V. Lope
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - N. Aragonés
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Epidemiology Section, Public Health Division, Department of Health of Madrid, Madrid, Spain
| | - A. J. Molina
- The Research Group in Gene—Environment and Health Interactions, Institute of Biomedicine (IBIOMED), University of León, León, Castilla y León, Spain
| | - T. Fernández-Villa
- The Research Group in Gene—Environment and Health Interactions, Institute of Biomedicine (IBIOMED), University of León, León, Castilla y León, Spain
| | - L. Gil-Majuelo
- Ministry of Health of the Basque Government, Sub-Directorate for Public Health and Addictions of Gipuzkoa, San Sebastián, Gipuzkoa, Spain
- Biodonostia Health Research Institute, Group of Epidemiology of Chronic and Communicable Diseases, San Sebastián, Gipuzkoa, Spain
| | - P. Amiano
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Ministry of Health of the Basque Government, Sub-Directorate for Public Health and Addictions of Gipuzkoa, San Sebastián, Gipuzkoa, Spain
- Biodonostia Health Research Institute, Group of Epidemiology of Chronic and Communicable Diseases, San Sebastián, Gipuzkoa, Spain
| | - T. Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Cantabria University, Santander, Cantabria, Spain
| | - I. Gómez-Acebo
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Cantabria University, Santander, Cantabria, Spain
| | - M. Guevara
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Navarra Public Health Institute, Pamplona, Navarra, Spain
- Navarra Institute for Health Research (IdiSNA), Pamplona, Navarra, Spain
| | - C. Moreno-Iribas
- Navarra Public Health Institute, Pamplona, Navarra, Spain
- Navarra Institute for Health Research (IdiSNA), Pamplona, Navarra, Spain
| | - M. Obón-Santacana
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), Barcelona, Catalonia, Spain
- ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain
| | - M. M. Rodríguez-Suárez
- Preventive Medicine and Public Health Area, Oviedo University, Oviedo, Asturias, Spain
- Central University Hospital of Asturias, Public Health Service of the Principe de Asturias, Oviedo, Asturias, Spain
| | - I. Salcedo-Bellido
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Andalucia, Spain
- Departamento de Medicina Preventiva y Salud Pública, Universidad de Granada, Granada, Andalucia, Spain
| | - A. Delgado-Parrilla
- Centre for Health and Environmental Research, Huelva University, Huelva, Andalucia, Spain
| | - R. Marcos-Gragera
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona, Catalonia, Spain
- Descriptive Epidemiology, Genetics and Cancer Prevention Group [Girona Biomedical Research Institute], Girona, Catalonia, Spain
| | - M. D. Chirlaque
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, El Palmar, Murcia, Spain
| | - M. Kogevinas
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Barcelona Institute for Global Health (ISGlobal), Barcelona, Catalonia, Spain
- Universitat Pompeu Fabra, Plaça de la Mercè, Barcelona, Catalonia, Spain
- Hospital del Mar Medical Research Institute, Barcelona, Catalonia, Spain
| | - M. Pollán
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
- Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - D. Salas
- Cancer and Public Health Area, Foundation for the Promotion of the Research in Healthcare and Biomedicine (FISABIO-Salud Pública), Valencia, Valencian Community, Spain
- General Directorate of Public Health, Valencia, Valencian Community, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBEResp), Madrid, Spain
| |
Collapse
|
25
|
Gil-Calderón J, Alonso-Molero J, Dierssen-Sotos T, Gómez-Acebo I, Llorca J. Burnout syndrome in Spanish medical students. BMC Med Educ 2021; 21:231. [PMID: 33888118 PMCID: PMC8063293 DOI: 10.1186/s12909-021-02661-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Accepted: 04/08/2021] [Indexed: 06/12/2023]
Abstract
BACKGROUND Burnout syndrome is a frequent syndrome related to people that feel a deterioration in their daily activities due to highly demandant psychological requirements in their workplaces. Within last decades, this syndrome has been studied across medical professionals, concluding that stress levels that physicians suffer is high enough to make them develop burnout syndrome. In the case of medical students, there are some recent studies, although with small samples. For this reason, given that this phenomenon may produce a huge impact in medical students' development, the aim of this study is to analyze the influential factors that may contribute to its occurrence. METHODS The necessary information was gathered through a web-based questionnaire, divided in two parts. The first part of the survey included questions related to personal aspects of the students. Burnout related questions (second part) were divided in three subscales to evaluate exhaustion, cynicism, and academic efficacy levels. RESULTS Family support for studying medicine is associated with lower burnout levels in all three scales of the Maslach Burnout Inventory. The number of years spent in the degree show the opposite trend: the more years in the degree, the higher score in all burnout scales. CONCLUSIONS Burnout syndrome is a problem among medical students in Spain that increases with the number of years studying medicine. It should be also noticed that family support and vocational studies are independent factors related to lower levels of burnout.
Collapse
Affiliation(s)
| | - Jéssica Alonso-Molero
- Universidad de Cantabria - IDIVAL, Avda. Herrera Oria s/n, 39011, Santander, Cantabria, Spain.
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
| | - Trinidad Dierssen-Sotos
- Universidad de Cantabria - IDIVAL, Avda. Herrera Oria s/n, 39011, Santander, Cantabria, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Inés Gómez-Acebo
- Universidad de Cantabria - IDIVAL, Avda. Herrera Oria s/n, 39011, Santander, Cantabria, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Javier Llorca
- Universidad de Cantabria, Santander, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| |
Collapse
|
26
|
Gómez-Acebo I, Dierssen-Sotos T, Mirones M, Pérez-Gómez B, Guevara M, Amiano P, Sala M, Molina AJ, Alonso-Molero J, Moreno V, Suarez-Calleja C, Molina-Barceló A, Alguacil J, Marcos-Gragera R, Fernández-Ortiz M, Sanz-Guadarrama O, Castaño-Vinyals G, Gil-Majuelo L, Moreno-Iribas C, Aragonés N, Kogevinas M, Pollán M, Llorca J. Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study. Sci Rep 2021; 11:5375. [PMID: 33686151 PMCID: PMC7970883 DOI: 10.1038/s41598-021-84825-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2020] [Accepted: 01/20/2021] [Indexed: 11/27/2022] Open
Abstract
The St Gallen Conference endorsed in 2013 a series of recommendations on early breast cancer treatment. The main purpose of this article is to ascertain the clinical factors associated with St Gallen-2013 recommendations accomplishment. A cohort of 1152 breast cancer cases diagnosed with pathological stage < 3 in Spain between 2008 and 2013 was begun and then followed-up until 2017/2018. Data on patient and tumour characteristics were obtained from medical records, as well as their first line treatment. First line treatments were classified in three categories, according on whether they included the main St Gallen-2013 recommendations, more than those recommended or less than those recommended. Multinomial logistic regression models were carried out to identify factors associated with this classification and Weibull regression models were used to find out the relationship between this classification and survival. About half of the patients were treated according to St Gallen recommendations; 21% were treated over what was recommended and 33% received less treatment than recommended. Factors associated with treatment over the recommendations were stage II (relative risk ratio [RRR] = 4.2, 2.9-5.9), cancer positive to either progesterone (RRR = 8.1, 4.4-14.9) or oestrogen receptors (RRR = 5.7, 3.0-11.0). Instead, factors associated with lower probability of treatment over the recommendations were age (RRR = 0.7 each 10 years, 0.6-0.8), poor differentiation (RRR = 0.09, 0.04-0.19), HER2 positive (RRR = 0.46, 0.26-0.81) and triple negative cancer (RRR = 0.03, 0.01-0.11). Patients treated less than what was recommended in St Gallen had cancers in stage 0 (RRR = 21.6, 7.2-64.5), poorly differentiated (RRR = 1.9, 1.2-2.9), HER2 positive (RRR = 3.4, 2.4-4.9) and luminal B-like subtype (RRR = 3.6, 2.6-5.1). Women over 65 years old had a higher probability of being treated less than what was recommended if they had luminal B-like, HER2 or triple negative cancer. Treatment over St Gallen was associated with younger women and less severe cancers, while treatment under St Gallen was associated with older women, more severe cancers and cancers expressing HER2 receptors.
Collapse
Affiliation(s)
- Inés Gómez-Acebo
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
- Universidad de Cantabria, Santander, Spain.
- IDIVAL, Santander, Spain.
- Medicina Preventiva y Salud Pública, Facultad de Medicina, Avda. Herrera Oria s/n, 39011, Santander, Cantabria, Spain.
| | - Trinidad Dierssen-Sotos
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Universidad de Cantabria, Santander, Spain
- IDIVAL, Santander, Spain
| | | | - Beatriz Pérez-Gómez
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Marcela Guevara
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Navarra Public Health Institute, Pamplona, Spain
- Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
| | - Pilar Amiano
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Public Health Division of Gipuzkoa, Biodonostia Health Research Institute, Ministry of Health of the Basque Government, San Sebastian, Spain
| | - Maria Sala
- Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Research Network on Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain
| | - Antonio J Molina
- Grupo de Investigación en Interacción Gen-Ambiente-Salud (GIIGAS), Instituto de Biomedicina (IBIOMED), Universidad de León, León, Spain
| | | | - Victor Moreno
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain
- Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
- Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | - Claudia Suarez-Calleja
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Instituto de Investigación Sanitaria del Principado de Asturias-ISPA, Oviedo, Spain
- IUOPA, Universidad de Oviedo, Oviedo, Spain
| | | | - Juan Alguacil
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, Huelva, Spain
| | - Rafael Marcos-Gragera
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona, Spain
| | | | - Oscar Sanz-Guadarrama
- Servicio de Cirugía General, Unidad de Mama, Complejo Asistencial Universitario de León, León, Spain
| | - Gemma Castaño-Vinyals
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- ISGlobal, Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Leire Gil-Majuelo
- Public Health Division of Gipuzkoa, Biodonostia Health Research Institute, Ministry of Health of the Basque Government, San Sebastian, Spain
| | - Conchi Moreno-Iribas
- Navarra Public Health Institute, Pamplona, Spain
- Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
| | - Nuria Aragonés
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Epidemiology Section, Public Health Division, Department of Health, Madrid, Spain
| | - Manolis Kogevinas
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- ISGlobal, Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Marina Pollán
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Javier Llorca
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- Universidad de Cantabria, Santander, Spain
| |
Collapse
|
27
|
Romaguera D, Fernández-Barrés S, Gracia-Lavedán E, Vendrell E, Azpiri M, Ruiz-Moreno E, Martín V, Gómez-Acebo I, Obón M, Molinuevo A, Fresán U, Molina-Barceló A, Olmedo-Requena R, Tardón A, Alguacil J, Solans M, Huerta JM, Ruiz-Dominguez JM, Aragonés N, Fernández-Villa T, Dierssen-Sotos T, Moreno V, Guevara M, Vanaclocha-Espi M, Lozano-Lorca M, Fernández-Tardón G, Castaño-Vinyals G, Pérez-Gómez B, Molina AJ, Llorca J, Gil L, Castilla J, Pollán M, Kogevinas M, Amiano P. Consumption of ultra-processed foods and drinks and colorectal, breast, and prostate cancer. Clin Nutr 2021; 40:1537-1545. [PMID: 33743289 DOI: 10.1016/j.clnu.2021.02.033] [Citation(s) in RCA: 39] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2020] [Revised: 02/12/2021] [Accepted: 02/14/2021] [Indexed: 12/11/2022]
Abstract
AIMS To study whether the consumption of ultra-processed foods and drinks is associated with breast, colorectal, and prostate cancers. METHODS Multicentric population-based case-control study (MCC-Spain) conducted in 12 Spanish provinces. Participants were men and women between 20 and 85 years of age with diagnoses of colorectal (n = 1852), breast (n = 1486), or prostate cancer (n = 953), and population-based controls (n = 3543) frequency-matched by age, sex, and region. Dietary intake was collected using a validated food frequency questionnaire. Foods and drinks were categorized according to their degree of processing based on the NOVA classification. Unconditional multivariable logistic regression was used to evaluate the association between ultra-processed food and drink consumption and colorectal, breast, and prostate cancer. RESULTS In multiple adjusted models, consumption of ultra-processed foods and drinks was associated with a higher risk of colorectal cancer (OR for a 10% increase in consumption: 1.11; 95% CI 1.04-1.18). The corresponding odds for breast (OR 1.03; 95% CI 0.96-1.11) and prostate cancer (OR 1.02; 95% CI 0.93-1.12) were indicative of no association. CONCLUSIONS Results of this large population-based case-control study suggest an association between the consumption of ultra-processed foods and drinks and colorectal cancer. Food policy and public health should include a focus on food processing when formulating dietary guidelines.
Collapse
Affiliation(s)
- Dora Romaguera
- Instituto de Salud Global de Barcelona (ISGlobal), Barcelona, Spain; Instituto de Investigación Sanitaria Illes Balears (IdISBa), Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Spain.
| | - Sílvia Fernández-Barrés
- Instituto de Salud Global de Barcelona (ISGlobal), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
| | - Esther Gracia-Lavedán
- Instituto de Salud Global de Barcelona (ISGlobal), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
| | - Eva Vendrell
- Faculty of Health Sciences, Universitat Oberta de Catalunya (Open University of Catalonia, UOC), 08018, Barcelona, Spain.
| | - Mikel Azpiri
- Public Health Division of Gipuzkoa, Biodonostia Research Institute, San Sebastian, Spain.
| | - Emma Ruiz-Moreno
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Cancer & Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
| | - Vicente Martín
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; The Research Group in Gene - Environment and Health Interactions (GIIGAS)/Institut of Biomedicine (IBIOMED), Universidad de León, León, Spain; Faculty of Health Sciences, Department of Biomedical Sciences, Area of Preventive Medicine and Public Health, Universidad de León, Spain.
| | - Inés Gómez-Acebo
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Universidad de Cantabria - IDIVAL, Santander, Spain.
| | - Mireia Obón
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, Spain; Bellvitge Biomedical Research Institute - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
| | - Amaia Molinuevo
- Public Health Division of Gipuzkoa, Biodonostia Research Institute, San Sebastian, Spain.
| | - Ujué Fresán
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Navarra Public Health Institute, Pamplona, Spain.
| | - Ana Molina-Barceló
- Cancer and Public Health Area, FISABIO - Public Health, Valencia, Spain.
| | - Rocío Olmedo-Requena
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Department of Preventive Medicine and Public Health, School of Medicine, University of Granada, Spain; Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Spain.
| | - Adonina Tardón
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Department of Medicine, University of Oviedo, Oviedo, Spain.
| | - Juan Alguacil
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, Huelva, Spain.
| | - Marta Solans
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, Girona, Spain.
| | - Jose M Huerta
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain.
| | | | - Nuria Aragonés
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Epidemiology Section, Public Health Division, Department of Health, Madrid, Spain.
| | - Tania Fernández-Villa
- The Research Group in Gene - Environment and Health Interactions (GIIGAS)/Institut of Biomedicine (IBIOMED), Universidad de León, León, Spain; Faculty of Health Sciences, Department of Biomedical Sciences, Area of Preventive Medicine and Public Health, Universidad de León, Spain.
| | - Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Universidad de Cantabria - IDIVAL, Santander, Spain.
| | - Victor Moreno
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, Spain; Bellvitge Biomedical Research Institute - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain.
| | - Marcela Guevara
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Navarra Public Health Institute, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
| | | | - Macarena Lozano-Lorca
- Department of Preventive Medicine and Public Health, School of Medicine, University of Granada, Spain.
| | - Guillermo Fernández-Tardón
- Department of Medicine, University of Oviedo, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Spain.
| | - Gemma Castaño-Vinyals
- Instituto de Salud Global de Barcelona (ISGlobal), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
| | - Beatriz Pérez-Gómez
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Cancer & Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
| | - Antonio J Molina
- The Research Group in Gene - Environment and Health Interactions (GIIGAS)/Institut of Biomedicine (IBIOMED), Universidad de León, León, Spain; Faculty of Health Sciences, Department of Biomedical Sciences, Area of Preventive Medicine and Public Health, Universidad de León, Spain.
| | - Javier Llorca
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Universidad de Cantabria - IDIVAL, Santander, Spain.
| | - Leire Gil
- Public Health Division of Gipuzkoa, Biodonostia Research Institute, San Sebastian, Spain.
| | - Jesús Castilla
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Navarra Public Health Institute, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
| | - Marina Pollán
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Cancer & Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
| | - Manolis Kogevinas
- Instituto de Salud Global de Barcelona (ISGlobal), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
| | - Pilar Amiano
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Public Health Division of Gipuzkoa, Biodonostia Research Institute, San Sebastian, Spain.
| |
Collapse
|
28
|
Erasun D, Alonso-Molero J, Gómez-Acebo I, Dierssen-Sotos T, Llorca J, Schneider J. Low birth weight trends in Organisation for Economic Co-operation and Development countries, 2000-2015: economic, health system and demographic conditionings. BMC Pregnancy Childbirth 2021; 21:13. [PMID: 33407233 PMCID: PMC7789240 DOI: 10.1186/s12884-020-03484-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2020] [Accepted: 12/08/2020] [Indexed: 03/11/2023] Open
Abstract
Background Low birth weight rates are increasing in both developed and developing countries. Although several maternal factors have been identified as associated with low birth weight, little is known of economic or organization factors influencing this increase. This study aims to ascertain the twenty-first century relationships between the contextual country factors and low birth weight rates. Methods We analyse trends of low birth weight rates in Organisation for Economic Co-operation and Development (OECD) countries. Data from 2000 to 2015 were obtained from the OECD data base. Their relationships with demographic and economic variables, health habits, woman-related preventive measures, health care system organization and funding, health care work force and obstetric care were analysed using random-effects linear regression. Results Low birth weight rates are higher in Southern Europe (7.61%) and lower in Northern Europe (4.68%). Low birth weight rates escalated about 20% in Southern Europe and to less extent in Easter Europe (7%) and Asian/Oceanian countries, while remained stable in America, Central Europe and Northern Europe. Investment in health care, private health system coverage, ratios of paediatricians and obstetricians, average length of admission due to pregnancy or birth and Caesarean section rate were associated with higher low birth weight rates. Factors associated with lower low birth weight rates were health care coverage, public health system coverage, hospitals per million inhabitants, and ratios of health care workers, physicians, midwives and nurses. Conclusions In OECD countries, LBW rates are related to contextual country characteristics such as GDP per capita, which is inversely related to LBW rate. Health care system factors, including health care coverage or investment in public health system, are directly associated with lower LBW rates. Supplementary Information The online version contains supplementary material available at 10.1186/s12884-020-03484-9.
Collapse
Affiliation(s)
- Diego Erasun
- University Hospital Marqués de Valdecilla, Santander, Spain
| | - Jéssica Alonso-Molero
- Department of Preventive Medicine and Public Health, University of Cantabria, Avda. Herrera Oria s/n, 39011, Santander, Spain. .,IDIVAL, Santander, Spain. .,CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
| | - Inés Gómez-Acebo
- Department of Preventive Medicine and Public Health, University of Cantabria, Avda. Herrera Oria s/n, 39011, Santander, Spain.,IDIVAL, Santander, Spain.,CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Trinidad Dierssen-Sotos
- Department of Preventive Medicine and Public Health, University of Cantabria, Avda. Herrera Oria s/n, 39011, Santander, Spain.,IDIVAL, Santander, Spain.,CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Javier Llorca
- Department of Preventive Medicine and Public Health, University of Cantabria, Avda. Herrera Oria s/n, 39011, Santander, Spain.,CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | | |
Collapse
|
29
|
Gómez-Acebo I, Prado SR, De La Mora Á, Puente RZ, de la Roza Varela B, Dierssen-Sotos T, Llorca J. Ocular lesions in hereditary hemorrhagic telangiectasia: genetics and clinical characteristics. Orphanet J Rare Dis 2020; 15:168. [PMID: 32600370 PMCID: PMC7322834 DOI: 10.1186/s13023-020-01433-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Accepted: 06/04/2020] [Indexed: 11/17/2022] Open
Abstract
Background The aim of our study is to study the association between eye lesions in Hereditary Hemorrhagic Telangiectasia (HHT) and other signs of the disease, as well as to characterize its genetics. Methods A cross-sectional study was conducted of a cohort of 206 patients studied in the HHT Unit of Hospital de Sierrallana, a reference centre for Spanish patients with HHT. Odds ratios for several symptoms or characteristics of HHT and ocular lesions were estimated using logistic regression adjusting for age and sex. Results The ocular involvement was associated with being a carrier of a mutation for the ENG gene, that is, suffering from a type 1 HHT involvement (OR = 2.09; 95% CI [1.17–3.72]). p = 0.012). In contrast, patients with ocular lesions have less frequently mutated ACVRL1/ALK1 gene (OR = 0.52; 95% CI [0.30–3.88], p = 0.022). Conclusions In conclusion, half of the patients with HHT in our study have ocular involvement. These eye lesions are associated with mutations in the ENG gene and ACVRL1/ALK1 gene. Thus, the ENG gene increases the risk of ocular lesions, while being a carrier of the mutated ACVRL1/ALK1 gene decreases said risk.
Collapse
|
30
|
Cabero-Pérez MJ, Gómez-Acebo I, Dierssen-Sotos T, Llorca J. [Infection by SARS-CoV-2 in pregnancy and possibility of transmission to neonates: A systematic revision]. Semergen 2020; 46 Suppl 1:40-47. [PMID: 32646729 PMCID: PMC7309772 DOI: 10.1016/j.semerg.2020.06.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Revised: 06/12/2020] [Accepted: 06/17/2020] [Indexed: 01/01/2023]
Abstract
En este trabajo se revisan los artículos publicados sobre COVID-19, embarazo y afectación del neonato hasta el 30 de abril de 2020. Se han encontrado un total de 33 publicaciones que se refieren a 553 gestantes y 456 partos. Los síntomas más frecuentes en la embarazada fueron fiebre, tos y disnea. Cerca de tercios de los partos se realizaron por cesárea; el 5,9% de las mujeres requirieron ingreso en la UCI y el 4% requirieron ventilación mecánica. No se produjo ninguna muerte materna. Hubo prematuridad en el 22,3% de los partos y el neonato requirió ingreso en la UCI en el 38,3%. Solo se informó de una muerte neonatal (0,4%) y de 13 casos de COVID-19 neonatal (3,4%). La información disponible no permite asegurar que la transmisión se produjera por vía transplacentaria.
Collapse
Affiliation(s)
- M J Cabero-Pérez
- Servicio de Pediatría, Hospital Universitario Marqués de Valdecilla, Santander, España; Universidad de Cantabria - IDIVAL, Santander, España
| | - I Gómez-Acebo
- Universidad de Cantabria - IDIVAL, Santander, España; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, España
| | - T Dierssen-Sotos
- Universidad de Cantabria - IDIVAL, Santander, España; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, España
| | - J Llorca
- Universidad de Cantabria - IDIVAL, Santander, España; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, España.
| |
Collapse
|
31
|
Gómez-Acebo I, Dierssen-Sotos T, Palazuelos-Calderón C, Pérez-Gómez B, Amiano P, Guevara M, Molina AJ, Domingo L, Fernández-Ortiz M, Moreno V, Alguacil J, Fernández-Tardón G, Ibáñez J, Marcos-Gragera R, Diaz-Santos M, Alonso MH, Alonso-Molero J, Castaño-Vinyals G, Palomo AG, Ardanaz E, Molinuevo A, Aragonés N, Kogevinas M, Pollán M, Llorca J. Tumour characteristics and survivorship in a cohort of breast cancer: the MCC-Spain study. Breast Cancer Res Treat 2020; 181:667-678. [PMID: 32356254 PMCID: PMC7220874 DOI: 10.1007/s10549-020-05600-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2019] [Accepted: 03/18/2020] [Indexed: 12/18/2022]
Abstract
Purpose The objective of this study is to analyse the relative survival with breast cancer in women diagnosed after new treatments were generalised and to ascertain the current effect that tumour characteristics such as grade, stage or subtype have on survival as well as the new AJCC-pathological prognostic score. Methods The breast cancer MCC-Spain follow-up study is a prospective cohort study of 1685 incident breast cancer cases. Women between 20 and 85 years old were recruited between the years 2008 and 2013 in 18 hospitals located in 10 Spanish provinces and they have been followed until 2017/2018. Relative survival was estimated after 3, 5 and 8 years of follow-up using Ederer II method. In addition, Weibull regression adjusted by age, hospital, grade and stage was used to investigate prognosis factors. Results Among components of TNM staging system, tumour size greater than 50 mm (i.e. T3 or T4) more than doubled the risk of dying, while N3 nodal involvement and presence of metastasis had a huge effect on mortality. The AJCC pathological prognostic score strongly correlated with survival; thus, hazard ratios increased as the score rose, being 2.31, 4.00, 4.94, 7.92, 2.26, 14.9 and 58.9 for scores IB, IIA, IIB, IIIA, IIIB, IIIC and IV, respectively. Conclusion Both TNM staging and histological/molecular biomarkers are associated with overall survival in Spanish women with breast cancer; when both are combined in the AJCC pathological prognosis score, the prognostic value improved with risk indices that increased rapidly as the pathological prognosis score increased Electronic supplementary material The online version of this article (10.1007/s10549-020-05600-x) contains supplementary material, which is available to authorised users.
Collapse
Affiliation(s)
- Inés Gómez-Acebo
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain. .,University of Cantabria - IDIVAL, Santander, Spain. .,Facultad de Medicina, Universidad de Cantabria, Avda. Herrera Oria s/n, 39011, Santander, Spain.
| | - Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,University of Cantabria - IDIVAL, Santander, Spain
| | | | - Beatriz Pérez-Gómez
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Pilar Amiano
- Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
| | - Marcela Guevara
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Navarra Public Health Institute, Pamplona, Spain.,IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - Antonio J Molina
- Instituto de Biomedicina (IBIOMED), Universidad de León, León, Spain
| | - Laia Domingo
- Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Passeig Marítim, 25-29, 08003, Barcelona, Spain.,Research Network On Health Services in Chronic Diseases (REDISSEC), Barcelona, Spain
| | | | - Victor Moreno
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Oncology Data Analytics Program, Hospitalet de Llobregat, Catalan Institute of Oncology (ICO), Barcelona, Spain.,Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.,Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | - Juan Alguacil
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, Huelva, Spain
| | - Guillermo Fernández-Tardón
- Instituto de Investigación Sanitaria del Principado de Asturias-ISPA, UNIOVI and CIBERESP, Oviedo, Spain
| | - Josefa Ibáñez
- Cancer and Public Health Area, FISABIO - Public Health, Valencia, Spain.,General Directorate of Public Health, Valencia, Valencian Community, Spain
| | - Rafael Marcos-Gragera
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Epidemiology Unit and Girona Cancer Registry. Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Av. França, s/n, 17007, Girona, Spain.,Descriptive Epidemiology, Genetics and Cancer Prevention Group, Biomedical Research Institute (IDIBGI), C/ Dr. Castany, s/n, 17190, Salt, Spain
| | - Marian Diaz-Santos
- Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, Huelva, Spain
| | - M Henar Alonso
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Oncology Data Analytics Program, Hospitalet de Llobregat, Catalan Institute of Oncology (ICO), Barcelona, Spain.,Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.,Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | | | - Gemma Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,ISGlobal, Barcelona, Spain.,IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | | | - Eva Ardanaz
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Navarra Public Health Institute, Pamplona, Spain.,IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - Amaia Molinuevo
- Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
| | - Nuria Aragonés
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Epidemiology Section, Department of Health, Public Health Division, Madrid, Spain
| | - Manolis Kogevinas
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,ISGlobal, Barcelona, Spain.,IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Marina Pollán
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Javier Llorca
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,University of Cantabria - IDIVAL, Santander, Spain
| |
Collapse
|
32
|
Gómez-Acebo I, Dierssen-Sotos T, Palazuelos C, Castaño-Vinyals G, Pérez-Gómez B, Amiano P, Fernández-Villa T, Ardanaz E, Suarez-Calleja C, Alguacil J, Molina-Barceló A, Jiménez-Moleón JJ, Molero JA, Roca-Barceló A, Chirlaque MD, Vázquez JPF, Molinuevo A, Aragonés N, Serra MS, Binefa G, Moreno V, Pollán M, Kogevinas M, Llorca J. Changes in individual and contextual socio-economic level influence on reproductive behavior in Spanish women in the MCC-Spain study. BMC Womens Health 2020; 20:72. [PMID: 32293415 PMCID: PMC7160989 DOI: 10.1186/s12905-020-00936-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/05/2019] [Accepted: 03/29/2020] [Indexed: 12/01/2022]
Abstract
Background The association between socioeconomic level and reproductive factors has been widely studied. For example, it is well known that women with lower socioeconomic status (SES) tend to have more children, the age at first-born being earlier. However, less is known about to what extent the great socioeconomic changes occurred in a country (Spain) could modify women reproductive factors. The main purpose of this article is to analyze the influence of individual and contextual socioeconomic levels on reproductive factors in Spanish women, and to explore whether this influence has changed over the last decades. Methods We performed a cross-sectional design using data from 2038 women recruited as population-based controls in an MCC-Spain case-control study. Results Higher parent’s economic level, education level, occupational level and lower urban vulnerability were associated with higher age at first delivery and lower number of pregnancies. These associations were stronger for women born after 1950: women with unfinished primary education had their first delivery 6 years before women with high education if they were born after 1950 (23.4 vs. 29.8 years) but only 3 years before if they were born before 1950 (25.7 vs. 28.0 years). For women born after 1950, the number of pregnancies dropped from 2.1 (unfinished primary school) to 1.7 (high education), whereas it remained almost unchanged in women born before 1950. Conclusions Reproductive behavior was associated with both individual and area-level socio-economic indicators. Such association was stronger for women born after 1950 regarding age at first delivery and number of pregnancies and for women born before 1950 regarding consumption of hormonal contraceptives or postmenopausal therapy.
Collapse
Affiliation(s)
- Inés Gómez-Acebo
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain. .,Facultad de Medicina, Universidad de Cantabria, Avda. Herrera Oria s/n, 39011, Santander, Spain.
| | - Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Facultad de Medicina, Universidad de Cantabria, Avda. Herrera Oria s/n, 39011, Santander, Spain
| | - Camilo Palazuelos
- Facultad de Medicina, Universidad de Cantabria, Avda. Herrera Oria s/n, 39011, Santander, Spain
| | - Gemma Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,ISGlobal, Barcelona, Spain.,IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Beatriz Pérez-Gómez
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.,Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro, IDIPHIM, Madrid, Spain
| | - Pilar Amiano
- Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
| | | | - Eva Ardanaz
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Navarra Public Health Institute, Pamplona, Navarra, Spain.,IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - Claudia Suarez-Calleja
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,IUOPA, Universidad de Oviedo, Oviedo, Asturias, Spain
| | - Juan Alguacil
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, Huelva, Spain
| | | | - José J Jiménez-Moleón
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain
| | - Jessica Alonso Molero
- Facultad de Medicina, Universidad de Cantabria, Avda. Herrera Oria s/n, 39011, Santander, Spain
| | - Aina Roca-Barceló
- Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Government of Catalonia, Catalan Institute of Oncology, Girona, Spain.,MRC-PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
| | - María-Dolores Chirlaque
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia University, Murcia, Spain
| | | | - Amaia Molinuevo
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,BioDonostia Research Institute, San Sebastian, Spain
| | - Nuria Aragonés
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.,Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro, IDIPHIM, Madrid, Spain
| | - Maria Sala Serra
- Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Gemma Binefa
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Catalan Institute of Oncology (ICO) and Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain
| | - Victor Moreno
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Catalan Institute of Oncology (ICO) and Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.,Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | - Marina Pollán
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Manolis Kogevinas
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,ISGlobal, Barcelona, Spain.,IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Javier Llorca
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Facultad de Medicina, Universidad de Cantabria, Avda. Herrera Oria s/n, 39011, Santander, Spain
| |
Collapse
|
33
|
Vitelli-Storelli F, Zamora-Ros R, Molina AJ, Fernández-Villa T, Castelló A, Barrio JP, Amiano P, Ardanaz E, Obón-Santacana M, Gómez-Acebo I, Fernández-Tardón G, Molina-Barceló A, Alguacil J, Marcos-Gragera R, Ruiz-Moreno E, Pedraza M, Gil L, Guevara M, Castaño-Vinyals G, Dierssen-Sotos T, Kogevinas M, Aragonés N, Martín V. Association between Polyphenol Intake and Breast Cancer Risk by Menopausal and Hormone Receptor Status. Nutrients 2020; 12:nu12040994. [PMID: 32260135 PMCID: PMC7231201 DOI: 10.3390/nu12040994] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Revised: 03/27/2020] [Accepted: 04/02/2020] [Indexed: 12/24/2022] Open
Abstract
There is limited evidence of phenolic compounds acting as protective agents on several cancer types, including breast cancer (BC). Nevertheless, some polyphenol classes have not been investigated and there is a lack of studies assessing the effect on menopausal status and hormone receptor status as influenced by these compounds. The objective of this study is to evaluate the association between the intake of all polyphenol classes in relation to the BC risk by menopausal and hormone receptor status. We used data from a population-based multi-case-control study (MCC-Spain) including 1472 BC cases and 1577 controls from 12 different regions of Spain. The odds ratios (ORs) with 95% CI were calculated using logistic regression of mixed effects by quartiles and log2 of polyphenol intakes (adjusted for the residual method) of overall BC, menopausal and receptor status. No associations were found between total intake of polyphenols and BC risk. However, inverse associations were found between stilbenes and all BC risk (ORQ4 vs. Q1: 0.70, 95%CI: 0.56–0.89, Ptrend = 0.001), the consumption of hydroxybenzaldehydes (ORQ4 vs. Q1: 0.75, 95%CI: 0.59–0.93, Ptrend = 0.012) and hydroxycoumarins (ORQ4 vs. Q1: 0.73, 95%CI: 0.57–0.93; Ptrend = 0.005) were also inversely associated. The intake of stilbenes, hydroxybenzaldehydes and hydroxycoumarins can contribute to BC reduction risk on all menopausal and receptor statuses.
Collapse
Affiliation(s)
- Facundo Vitelli-Storelli
- Group of Investigation in Interactions Gene-Environment and Health (GIIGAS)/Institute of Biomedicine (IBIOMED), Universidad de León, 24071 León, Spain; (F.V.-S.); (A.J.M.); (T.F.-V.); (J.P.B.); (V.M.)
| | - Raul Zamora-Ros
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet del Llobregat, 08908 Barcelona, Spain
- Correspondence: ; Tel.: +34-932607401
| | - Antonio J. Molina
- Group of Investigation in Interactions Gene-Environment and Health (GIIGAS)/Institute of Biomedicine (IBIOMED), Universidad de León, 24071 León, Spain; (F.V.-S.); (A.J.M.); (T.F.-V.); (J.P.B.); (V.M.)
| | - Tania Fernández-Villa
- Group of Investigation in Interactions Gene-Environment and Health (GIIGAS)/Institute of Biomedicine (IBIOMED), Universidad de León, 24071 León, Spain; (F.V.-S.); (A.J.M.); (T.F.-V.); (J.P.B.); (V.M.)
| | - Adela Castelló
- School of Medicine, University of Alcalá, 28871 Alcalá de Henares, Madrid, Spain;
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública—CIBERESP), 28029 Madrid, Spain; (P.A.); (E.A.); (I.G.-A.);
(G.F.-T.); (J.A.); (R.M.-G.); (E.R.-M.); (L.G.); (M.G.); (G.C.-V.); (T.D.-S.); (M.K.); (N.A.)
| | - Juan Pablo Barrio
- Group of Investigation in Interactions Gene-Environment and Health (GIIGAS)/Institute of Biomedicine (IBIOMED), Universidad de León, 24071 León, Spain; (F.V.-S.); (A.J.M.); (T.F.-V.); (J.P.B.); (V.M.)
| | - Pilar Amiano
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública—CIBERESP), 28029 Madrid, Spain; (P.A.); (E.A.); (I.G.-A.);
(G.F.-T.); (J.A.); (R.M.-G.); (E.R.-M.); (L.G.); (M.G.); (G.C.-V.); (T.D.-S.); (M.K.); (N.A.)
- Public Health Division of Gipuzkoa, BioDonostia Research Institute, 20014 San Sebastian, Spain
| | - Eva Ardanaz
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública—CIBERESP), 28029 Madrid, Spain; (P.A.); (E.A.); (I.G.-A.);
(G.F.-T.); (J.A.); (R.M.-G.); (E.R.-M.); (L.G.); (M.G.); (G.C.-V.); (T.D.-S.); (M.K.); (N.A.)
- Public Health Institute of Navarra, IdiSNA, 31003 Pamplona, Spain
| | - Mireia Obón-Santacana
- Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L’Hospitalet del Llobregat, 08908 Barcelona, Spain;
- ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, 08908 Barcelona, Spain
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain
| | - Inés Gómez-Acebo
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública—CIBERESP), 28029 Madrid, Spain; (P.A.); (E.A.); (I.G.-A.);
(G.F.-T.); (J.A.); (R.M.-G.); (E.R.-M.); (L.G.); (M.G.); (G.C.-V.); (T.D.-S.); (M.K.); (N.A.)
| | - Guillermo Fernández-Tardón
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública—CIBERESP), 28029 Madrid, Spain; (P.A.); (E.A.); (I.G.-A.);
(G.F.-T.); (J.A.); (R.M.-G.); (E.R.-M.); (L.G.); (M.G.); (G.C.-V.); (T.D.-S.); (M.K.); (N.A.)
- Oncology Institute, University of Oviedo, 33003 Oviedo, Spain
| | - Ana Molina-Barceló
- Cancer and Public Health Area, FISABIO—Public Health, 46035 Valencia, Spain;
| | - Juan Alguacil
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública—CIBERESP), 28029 Madrid, Spain; (P.A.); (E.A.); (I.G.-A.);
(G.F.-T.); (J.A.); (R.M.-G.); (E.R.-M.); (L.G.); (M.G.); (G.C.-V.); (T.D.-S.); (M.K.); (N.A.)
- Centro de Investigación en Salud y Medio Ambiente (CYSMA), Universidad de Huelva, Campus Universitario de El Carmen, 21071 Huelva, Spain
| | - Rafael Marcos-Gragera
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública—CIBERESP), 28029 Madrid, Spain; (P.A.); (E.A.); (I.G.-A.);
(G.F.-T.); (J.A.); (R.M.-G.); (E.R.-M.); (L.G.); (M.G.); (G.C.-V.); (T.D.-S.); (M.K.); (N.A.)
- Catalan Institute of Oncology, Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, 17007 Girona, Spain
- Descriptive Epidemiology, Genetics and Cancer Prevention Group, Biomedical Research Institute (IDIBGI), 17090 Girona, Spain
- Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, 17004 Girona, Spain
| | - Emma Ruiz-Moreno
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública—CIBERESP), 28029 Madrid, Spain; (P.A.); (E.A.); (I.G.-A.);
(G.F.-T.); (J.A.); (R.M.-G.); (E.R.-M.); (L.G.); (M.G.); (G.C.-V.); (T.D.-S.); (M.K.); (N.A.)
- National Center for Epidemiology, Carlos III Institute of Health, 20014 San Sebastián, Spain
| | - Manuela Pedraza
- Department of Oncology, Complejo Asistencial Universitario de León, 24071 León, Spain;
| | - Leire Gil
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública—CIBERESP), 28029 Madrid, Spain; (P.A.); (E.A.); (I.G.-A.);
(G.F.-T.); (J.A.); (R.M.-G.); (E.R.-M.); (L.G.); (M.G.); (G.C.-V.); (T.D.-S.); (M.K.); (N.A.)
- Biodonostia Health Research Institute, 20013 San Sebastian, Spain
| | - Marcela Guevara
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública—CIBERESP), 28029 Madrid, Spain; (P.A.); (E.A.); (I.G.-A.);
(G.F.-T.); (J.A.); (R.M.-G.); (E.R.-M.); (L.G.); (M.G.); (G.C.-V.); (T.D.-S.); (M.K.); (N.A.)
- Public Health Institute of Navarra, IdiSNA, 31003 Pamplona, Spain
| | - Gemma Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública—CIBERESP), 28029 Madrid, Spain; (P.A.); (E.A.); (I.G.-A.);
(G.F.-T.); (J.A.); (R.M.-G.); (E.R.-M.); (L.G.); (M.G.); (G.C.-V.); (T.D.-S.); (M.K.); (N.A.)
- ISGlobal, Barcelona, 08036 Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Campus del Mar, 08003 Barcelona, Spain
| | - Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública—CIBERESP), 28029 Madrid, Spain; (P.A.); (E.A.); (I.G.-A.);
(G.F.-T.); (J.A.); (R.M.-G.); (E.R.-M.); (L.G.); (M.G.); (G.C.-V.); (T.D.-S.); (M.K.); (N.A.)
- Universidad de Cantabria—IDIVAL, 39011 Santander, Spain
| | - Manolis Kogevinas
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública—CIBERESP), 28029 Madrid, Spain; (P.A.); (E.A.); (I.G.-A.);
(G.F.-T.); (J.A.); (R.M.-G.); (E.R.-M.); (L.G.); (M.G.); (G.C.-V.); (T.D.-S.); (M.K.); (N.A.)
- ISGlobal, Barcelona, 08036 Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Campus del Mar, 08003 Barcelona, Spain
| | - Nuria Aragonés
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública—CIBERESP), 28029 Madrid, Spain; (P.A.); (E.A.); (I.G.-A.);
(G.F.-T.); (J.A.); (R.M.-G.); (E.R.-M.); (L.G.); (M.G.); (G.C.-V.); (T.D.-S.); (M.K.); (N.A.)
- Epidemiology Section, Public Health Division, Department of Health of Madrid, 28035 Madrid, Spain
| | - Vicente Martín
- Group of Investigation in Interactions Gene-Environment and Health (GIIGAS)/Institute of Biomedicine (IBIOMED), Universidad de León, 24071 León, Spain; (F.V.-S.); (A.J.M.); (T.F.-V.); (J.P.B.); (V.M.)
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública—CIBERESP), 28029 Madrid, Spain; (P.A.); (E.A.); (I.G.-A.);
(G.F.-T.); (J.A.); (R.M.-G.); (E.R.-M.); (L.G.); (M.G.); (G.C.-V.); (T.D.-S.); (M.K.); (N.A.)
| |
Collapse
|
34
|
Davila-Batista V, Molina AJ, Fernández-Villa T, Romaguera D, Pérez-Gómez B, Vilorio-Marqués L, Dierssen-Sotos T, Altzibar JM, Moreno V, Ardanaz E, Salcedo-Bellido I, Fernández-Tardon G, Capelo R, Salas D, Marcos-Gragera R, Huerta JM, de Sanjosé S, Sierra MÁ, Canga-Presa JM, Gómez-Acebo I, Amiano P, Pollan M, Aragones N, Castaño-Vinyals G, Kogevinas M, Martín V. The Relation of CUN-BAE Index with Body Mass Index and Waist Circumference in Adults Aged 50 to 85 Years: The MCC-Spain Study. Nutrients 2020; 12:E996. [PMID: 32260185 PMCID: PMC7231053 DOI: 10.3390/nu12040996] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2020] [Revised: 03/28/2020] [Accepted: 03/30/2020] [Indexed: 02/07/2023] Open
Abstract
Backgound: Traditional anthropometrics such as body mass index (BMI) or waist circumference (WC) do not fully capture the complex biology of body fat (BF) in the elderly. The Clinica Universidad de Navarra-Body Adiposity Estimator (CUN-BAE) index, based on BMI, is proposed as a better indicator of BF. However, its relation with BMI is not clear. The aim was to compare the agreement between CUN-BAE, BMI, and WC in those aged ≥50 years. Methods: A cross-sectional sample of 3153 Caucasian healthy adults was taken from the MCC-Spain study. The Pearson's correlation and its 95% confidence interval (CI), adiposity distribution, and Kappa Index (95%CI) were calculated. Results: The correlation of CUN-BAE with WC is 0.18 (95%CI 0.14-0.21) and that with BMI is moderate (r 0.58; 95%CI 0.55-0.60), but both increased strongly by sex. Agreement (normal weight/overweight/obesity) of CUN-BAE with BMI is 7% and with WC is 18%. Conclusions: The correlation and the degree of agreement of CUN-BAE with BMI and WC are low in individuals aged over 50, but it is higher by sex. Thus, this different criterion of obesity may have clinical applications. More studies with a gold standard are needed to evaluate the CUN-BAE in elderly adults.
Collapse
Affiliation(s)
- Veronica Davila-Batista
- Research Group on Gene-Environment Interactions and Health (GIIGAS), Instituto de Biomedicina (IBIOMED), University of León, 24071 León, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Nutritional Methodology and Biostatistics Group, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon, France
| | - Antonio J. Molina
- Research Group on Gene-Environment Interactions and Health (GIIGAS), Instituto de Biomedicina (IBIOMED), University of León, 24071 León, Spain
| | - Tania Fernández-Villa
- Research Group on Gene-Environment Interactions and Health (GIIGAS), Instituto de Biomedicina (IBIOMED), University of León, 24071 León, Spain
| | - Dora Romaguera
- ISGlobal, 08003 Barcelona, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBER-OBN), 28029 Madrid, Spain
- Instituto de Investigación Sanitaria de Palma (IdISPa) – Hospital Universitario Son Espases, 07120 Palma de Mallorca, Spain
| | - Beatriz Pérez-Gómez
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Environmental and Cancer Epidemiology Area, National Center of Epidemiology, Instituto de Salud Carlos III, 28029 Madrid, Spain
- Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro, 28222 Madrid, Spain
| | - Laura Vilorio-Marqués
- Research Group on Gene-Environment Interactions and Health (GIIGAS), Instituto de Biomedicina (IBIOMED), University of León, 24071 León, Spain
- Grupo de Investigación en Neoplasias Hematológicas, Instituto de Investigación Sanitaria Principado de Asturias (ISPA) and Fundación para la investigación Biosanitaria (FINBA), 33011 Oviedo, Spain
| | - Trinidad Dierssen-Sotos
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Division of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, 39011 Santander, Spain
| | - Jone M. Altzibar
- Public Health Division of Gipuzkoa, BioDonostia Research Institute, Osakidetza-Basque Health Service, Directorate General, 20014 San Sebastian, Spain
| | - Victor Moreno
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Oncology Data Analytics Program, Catalan Institute of Oncology (ICO) and Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, 08908 Barcelona, Spain
- Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, 08036 Barcelona, Spain
| | - Eva Ardanaz
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain
| | - Inmaculada Salcedo-Bellido
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Preventive Medicine and Public Health Department, University of Granada and Instituto de Investigación Biosanitaria de Granada, Hospitales Universitarios de Granada, 18071 Granada, Spain
| | - Guillermo Fernández-Tardon
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Instituto de Investigación Sanitaria del Principado de Asturias (ISPA) and IUOPA, Universidad de Oviedo, 33006 Oviedo, Spain
| | - Rocio Capelo
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Centro de Investigación en Recursos Naturales, Salud, y Medio Ambiente (RENSMA), University of Huelva, 21071 Huelva, Spain
| | - Dolores Salas
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), 46020 Valencia, Spain
| | - Rafael Marcos-Gragera
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Epidemiology Unit and Girona Cancer Registry (UERCG), Oncology Coordination Plan (PDO), Department of Health, Autonomous Government of Catalonia, 17071 Girona, Spain
| | - José María Huerta
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, 30007 Murcia, Spain
| | - Silvia de Sanjosé
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Oncology Data Analytics Program, Catalan Institute of Oncology (ICO) and Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, 08908 Barcelona, Spain
| | - María Ángeles Sierra
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Environmental and Cancer Epidemiology Area, National Center of Epidemiology, Instituto de Salud Carlos III, 28029 Madrid, Spain
- Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro, 28222 Madrid, Spain
| | - José M. Canga-Presa
- Servicio de Cirugía General y Aparato Digestivo, Complejo Asistencial Universitario de León, 24001 León, Spain
| | - Ines Gómez-Acebo
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Division of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, 39011 Santander, Spain
| | - Pilar Amiano
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Public Health Division of Gipuzkoa, BioDonostia Research Institute, Osakidetza-Basque Health Service, Directorate General, 20014 San Sebastian, Spain
| | - Marina Pollan
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Environmental and Cancer Epidemiology Area, National Center of Epidemiology, Instituto de Salud Carlos III, 28029 Madrid, Spain
- Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro, 28222 Madrid, Spain
| | - Nuria Aragones
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- Epidemiology Section, Public Health Division, Department of Health of Madrid, 28035 Madrid, Spain
| | - Gemma Castaño-Vinyals
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- ISGlobal, 08003 Barcelona, Spain
- IMIM (Hospital Del Mar Medical Research Institute), 08003 Barcelona, Spain
- Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
| | - Manolis Kogevinas
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
- ISGlobal, 08003 Barcelona, Spain
- IMIM (Hospital Del Mar Medical Research Institute), 08003 Barcelona, Spain
- Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
| | - Vicente Martín
- Research Group on Gene-Environment Interactions and Health (GIIGAS), Instituto de Biomedicina (IBIOMED), University of León, 24071 León, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
| | | |
Collapse
|
35
|
Dierssen-Sotos T, Gómez-Acebo I, Palazuelos C, Fernández-Navarro P, Altzibar JM, González-Donquiles C, Ardanaz E, Bustamante M, Alonso-Molero J, Vidal C, Bayo-Calero J, Tardón A, Salas D, Marcos-Gragera R, Moreno V, Rodriguez-Cundin P, Castaño-Vinyals G, Ederra M, Vilorio-Marqués L, Amiano P, Pérez-Gómez B, Aragonés N, Kogevinas M, Pollán M, Llorca J. Author Correction: Validating a breast cancer score in Spanish women. The MCC-Spain study. Sci Rep 2020; 10:5980. [PMID: 32238823 PMCID: PMC7113259 DOI: 10.1038/s41598-020-62511-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Collapse
Affiliation(s)
- Trinidad Dierssen-Sotos
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. .,University of Cantabria - IDIVAL, Santander, Spain.
| | - Inés Gómez-Acebo
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,University of Cantabria - IDIVAL, Santander, Spain
| | | | - Pablo Fernández-Navarro
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.,Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (IDIPHIM), Madrid, Spain
| | - Jone M Altzibar
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Breast Cancer Screening Programme, Basque Health Department, Osakidetza, Spain
| | - Carmen González-Donquiles
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Grupo de Investigación Interacciones Gen-Ambiente y Salud, Universidad de León, León, Spain
| | - Eva Ardanaz
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Navarra Public Health Institute, Navarra, Spain.,IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - Mariona Bustamante
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,ISGlobal Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain.,Centre for Genomic Regulation (CRG), the Barcelona Institute of Science and Technology, Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | | | - Carmen Vidal
- Cancer Prevention and Control Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Juan Bayo-Calero
- Complejo Hospitalario Universitario de Huelva, Centro de Investigación en Salud y Medio Ambiente (CYSMA), Universidad de Huelva, Huelva, Spain
| | - Adonina Tardón
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,IUOPA, Universidad de Oviedo, Asturias, Spain
| | - Dolores Salas
- Valencia Cancer and Public Health Area, FISABIO - Public Health, Valencia, Spain.,General Directorate Public Health, Valencian Community, Valencia, Spain
| | - Rafael Marcos-Gragera
- Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia and Descriptive Epidemiology, Genetics and Cancer Prevention Group [Girona Biomedical Research Institute (IdIBGi)], Catalan Institute of Oncology, Girona, Spain
| | - Víctor Moreno
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Cancer Prevention and Control Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.,Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | | | - Gemma Castaño-Vinyals
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,ISGlobal Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain.,IMIM (Hospital Del Mar Medical Research Institute), Barcelona, Spain
| | - María Ederra
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Navarra Public Health Institute, Navarra, Spain.,IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - Laura Vilorio-Marqués
- Grupo de Investigación Interacciones Gen-Ambiente y Salud, Universidad de León, León, Spain
| | - Pilar Amiano
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
| | - Beatriz Pérez-Gómez
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.,Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (IDIPHIM), Madrid, Spain
| | - Nuria Aragonés
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.,Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (IDIPHIM), Madrid, Spain
| | - Manolis Kogevinas
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,ISGlobal Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain.,IMIM (Hospital Del Mar Medical Research Institute), Barcelona, Spain.,School of Public Health, Athens, Greece
| | - Marina Pollán
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.,Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (IDIPHIM), Madrid, Spain
| | - Javier Llorca
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,University of Cantabria - IDIVAL, Santander, Spain
| |
Collapse
|
36
|
Castelló A, Pérez-Gómez B, Lora-Pablos D, Lope V, Castaño-Vinyals G, Vitelli-Storelli F, Dierssen-Sotos T, Amiano P, Guevara M, Moreno V, Lozano-Lorca M, Tardón A, Alguacil J, Hernández-García M, Marcos-Gragera R, Chirlaque López MD, Ardanaz E, Ibarluzea J, Gómez-Acebo I, Molina AJ, O'Callaghan-Gordo C, Aragonés N, Kogevinas M, Pollán M, García-Pérez J. Validation of self-reported perception of proximity to industrial facilities: MCC-Spain study. Environ Int 2020; 135:105316. [PMID: 31918152 DOI: 10.1016/j.envint.2019.105316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/23/2019] [Revised: 11/05/2019] [Accepted: 11/06/2019] [Indexed: 06/10/2023]
Abstract
BACKGROUND Self-reported data about environmental exposures can lead to measurement error. OBJECTIVES To validate the self-reported perception of proximity to industrial facilities. METHODS MCC-Spain is a population-based multicase-control study of cancer in Spain that recruited incident cases of breast, colorectal, prostate, and stomach cancer. The participant's current residence and the location of the industries were geocoded, and the linear distance between them was calculated (gold standard). The epidemiological questionnaire included a question to determine whether the participants perceived the presence of any industry at ≤1 km from their residences. Sensitivity and specificity of individuals' perception of proximity to industries were estimated as measures of classification accuracy, and the area under the curve (AUC) and adjusted odds ratios (aORs) of misclassification were calculated as measures of discrimination. Analyses were performed for all cases and controls, and by tumor location, educational level, sex, industrial sector, and length of residence. Finally, aORs of cancer associated with real and self-reported distances were calculated to explore differences in the estimation of risk between these measures. RESULTS Sensitivity of the questionnaire was limited (0.48) whereas specificity was excellent (0.89). AUC was sufficient (0.68). Participants with breast (aOR(95%CI) = 2.03 (1.67;2.46)), colorectal (aOR(95%CI) = 1.41 (1.20;1.64)) and stomach (aOR(95%CI) = 1.59 (1.20;2.10)) cancer showed higher risk of misclassification than controls. This risk was higher for lower educational levels (aOR<primaryvs.university (95%CI) = 1.78 (1.44;2.20)), among younger participants (aOR22-54 yearsvs. 73-85 years (95%CI) = 1.32 (1.09;1.60)), and for some industrial sectors: pharmaceutical (aOR(95%CI) = 29.02 (19.52;43.14)), galvanization (aOR(95%CI) = 14.14 (6.78;29.47)), and ceramic (aOR(95%CI) = 12.73 (7.22;22.44)). Participants living ≤1 year in the study area showed a lower risk of misclassification ((aOR≤1vs.>15 years (95%CI) = 0.56 (0.36;0.85)). The use of self-reported proximity vs. real distance to industrial facilities biased the effect on cancer risk towards the nullity. CONCLUSIONS Self-reported distance to industrial facilities can be a useful tool for hypothesis generation, but hypothesis-testing studies should use real distance to report valid conclusions. The sensitivity of the question might be improved with a more specific formulation.
Collapse
Affiliation(s)
- Adela Castelló
- School of Medicine, University of Alcalá, Av. de Madrid, Km 33,600, 28871 Alcalá de Henares, Madrid, Spain; Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Calle de Melchor Fernández Almagro, 5, 28029 Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain.
| | - Beatriz Pérez-Gómez
- Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Calle de Melchor Fernández Almagro, 5, 28029 Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain.
| | - David Lora-Pablos
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Clinical Research Unit (i+12), Hospital Universitario, 12 de Octubre, Av. de Córdoba, s/n, 28041 Madrid, Spain; Spanish Clinical Research Network (SCReN), C/ Profesor Martín Lagos S/N, 28040 Madrid, Spain.
| | - Virginia Lope
- Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Calle de Melchor Fernández Almagro, 5, 28029 Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain.
| | - Gemma Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; ISGlobal, Barcelona, Carrer del Rosselló, 132, 08036 Barcelona, Spain; IMIM (Hospital del Mar Medical Research Institute), Carrer del Dr. Aiguader, 88, 08003 Barcelona, Spain; Universitat Pompeu Fabra (UPF), Campus del Mar, Carrer del Dr. Aiguader, 80, 08003 Barcelona, Spain.
| | - Facundo Vitelli-Storelli
- The Research Group in Gene - Environment and Health Interactions (GIIGAS)/Institut of Biomedicine (IBIOMED), Universidad de León, Campus Universitario de Vegazana, 24071 León, Spain; Faculty of Health Sciences, Department of Biomedical Sciences, Area of Preventive Medicine and Public Health, Universidad de León, Campus Universitario de Vegazana, 24071 León, Spain.
| | - Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Universidad de Cantabria - IDIVAL, Avenida Cardenal Herrera Oria s/n, 39011 Santander, Spain.
| | - Pilar Amiano
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Public Health Division of Gipuzkoa, Biodonostia Health Research Institute, Ministry of Health of the Basque Government, P° Dr. Beguiristain s/n, 20014 San Sebastian, Spain.
| | - Marcela Guevara
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Instituto de Salud Pública de Navarra, IdiSNA, Calle Leyre, 15, 31003 Pamplona, Spain.
| | - Víctor Moreno
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO) and Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospital Duran i Reynals, Avinguda de la Gran Via de l'Hospitalet, 199-203, 08908 Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Carrer de Casanova, 143, 08036 Barcelona, Spain.
| | - Macarena Lozano-Lorca
- Department of Preventive Medicine and Public Health, School of Medicine, University of Granada, Av. de la Investigación, 11, 18016 Granada, Spain; Granada Health Research Institute (ibs.GRANADA), Doctor Azpitarte 4 4ª Planta, Edificio Licinio de la Fuente, 18012 Granada, Spain.
| | - Adonina Tardón
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Instituto Universitario de Oncología, Universidad de Oviedo. Facultad de Medicina, Oviedo, Spain; Spain Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.
| | - Juan Alguacil
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Centro de Investigación en Salud y Medio Ambiente (CYSMA), Universidad de Huelva, Campus Universitario de El Carmen, 21071 Huelva, Spain.
| | - Marta Hernández-García
- Cancer and Public Health Area, FISABIO - Public Health, Avda. de Catalunya, 21, 46020 Valencia, Spain.
| | - Rafael Marcos-Gragera
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Carrer del Sol, 15, 17004 Girona, Spain; Descriptive Epidemiology, Genetics and Cancer Prevention Group, Biomedical Research Institute (IDIBGI), Carrer de Santiago Ramón y Cajal, 30, 17190 Salt, Girona, Spain.
| | - Maria Dolores Chirlaque López
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Campus de Ciencias de la Salud, Carretera Buenavista s/n, 30120 El Palmar, Murcia, Spain.
| | - Eva Ardanaz
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Instituto de Salud Pública de Navarra, IdiSNA, Calle Leyre, 15, 31003 Pamplona, Spain.
| | - Jesús Ibarluzea
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Public Health Division of Gipuzkoa, Biodonostia Health Research Institute, Ministry of Health of the Basque Government, P° Dr. Beguiristain s/n, 20014 San Sebastian, Spain; School of Psychology, University of the Basque Country (UPV/EHU), Tolosa Hiribidea, 70, 20018 San Sebastián, Spain.
| | - Inés Gómez-Acebo
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Universidad de Cantabria - IDIVAL, Avenida Cardenal Herrera Oria s/n, 39011 Santander, Spain.
| | - Antonio J Molina
- The Research Group in Gene - Environment and Health Interactions (GIIGAS)/Institut of Biomedicine (IBIOMED), Universidad de León, Campus Universitario de Vegazana, 24071 León, Spain; Faculty of Health Sciences, Department of Biomedical Sciences, Area of Preventive Medicine and Public Health, Universidad de León, Campus Universitario de Vegazana, 24071 León, Spain.
| | - Cristina O'Callaghan-Gordo
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; ISGlobal, Barcelona, Carrer del Rosselló, 132, 08036 Barcelona, Spain; Universitat Pompeu Fabra (UPF), Campus del Mar, Carrer del Dr. Aiguader, 80, 08003 Barcelona, Spain.
| | - Nuria Aragonés
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; Epidemiology Section, Public Health Division, Department of Health of Madrid, C/San Martín de Porres, 6, 28035 Madrid, Spain.
| | - Manolis Kogevinas
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain; ISGlobal, Barcelona, Carrer del Rosselló, 132, 08036 Barcelona, Spain; IMIM (Hospital del Mar Medical Research Institute), Carrer del Dr. Aiguader, 88, 08003 Barcelona, Spain; Universitat Pompeu Fabra (UPF), Campus del Mar, Carrer del Dr. Aiguader, 80, 08003 Barcelona, Spain.
| | - Marina Pollán
- Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Calle de Melchor Fernández Almagro, 5, 28029 Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain.
| | - Javier García-Pérez
- Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Calle de Melchor Fernández Almagro, 5, 28029 Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Av. de Monforte de Lemos, 3-5, 28029 Madrid, Spain.
| |
Collapse
|
37
|
O'Callaghan-Gordo C, Espinosa A, Valentin A, Tonne C, Pérez-Gómez B, Castaño-Vinyals G, Dierssen-Sotos T, Moreno-Iribas C, de Sanjose S, Fernandez-Tardón G, Vanaclocha-Espi M, Chirlaque MD, Cirach M, Aragonés N, Gómez-Acebo I, Ardanaz E, Moreno V, Pollan M, Bustamante M, Nieuwenhuijsen MJ, Kogevinas M. Green spaces, excess weight and obesity in Spain. Int J Hyg Environ Health 2020; 223:45-55. [DOI: 10.1016/j.ijheh.2019.10.007] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2019] [Revised: 10/17/2019] [Accepted: 10/18/2019] [Indexed: 12/19/2022]
|
38
|
Flores JC, Gracia-Lavedan E, Benavente Y, Amiano P, Romaguera D, Costas L, Robles C, Gonzalez-Barca E, de la Banda E, Alonso E, Aymerich M, Campo E, Dierssen-Sotos T, Marcos-Gragera R, Rodriguez-Suarez MM, Solans M, Gimeno E, Garcia Martin P, Aragones N, Shivappa N, Hébert JR, Pollan M, Kogevinas M, de Sanjose S, Castaño-Vinyals G, Casabonne D. The Dietary Inflammatory Index and Chronic Lymphocytic Leukaemia in the MCC Spain Study. Nutrients 2019; 12:nu12010048. [PMID: 31878004 PMCID: PMC7019557 DOI: 10.3390/nu12010048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2019] [Revised: 12/09/2019] [Accepted: 12/09/2019] [Indexed: 12/17/2022] Open
Abstract
Chronic inflammation plays a role in the development of chronic lymphocytic leukaemia (CLL), and diet might modulate chronic inflammation. This study aims to evaluate the association between the dietary inflammatory index (DII®) and CLL. A total of 366 CLL cases and 1643 controls of the Spanish multicase-control (MCC) Spain study were included. The inflammatory potential of the diet was assessed using the energy-adjusted dietary inflammatory index (E-DII) based on 30 items from a validated semi-quantitative food frequency questionnaire. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using logistic regression models controlling for potential confounders. Overall, a modest, non-statistically significant, positive association was observed between CLL and E-DII scores (OR for a one-unit increase in E-DII: 1.05 (CI 95%: 0.99, 1.12), p-value = 0.09 and by tertiles: ORT2vsT1: 1.20 (CI 95%: 0.90, 1.59); OR T3vsT1: 1.21 (CI 95%: 0.90, 1.62), p trend = 0.21). These results were independent from disease severity (p-het: 0.70), time from diagnosis (p-het: 0.67) and CLL treatment received (p-het: 0.56). No interactions were detected. In conclusion, the consumption of a diet with high pro-inflammatory components was not significantly associated with CLL. Changes towards a more pro-inflammatory dietary pattern in younger generations not included here warrant future research.
Collapse
Affiliation(s)
- José Carlos Flores
- Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona 08002, Spain; (J.C.F.); (E.G.-L.); (M.K.)
| | - Esther Gracia-Lavedan
- Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona 08002, Spain; (J.C.F.); (E.G.-L.); (M.K.)
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid 28029, Spain; (Y.B.); (P.A.); (T.D.-S.); (R.M.-G.); (M.S.); (N.A.); (M.P.); (S.d.S.)
- Instituto de Salud Global de Barcelona (ISGlobal), Barcelona 08003, Spain;
| | - Yolanda Benavente
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid 28029, Spain; (Y.B.); (P.A.); (T.D.-S.); (R.M.-G.); (M.S.); (N.A.); (M.P.); (S.d.S.)
- Unit of Molecular Epidemiology and Genetic in Infections and Cancer (UNIC-Molecular), Cancer Epidemiology Research Programme (IDIBELL), Catalan Institute of Oncology, L’Hospitalet de Llobregat 08908, Spain;
| | - Pilar Amiano
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid 28029, Spain; (Y.B.); (P.A.); (T.D.-S.); (R.M.-G.); (M.S.); (N.A.); (M.P.); (S.d.S.)
- Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian 20014, Spain
| | - Dora Romaguera
- Instituto de Salud Global de Barcelona (ISGlobal), Barcelona 08003, Spain;
- Instituto de Investigación Sanitaria Illes Balears (IdISBa), Palma 07120, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Madrid 28029, Spain
| | - Laura Costas
- Unit of Molecular Epidemiology and Genetic in Infections and Cancer (UNIC-Molecular), Cancer Epidemiology Research Programme (IDIBELL), Catalan Institute of Oncology, L’Hospitalet de Llobregat 08908, Spain;
| | - Claudia Robles
- Unit of Information and Interventions in Infections and Cancer (UNIC-I&I), Cancer Epidemiology Research Programme, (IDIBELL), Catalan Institute of Oncology, L’Hospitalet de Llobregat 08908, Spain;
| | - Eva Gonzalez-Barca
- Haematology, Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology, L’Hospitalet de Llobregat 08908, Spain;
| | - Esmeralda de la Banda
- Haematology Laboratory, Department of Pathology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat 08908, Spain; (E.d.l.B.); (E.A.)
| | - Esther Alonso
- Haematology Laboratory, Department of Pathology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat 08908, Spain; (E.d.l.B.); (E.A.)
| | - Marta Aymerich
- Hematopathology Unit, Department of Pathology, Hospital Clínic, (IDIBAPS), Barcelona 08036, Spain; (M.A.); (E.C.)
| | - Elias Campo
- Hematopathology Unit, Department of Pathology, Hospital Clínic, (IDIBAPS), Barcelona 08036, Spain; (M.A.); (E.C.)
- Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid 28029, Spain
| | - Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid 28029, Spain; (Y.B.); (P.A.); (T.D.-S.); (R.M.-G.); (M.S.); (N.A.); (M.P.); (S.d.S.)
- Marqués de Valdecilla Research Institute (IDIVAL), University of Cantabria, Santander 39011, Spain
| | - Rafael Marcos-Gragera
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid 28029, Spain; (Y.B.); (P.A.); (T.D.-S.); (R.M.-G.); (M.S.); (N.A.); (M.P.); (S.d.S.)
- Research group on Statistics, Econometrics and Health (GRECS), University of Girona, Girona 17071, Spain
- Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Girona 17007, Spain
| | - Marta María Rodriguez-Suarez
- Universidad de Oviedo, área de medicina Preventiva y Salud Pública, Oviedo 33003, Spain;
- Hospital Universitario Central de Asturias (HUCA), Oviedo 33011, Spain
- IUOPA: Instituto de Oncología de Asturias (IUOPA), Oviedo 33003, Spain
| | - Marta Solans
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid 28029, Spain; (Y.B.); (P.A.); (T.D.-S.); (R.M.-G.); (M.S.); (N.A.); (M.P.); (S.d.S.)
- Research group on Statistics, Econometrics and Health (GRECS), University of Girona, Girona 17071, Spain
- Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Girona 17007, Spain
| | - Eva Gimeno
- Haematology Department, Hospital del Mar, Barcelona 08003, Spain;
| | - Paloma Garcia Martin
- Unidad de Gestión Clínica de Hematología. Hospital Universitario San Cecilio PTS de Granada, Granada 18016, Spain;
| | - Nuria Aragones
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid 28029, Spain; (Y.B.); (P.A.); (T.D.-S.); (R.M.-G.); (M.S.); (N.A.); (M.P.); (S.d.S.)
- Epidemiology Section, Public Health Division, Department of Health of Madrid, Madrid 28035, Spain
| | - Nitin Shivappa
- Cancer Prevention and Control Program, University of South Carolina, Columbia, SC 29208, USA; (N.S.); (J.R.H.)
- Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC 29208, USA
- Department of Nutrition, Connecting Health Innovations LLC (CHI), Columbia, SC 29201, USA
| | - James R. Hébert
- Cancer Prevention and Control Program, University of South Carolina, Columbia, SC 29208, USA; (N.S.); (J.R.H.)
- Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC 29208, USA
- Department of Nutrition, Connecting Health Innovations LLC (CHI), Columbia, SC 29201, USA
| | - Marina Pollan
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid 28029, Spain; (Y.B.); (P.A.); (T.D.-S.); (R.M.-G.); (M.S.); (N.A.); (M.P.); (S.d.S.)
- Cancer Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid 28029, Spain
| | - Manolis Kogevinas
- Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona 08002, Spain; (J.C.F.); (E.G.-L.); (M.K.)
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid 28029, Spain; (Y.B.); (P.A.); (T.D.-S.); (R.M.-G.); (M.S.); (N.A.); (M.P.); (S.d.S.)
- Instituto de Salud Global de Barcelona (ISGlobal), Barcelona 08003, Spain;
- Hospital del Mar Medical Research Institute (IMIM), Barcelona 08003, Spain
| | - Silvia de Sanjose
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid 28029, Spain; (Y.B.); (P.A.); (T.D.-S.); (R.M.-G.); (M.S.); (N.A.); (M.P.); (S.d.S.)
- Unit of Molecular Epidemiology and Genetic in Infections and Cancer (UNIC-Molecular), Cancer Epidemiology Research Programme (IDIBELL), Catalan Institute of Oncology, L’Hospitalet de Llobregat 08908, Spain;
- PATH, Sexual and Reproductive Health, Seattle, WA 98121, USA
| | - Gemma Castaño-Vinyals
- Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona 08002, Spain; (J.C.F.); (E.G.-L.); (M.K.)
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid 28029, Spain; (Y.B.); (P.A.); (T.D.-S.); (R.M.-G.); (M.S.); (N.A.); (M.P.); (S.d.S.)
- Instituto de Salud Global de Barcelona (ISGlobal), Barcelona 08003, Spain;
- Hospital del Mar Medical Research Institute (IMIM), Barcelona 08003, Spain
- Correspondence: (G.C.-V.); (D.C.); Tel.: +34-93-214-7303 (G.C.-V.); +34-93-260-7812 (D.C.)
| | - Delphine Casabonne
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid 28029, Spain; (Y.B.); (P.A.); (T.D.-S.); (R.M.-G.); (M.S.); (N.A.); (M.P.); (S.d.S.)
- Unit of Molecular Epidemiology and Genetic in Infections and Cancer (UNIC-Molecular), Cancer Epidemiology Research Programme (IDIBELL), Catalan Institute of Oncology, L’Hospitalet de Llobregat 08908, Spain;
- Correspondence: (G.C.-V.); (D.C.); Tel.: +34-93-214-7303 (G.C.-V.); +34-93-260-7812 (D.C.)
| |
Collapse
|
39
|
Butt J, Fernández de Larrea N, Tjalsma H, Roelofs R, Kato I, Martín V, Pérez-Gómez B, Moreno V, Dierssen-Sotos T, Castilla J, Fernández-Tardón G, Amiano P, Salas D, Alguacil J, Jiménez-Moleón JJ, Huerta JM, de Sanjosé S, Del Campo R, Kogevinas M, Pollán M, Pawlita M, Waterboer T, Boleij A, Aragonés N. Antibody responses to flagellin C and Streptococcus gallolyticus pilus proteins in colorectal cancer. Sci Rep 2019; 9:10847. [PMID: 31350458 PMCID: PMC6659640 DOI: 10.1038/s41598-019-47347-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2019] [Accepted: 07/10/2019] [Indexed: 11/13/2022] Open
Abstract
Antibodies to Streptococcus gallolyticus subspecies gallolyticus (SGG) have been associated with colorectal cancer (CRC). Because SGG may correlate with impaired gut epithelia, we assessed the association of antibodies to bacterial flagellin C (FliC), a measure potentially related to this impairment, with CRC and the CRC-specific interaction with antibodies to SGG proteins. Antibodies to FliC and SGG pilus proteins Gallo2178 and Gallo2179 were measured in two independent studies, a combined study from Nijmegen and Detroit (93 CRC cases, 74 controls) and a replication data set including 576 cases and 576 controls from the Spanish multicenter multicase-control study (MCC-Spain). Logistic regression was applied to assess whether antibodies to FliC were associated with CRC and modified the association of antibodies to SGG proteins with CRC. Antibodies to FliC were associated with those to SGG Gallo2178 among CRC cases, resulting in an interaction in the association of antibodies to Gallo2178 with CRC (p = 0.007). This association was only present among individuals with high antibody responses to FliC (OR: 2.42, 95% CI: 1.45–4.06). In conclusion, our findings suggest that colorectal tumorigenesis could be accompanied by an impaired integrity of the epithelium that could result in associated increased antibody responses to bacterial proteins.
Collapse
Affiliation(s)
- Julia Butt
- Infection and Cancer Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany. .,Faculty of Biosciences, University of Heidelberg, Heidelberg, Germany.
| | - Nerea Fernández de Larrea
- Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.,Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain
| | - Harold Tjalsma
- Independent researcher. Experimental work conducted at the Department of Laboratory Medicine, Radboud University Medical Centre (RadboudUMC), Nijmegen, The Netherlands
| | - Rian Roelofs
- Department of Laboratory Medicine, Radboud Institute for Molecular Life Sciences (RIMLS), Radboud university medical centre (Radboudumc), Nijmegen, The Netherlands
| | - Ikuko Kato
- Departments of Oncology and Pathology, Wayne State University, Detroit, Michigan, USA
| | - Vicente Martín
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,The Research Group in Gene Environment and Health Interactions, University of León, León, Spain
| | - Beatriz Pérez-Gómez
- Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.,Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,Cardiovascular and Metabolic Diseases Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Victor Moreno
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain.,Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.,Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | - Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,University of Cantabria - IDIVAL, Santander, Spain
| | - Jesús Castilla
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,Public Health Institute of Navarra, IdiSNA- Navarra Institute for Health Research, Pamplona, Spain
| | - Guillermo Fernández-Tardón
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,IUOPA, University of Oviedo, Oviedo, Spain
| | - Pilar Amiano
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,Public Health Division of Gipuzkoa, BioDonostia Research institute, San Sebastian, Spain
| | - Dolores Salas
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,Cancer and Public Health Area, FISABIO - Public Health, Valencia, Spain.,General Directorate Public Health, Valencian Community, Valencia, Spain
| | - Juan Alguacil
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,Natural Resources, Health and Environment Research Center (RENSMA), University of Huelva, Huelva, Spain
| | - José Juan Jiménez-Moleón
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,Granada Health Research Institute (ibs.GRANADA), Granada, Spain.,Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain
| | - José María Huerta
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain
| | - Silvia de Sanjosé
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.,PATH, Reproductive Health, Seattle, USA
| | - Rosa Del Campo
- Department of Microbiology, Ramón y Cajal Health Research Institute (IRYCIS), Hospital Universitario Ramón y Cajal, Madrid, Spain.,Spanish Network for Research in Infectious Diseases (REIPI), Madrid, Spain
| | - Manolis Kogevinas
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,ISGlobal, Barcelona, Spain.,IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.,Pompeu Fabra University (UPF), Barcelona, Spain
| | - Marina Pollán
- Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.,Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain
| | - Michael Pawlita
- Infection and Cancer Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Tim Waterboer
- Infection and Cancer Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Annemarie Boleij
- Department of Pathology, Radboud Institute for Molecular Life Sciences (RIMLS), Radboud university medical centre (Radboudumc), Nijmegen, The Netherlands
| | - Nuria Aragonés
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,Epidemiology Section, Public Health Division, Department of Health of Madrid, Madrid, Spain
| |
Collapse
|
40
|
Dierssen-Sotos T, Gómez-Acebo I, Palazuelos C, Gracia-Lavedan E, Pérez-Gómez B, Oribe M, Martín V, Guevara M, Rodríguez-Cundín P, Fernández-Tardón G, Marcos-Gragera R, Molina-Barceló A, Díaz-Santos M, Castaño-Vinyals G, Aragonés N, López-Gonzalez A, Amiano P, Castilla J, Alonso-Molero J, Kogevinas M, Pollán M, Llorca J. Fatty acid intake and breast cancer in the Spanish multicase-control study on cancer (MCC-Spain). Eur J Nutr 2019; 59:1171-1179. [PMID: 31069457 DOI: 10.1007/s00394-019-01977-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2018] [Accepted: 04/25/2019] [Indexed: 12/24/2022]
Abstract
PURPOSE To evaluate the association between dietary fat and fat subtype and breast cancer development. METHODS We conducted a case-control study with 1181 cases of incident breast cancer, diagnosed between 2007 and 2012, and 1682 population controls frequency matched (by age, sex, and region) from the Spanish multicenter case-control study MCC-Spain. RESULTS We found a significant protective effect in premenopausal women of total fat intake [OR 0.51 95% CI (0.31-0.86) highest versus lowest tertile], but no effect was observed in menopausal women [OR 1.15 95% CI (0.83-1.60)]. Analyzing by type of fat, this protective effect persisted only for the monounsaturated fatty acids [OR 0.51 95% CI (0.32-0.82)]. In contrast, other fatty acids did not have a significant effect. In addition, a protection against risk of breast cancer was found when polyunsaturated fats were "substituted" by monounsaturated, maintaining the same total fat intake [OR 0.68 95% CI (0.47-0.99)]. Finally, analyzing by breast cancer subtype, we found no effect, except in premenopausal women where intake of moderate [OR 0.52 95% CI (0.33-0.82)] and high monounsaturated fatty acids [OR 0.47 95% CI (0.27-0.82)] maintains a protective effect against ER/PR + tumors. In contrast, in menopausal women, a high intake of monounsaturated fatty acids was associated with higher risk of HER2 + tumors [OR 2.00 95% CI (0.97-4.13)]. CONCLUSION Our study shows a differential effect of monounsaturated fatty acids according to menopausal status and breast cancer subtype.
Collapse
Affiliation(s)
- Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología Y Salud Pública-CIBERESP), Madrid, Spain. .,Facultad de Medicina, Universidad de Cantabria-IDIVAL, Avda. Herrera Oria s/n, 39011, Santander, Spain.
| | - Inés Gómez-Acebo
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología Y Salud Pública-CIBERESP), Madrid, Spain.,Facultad de Medicina, Universidad de Cantabria-IDIVAL, Avda. Herrera Oria s/n, 39011, Santander, Spain
| | - Camilo Palazuelos
- Facultad de Medicina, Universidad de Cantabria-IDIVAL, Avda. Herrera Oria s/n, 39011, Santander, Spain
| | - Esther Gracia-Lavedan
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología Y Salud Pública-CIBERESP), Madrid, Spain.,ISGlobal, Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Beatriz Pérez-Gómez
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología Y Salud Pública-CIBERESP), Madrid, Spain.,Cardiovascular and Metabolic Diseases Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Madalen Oribe
- Public Health Division of Gipuzkoa, Health Department, BioDonostia Research Institute, San Sebastian, Basque Country, Spain
| | - Vicente Martín
- Instituto de Biomedicina (IBIOMED), Universidad de León, León, Spain
| | - Marcela Guevara
- Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Spain
| | - Paz Rodríguez-Cundín
- Servicio de Medicina Preventiva, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | | | - Rafael Marcos-Gragera
- Research Group on Statistics, Econometrics and Health (GRECS), Universitat de Girona, Girona, Spain.,Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona, Spain
| | | | - Marian Díaz-Santos
- Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, Huelva, Spain
| | - Gemma Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología Y Salud Pública-CIBERESP), Madrid, Spain.,ISGlobal, Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain.,IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Nuria Aragonés
- Epidemiology Section, Public Health Division, Department of Health of Madrid, Madrid, Spain
| | - Ana López-Gonzalez
- Servicio de Oncología, Complejo Asistencial Universitario de León, León, Spain
| | - Pilar Amiano
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología Y Salud Pública-CIBERESP), Madrid, Spain.,Public Health Division of Gipuzkoa, Health Department, BioDonostia Research Institute, San Sebastian, Basque Country, Spain
| | - Jesús Castilla
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología Y Salud Pública-CIBERESP), Madrid, Spain.,Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Spain
| | - Jessica Alonso-Molero
- Facultad de Medicina, Universidad de Cantabria-IDIVAL, Avda. Herrera Oria s/n, 39011, Santander, Spain
| | - Manolis Kogevinas
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología Y Salud Pública-CIBERESP), Madrid, Spain.,ISGlobal, Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain.,IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Marina Pollán
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología Y Salud Pública-CIBERESP), Madrid, Spain.,Cancer Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Javier Llorca
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER de Epidemiología Y Salud Pública-CIBERESP), Madrid, Spain.,Facultad de Medicina, Universidad de Cantabria-IDIVAL, Avda. Herrera Oria s/n, 39011, Santander, Spain.,ISGlobal, Barcelona, Spain
| |
Collapse
|
41
|
Olmedo-Requena R, González-Donquiles C, Dávila-Batista V, Romaguera D, Castelló A, Molina de la Torre AJ, Amiano P, Dierssen-Sotos T, Guevara M, Fernández-Tardón G, Lozano-Lorca M, Alguacil J, Peiró R, Huerta JM, Gracia-Lavedan E, Aragonés N, Fernández-Villa T, Solans M, Gómez-Acebo I, Castaño-Vinyals G, Kogevinas M, Pollán M, Martín V. Agreement among Mediterranean Diet Pattern Adherence Indexes: MCC-Spain Study. Nutrients 2019; 11:E488. [PMID: 30813581 PMCID: PMC6471750 DOI: 10.3390/nu11030488] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2019] [Revised: 02/07/2019] [Accepted: 02/21/2019] [Indexed: 11/29/2022] Open
Abstract
There are many different methods used to measure the degree of adherence to a Mediterranean diet (MD), limiting comparison and interpretation of their results. The concordance between different methodologies has been questioned and their evaluation recommended. The aim of this study was to evaluate the agreement among five indexes that measure adherence to a Mediterranean dietary pattern. The study population included healthy adults selected in the Multi-Case Control Spain (MCC-Spain) study recruited in 12 provinces. A total of 3640 controls were matched to cases by age and sex. To reach the aim, the following scores of adherence to a Mediterranean dietary pattern were calculated: Mediterranean diet score (MDS), alternative Mediterranean diet (aMED), relative Mediterranean diet (rMED), dietary score (DS) and literature-based adherence score (LBAS). The relative frequency of subjects with a high level of adherence to a MD varied from 22% (aMED index) to 37.2% (DS index). Similarly, a high variability was observed for the prevalence of a low level of MD: from 24% (rMED) to 38.4% (aMED). The correlation among MDS, aMED and rMED indexes was moderate, except for MDS and aMED with a high coefficient of correlation 0.75 (95% CI 0.74⁻0.77). The Cohen's Kappa coefficient among indexes showed a moderate⁻fair concordance, except for MDS and aMED with a 0.56 (95% CI 0.55⁻0.59) and 0.67 (95% CI 0.66⁻0.68) using linear and quadratic weighting, respectively. The existing MD adherence indexes measured the same, although they were based on different constructing algorithms and varied in the food groups included, leading to a different classification of subjects. Therefore, concordance between these indexes was moderate or low.
Collapse
Affiliation(s)
- Rocío Olmedo-Requena
- Department of Preventive Medicine and Public Health, University of Granada, 18071 Granada, Spain.
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
- Inst Invest Biosanitaria Ibs GRANADA, 18071 Granada, Spain.
| | - Carmen González-Donquiles
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
- The Research Group in Gene-Environment and Health Interactions (GIIGAS), University of León, 24071 León, Spain.
- Instituto de Biomedicina (IBIOMED), University of León, 24071 León, Spain.
| | - Verónica Dávila-Batista
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
- The Research Group in Gene-Environment and Health Interactions (GIIGAS), University of León, 24071 León, Spain.
- Instituto de Biomedicina (IBIOMED), University of León, 24071 León, Spain.
| | - Dora Romaguera
- ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), 08003 Barcelona, Spain.
- Instituto de Investigación Sanitaria de Palma (IdISPa), Hospital Universitario Son Espases, Unidad de Investigación, I-1. Carretera de Valldemossa, 79, 07120 Palma de Mallorca, Spain.
- CIBER Fisiopatología de la Obesidad y la Nutrición (CIBER-OBN), 28029 Madrid, Spain.
| | - Adela Castelló
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
- Cancer Epidemiology Unit, National Centre for Epidemiology, Instituto de Salud Carlos III, Av/Monforte de Lemos, 5, 28029 Madrid, Spain.
- Faculty of Medicine, University of Alcalá, Alcalá de Henares, 28801 Madrid, Spain.
| | - Antonio José Molina de la Torre
- The Research Group in Gene-Environment and Health Interactions (GIIGAS), University of León, 24071 León, Spain.
- Instituto de Biomedicina (IBIOMED), University of León, 24071 León, Spain.
| | - Pilar Amiano
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
- Public Health Division of Guipuzkoa, BioDonostia Research Institute, 20014 San Sebastian, Spain.
| | - Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
- Universidad de Cantabria-IDIVAL, 39011 Santander, Spain.
| | - Marcela Guevara
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
- Instituto de Salud Pública de Navarra, IdiSNA, 31003 Pamplona, Spain.
| | - Guillermo Fernández-Tardón
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
- Instituto de Oncología IUOPA (Instituto Universitario de Oncología del Principado de Asturias), University of Oviedo, 33003 Oviedo, Spain.
| | - Macarena Lozano-Lorca
- Department of Preventive Medicine and Public Health, University of Granada, 18071 Granada, Spain.
| | - Juan Alguacil
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
- Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente (RENSMA), Universidad de Huelva, 21071 Huelva, Spain.
| | - Rosana Peiró
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana FISABIO-Salud Pública, 46020 Valencia, Spain.
| | - José María Huerta
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
- Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, 30007 Murcia, Spain.
| | - Esther Gracia-Lavedan
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
- ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), 08003 Barcelona, Spain.
- Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.
| | - Nuria Aragonés
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
- Epidemiology Section, Public Health Division, Department of Health of Madrid, 28035 Madrid, Spain.
| | - Tania Fernández-Villa
- The Research Group in Gene-Environment and Health Interactions (GIIGAS), University of León, 24071 León, Spain.
- Instituto de Biomedicina (IBIOMED), University of León, 24071 León, Spain.
| | - Marta Solans
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
- Research Group on Statistics, Econometrics and Health (GRECS), Universitat de Girona, Campus Montilivi, 17003 Girona, Spain.
- Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, 17004 Girona, Spain.
| | - Inés Gómez-Acebo
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
- Universidad de Cantabria-IDIVAL, 39011 Santander, Spain.
| | - Gemma Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
- ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), 08003 Barcelona, Spain.
- Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.
- IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.
| | - Manolis Kogevinas
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
- ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), 08003 Barcelona, Spain.
- Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.
- IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.
| | - Marina Pollán
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
- Cancer Epidemiology Unit, National Centre for Epidemiology, Instituto de Salud Carlos III, Av/Monforte de Lemos, 5, 28029 Madrid, Spain.
| | - Vicente Martín
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
- The Research Group in Gene-Environment and Health Interactions (GIIGAS), University of León, 24071 León, Spain.
- Instituto de Biomedicina (IBIOMED), University of León, 24071 León, Spain.
| |
Collapse
|
42
|
Peremiquel-Trillas P, Benavente Y, Martín-Bustamante M, Casabonne D, Pérez-Gómez B, Gómez-Acebo I, Oliete-Canela A, Diéguez-Rodríguez M, Tusquets I, Amiano P, Mengual L, Ardanaz E, Capelo R, Molina de la Torre AJ, Salas Trejo D, Fernández-Tardón G, Lope V, Jimenez-Moleon JJ, Marcos-Gragera R, Dierssen-Sotos T, Azpiri M, Muñoz M, Guevara M, Fernández-Villa T, Molina-Barceló A, Aragonés N, Pollán M, Castaño-Vinyals G, Alguacil J, Kogevinas M, de Sanjosé S, Costas L. Alkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain study. Environ Int 2019; 122:389-399. [PMID: 30553564 DOI: 10.1016/j.envint.2018.12.007] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/07/2018] [Revised: 11/30/2018] [Accepted: 12/04/2018] [Indexed: 06/09/2023]
Abstract
BACKGROUND Alkylphenolic compounds are chemicals with endocrine disrupting properties that have been widely used in industry with important changes in their usage over time. Few epidemiologic studies have evaluated the effect of alkylphenolic compounds on human health. OBJECTIVES We investigated whether occupational exposure to alkylphenolic compounds is associated with breast and prostate cancer. METHODS We carried out a population-based case-control study including 1513 incident cases of breast cancer, 1095 of prostate cancer, and 3055 controls, frequency matched by sex, age and region. Occupational exposure to alkylphenolic compounds was estimated using a recently developed job-exposure matrix, which considered different scenarios of exposure and different subtypes of alkylphenolic compounds. RESULTS History of occupational exposure to alkylphenolic compounds was modestly associated with breast cancer (OR = 1.23; 95% CI = 1.01-1.48). Within the different scenarios, the occupational use of domestic tensioactives was positively associated with breast cancer (OR = 1.28; 95% CI = 1.02-1.60), while occupational exposure in other scenarios showed mostly a suggestion of a similar positive associations. Exposure to nonylphenol ethoxylates was positively associated with breast cancer (OR = 1.21; 95% CI = 1.00-1.47), while exposure to other compounds was uncommon. In general, we did not observe associations between alkylphenolic compounds and prostate cancer, except for a positive association among men occupationally exposed to cosmetic, hair and personal hygiene products. CONCLUSIONS Our findings suggest a modest association between breast cancer risk and occupational exposure to alkylphenolic compounds, and no associations between these compounds and prostate cancer risk. These findings warrant further corroboration in other studies.
Collapse
Affiliation(s)
- Paula Peremiquel-Trillas
- Preventive Medicine and Epidemiology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Unit of Molecular Epidemiology and Genetics in Infections and Cancer, IDIBELL, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Yolanda Benavente
- Unit of Molecular Epidemiology and Genetics in Infections and Cancer, IDIBELL, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; CIBER Epidemiología y Salud Pública - CIBERESP, Madrid, Spain
| | - Mayte Martín-Bustamante
- Institut Català de Seguretat i Salut Laboral, Departament de Treball, Afers Socials i Famílies, Generalitat de Catalunya, Barcelona, Spain
| | - Delphine Casabonne
- Unit of Molecular Epidemiology and Genetics in Infections and Cancer, IDIBELL, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; CIBER Epidemiología y Salud Pública - CIBERESP, Madrid, Spain
| | - Beatriz Pérez-Gómez
- CIBER Epidemiología y Salud Pública - CIBERESP, Madrid, Spain; Cancer Epidemiology Unit, National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain; Cardiovascular & Metabolic Diseases Unit, National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
| | - Inés Gómez-Acebo
- CIBER Epidemiología y Salud Pública - CIBERESP, Madrid, Spain; Universidad de Cantabria - IDIVAL, Santander, Spain
| | - Anna Oliete-Canela
- Institut Català de Seguretat i Salut Laboral, Departament de Treball, Afers Socials i Famílies, Generalitat de Catalunya, Barcelona, Spain
| | - Marta Diéguez-Rodríguez
- Institut Català de Seguretat i Salut Laboral, Departament de Treball, Afers Socials i Famílies, Generalitat de Catalunya, Barcelona, Spain
| | - Ignasi Tusquets
- Universitat Autònoma de Barcelona, Parc de Salut Mar Hospital del Mar, Barcelona, Spain; Medical Oncology Department, Parc de Salut Mar Hospital del Mar, Barcelona, Spain
| | - Pilar Amiano
- CIBER Epidemiología y Salud Pública - CIBERESP, Madrid, Spain; Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
| | - Lourdes Mengual
- Department and Laboratory of Urology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain
| | - Eva Ardanaz
- CIBER Epidemiología y Salud Pública - CIBERESP, Madrid, Spain; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain
| | - Rocío Capelo
- Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente, Universidad de Huelva, Huelva, Spain
| | - Antonio J Molina de la Torre
- Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS), Instituto de Biomedicina (IBIOMED), Universidad de León, León, Spain
| | - Dolores Salas Trejo
- CIBER Epidemiología y Salud Pública - CIBERESP, Madrid, Spain; Cancer and Public Health Area, FISABIO - Public Health, Valencia, Spain; General Directorate Public Health, Valencian Community, Valencia, Spain
| | - Guillermo Fernández-Tardón
- CIBER Epidemiología y Salud Pública - CIBERESP, Madrid, Spain; Instituto de Oncología de Asturias (IUOPA), Área de Medicina Preventiva, Universidad de Oviedo, Oviedo, Spain
| | - Virginia Lope
- CIBER Epidemiología y Salud Pública - CIBERESP, Madrid, Spain; Cancer Epidemiology Unit, National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
| | - José J Jimenez-Moleon
- CIBER Epidemiología y Salud Pública - CIBERESP, Madrid, Spain; Department of Preventive Medicine and Public Health, Faculty of Medicine, University of Granada, Granada, Spain; Instituto de Investigación Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada, University of Granada, Granada, Spain
| | - Rafael Marcos-Gragera
- CIBER Epidemiología y Salud Pública - CIBERESP, Madrid, Spain; Epidemiology Unit and Girona Cancer Registry (UERCG), Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology (ICO), Girona, Spain; Girona Biomedical Research Institute (IDIBGI), University of Girona, Girona, Spain
| | - Trinidad Dierssen-Sotos
- CIBER Epidemiología y Salud Pública - CIBERESP, Madrid, Spain; Universidad de Cantabria - IDIVAL, Santander, Spain
| | - Mikel Azpiri
- Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
| | - Montse Muñoz
- Translational Genomics and Targeted Therapeutics in Solid Tumors, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Marcela Guevara
- CIBER Epidemiología y Salud Pública - CIBERESP, Madrid, Spain; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain
| | - Tania Fernández-Villa
- Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS), Instituto de Biomedicina (IBIOMED), Universidad de León, León, Spain
| | | | - Nuria Aragonés
- CIBER Epidemiología y Salud Pública - CIBERESP, Madrid, Spain; Epidemiology Section, Public Health Division, Department of Health of Madrid, Madrid, Spain
| | - Marina Pollán
- CIBER Epidemiología y Salud Pública - CIBERESP, Madrid, Spain; Cancer Epidemiology Unit, National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
| | - Gemma Castaño-Vinyals
- ISGlobal, Barcelona, Spain; Hospital del Mar Medical Research Institute - IMIM, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Juan Alguacil
- Centro de Investigación en Recursos Naturales, Salud y Medio Ambiente, Universidad de Huelva, Huelva, Spain
| | - Manolis Kogevinas
- ISGlobal, Barcelona, Spain; Hospital del Mar Medical Research Institute - IMIM, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; National School of Public Health, Athens, Greece
| | | | - Laura Costas
- Unit of Molecular Epidemiology and Genetics in Infections and Cancer, IDIBELL, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.
| |
Collapse
|
43
|
Vallès X, Alonso MH, López-Caleya JF, Díez-Obrero V, Dierssen-Sotos T, Lope V, Molina-Barceló A, Chirlaque MD, Jiménez-Moleón JJ, Fernández Tardón G, Castilla J, Amiano P, Capelo R, Castaño-Vinyals G, Guinó E, Molina de la Torre AJ, Moreno-Iribas C, Pérez Gómez B, Aragonés N, Llorca J, Martín V, Kogevinas M, Pollán M, Moreno V. Colorectal cancer, sun exposure and dietary vitamin D and calcium intake in the MCC-Spain study. Environ Int 2018; 121:428-434. [PMID: 30266013 DOI: 10.1016/j.envint.2018.09.030] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Revised: 09/17/2018] [Accepted: 09/17/2018] [Indexed: 06/08/2023]
Abstract
OBJECTIVES To explore the association of colorectal cancer with environmental solar radiation and sun exposure behavior, considering phenotypic variables (eye color, hair color and skin phenotype), dietary intake of vitamin D and calcium, and socio-demographic factors. STUDY DESIGN Multicenter population-based frequency matched case-control study in Spain (MCC-Spain), with 2140 CRC cases and 3950 controls. METHODS Data were obtained through personal interviews using a structured epidemiological questionnaire that included socio-demographic data, residential history, environmental exposures, behavior, phenotypic and dietary information. An environmental-lifetime sun exposure score was constructed combining residential history and average daily solar radiation, direct and diffuse. Logistic regression was used to explore the association between different variables. A structural equation model was used to verify the associations of the conceptual model. RESULTS We found a lower risk of CRC in subjects frequently exposed to sunlight during the previous summer and skin burning due to sun exposure. No association was observed in relation to the residential solar radiation scores. Subjects with light eye or light hair colors had a lower risk of CRC that those with darker colors. Dietary calcium and vitamin D were also protective factors, but not in the multivariate model. The structural equation model analysis suggested that higher sun exposure was associated with a decreased risk of CRC, as well as dietary intake of calcium and vitamin D, and these factors are correlated among themselves and with environmental solar radiation and skin phenotypes. CONCLUSION The results agree with previous observations that sun exposure, dietary vitamin D and calcium intake, and serum 25(OH)D concentration reduce the risk of CRC and indicate that these factors may be relevant for cancer prevention.
Collapse
Affiliation(s)
- Xavier Vallès
- Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO) and Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain
| | - M Henar Alonso
- Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO) and Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Department of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain
| | - Juan Francisco López-Caleya
- Instituto de Biomedicina (IBIOMED), Universidad de León, Spain; Servicio de Medicina Interna, Hospital de Cabueñes, Gijón, Asturias, Spain
| | - Virginia Díez-Obrero
- Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO) and Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain
| | - Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Universidad de Cantabria - IDIVAL, Santander, Spain
| | - Virginia Lope
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Environmental and Cancer Epidemiology Unit, National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
| | | | - María Dolores Chirlaque
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain; Department of Health and Social Sciences, Universidad de Murcia, Murcia, Spain
| | - José Juan Jiménez-Moleón
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Department of Preventive Medicine and Public Health, Faculty of Medicine, University of Granada, Spain; Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Hospitales Universitarios de Granada, Universidad de Granada, Granada, Spain
| | - Guillermo Fernández Tardón
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Oncology Institute IUOPA (Instituto Universitario de Oncología del Principado de Asturias), Universidad de Oviedo, Asturias, Spain
| | - Jesús Castilla
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Instituto de Salud Pública Navarra - IdiSNA, Pamplona, Navarra, Spain
| | - Pilar Amiano
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastián, Spain
| | - Rocío Capelo
- Centro de Investigación en Recursos Naturales, Salud, y Medio Ambiente (RENSMA), Universidad de Huelva, Huelva, Spain
| | - Gemma Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; ISGlobal, Barcelona, Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Elisabet Guinó
- Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO) and Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain
| | | | - Conchi Moreno-Iribas
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Instituto de Salud Pública Navarra - IdiSNA, Pamplona, Navarra, Spain
| | - Beatriz Pérez Gómez
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Environmental and Cancer Epidemiology Unit, National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
| | - Nuria Aragonés
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Epidemiology Section, Public Health Division, Department of Health of Madrid, Madrid, Spain
| | - Javier Llorca
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Universidad de Cantabria - IDIVAL, Santander, Spain
| | - Vicente Martín
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Instituto de Biomedicina (IBIOMED), Universidad de León, Spain
| | - Manolis Kogevinas
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; ISGlobal, Barcelona, Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Marina Pollán
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Environmental and Cancer Epidemiology Unit, National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
| | - Victor Moreno
- Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO) and Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Department of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
| |
Collapse
|
44
|
Gómez-Acebo I, Dierssen-Sotos T, de Pedro M, Pérez-Gómez B, Castaño-Vinyals G, Fernández-Villa T, Palazuelos-Calderón C, Amiano P, Etxeberria J, Benavente Y, Fernández-Tardón G, Salcedo-Bellido I, Capelo R, Peiró R, Marcos-Gragera R, Huerta JM, Tardón A, Barricarte A, Altzibar JM, Alonso-Molero J, Dávila-Batista V, Aragonés N, Pollán M, Kogevinas M, Llorca J. Epidemiology of non-steroidal anti-inflammatory drugs consumption in Spain. The MCC-Spain study. BMC Public Health 2018; 18:1134. [PMID: 30241493 PMCID: PMC6150967 DOI: 10.1186/s12889-018-6019-z] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Accepted: 09/04/2018] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used despite their risk of gastrointestinal bleeding or cardiovascular events. We report the profile of people taking NSAIDs in Spain, and we include demographic factors, health-related behaviours and cardiovascular disease history. METHODS Four thousand sixtyparticipants were selected using a pseudorandom number list from Family Practice lists in 12 Spanish provinces. They completed a face-to-face computerized interview on their NSAID consumption, demographic characteristics, body mass index, alcohol and tobacco consumption and medical history. In addition, participants completed a self-administered food-frequency and alcohol consumption questionnaire. Factors associated with ever and current NSAID consumption were identified by logistic regression. RESULTS Women consumed more non-aspirin NSAIDs (38.8% [36.7-41.0]) than men (22.3 [20.5-24.2]), but men consumed more aspirin (11.7% [10.3-13.2]) than women (5.2% [4.3-6.3]). Consumption of non-aspirin NSAIDs decrease with age from 44.2% (39.4-49.1) in younger than 45 to 21.1% (18.3-24.2) in older than 75, but the age-pattern for aspirin usage was the opposite. Aspirin was reported by about 11% patients, as being twice as used in men (11.7%) than in women (5.2%); its consumption increased with age from 1.7% (< 45 years old) to 12.4% (≥75 years old). Aspirin was strongly associated with the presence of cardiovascular risk factors or established cardiovascular disease, reaching odds ratios of 15.2 (7.4-31.2) in women with acute coronary syndrome, 13.3 (6.2-28.3) in women with strokes and 11.1 (7.8-15.9) in men with acute coronary syndrome. Participants with cardiovascular risk factors or diseases consumed as much non-aspirin NSAID as participants without such conditions. CONCLUSIONS Non-aspirin NSAIDs were more consumed by women and aspirin by men. The age patterns of aspirin and non-aspirin NSAIDs were opposite: the higher the age, the lower the non-aspirin NSAIDs usage and the higher the aspirin consumption. People with cardiovascular risk factors or diseases consumed more aspirin, but they did not decrease their non-aspirin NSAIDs usage.
Collapse
Affiliation(s)
- Inés Gómez-Acebo
- CIBER Epidemiología y Salud Pública, Madrid, Spain.
- Facultad de Medicina, Universidad de Cantabria - IDIVAL, Avda Herrera Oria s/n, 39011, Santander, Spain.
| | - Trinidad Dierssen-Sotos
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Facultad de Medicina, Universidad de Cantabria - IDIVAL, Avda Herrera Oria s/n, 39011, Santander, Spain
| | - María de Pedro
- Facultad de Medicina, Universidad de Cantabria - IDIVAL, Avda Herrera Oria s/n, 39011, Santander, Spain
- Department of Obstetrics and Gynecology, Nuevo Belén University Hospital, Madrid, Spain
| | - Beatriz Pérez-Gómez
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Environmental and Cancer Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health (Instituto de Salud Carlos III-ISCIII), Avda. Monforte de Lemos, 5, 28029, Madrid, Spain
- Institute of Health Research "Puerta de Hierro", IDIPHIM, Madrid, Spain
| | - Gemma Castaño-Vinyals
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | | | | | - Pilar Amiano
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
| | - Jaione Etxeberria
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Department of Statistics and O.R., INAMAT, Public University of Navarre, Pamplona, Spain
| | - Yolanda Benavente
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Barcelona, Spain
| | | | | | - Rocío Capelo
- Centro de Investigación en Recursos Naturales, Salud, y Medio Ambiente. (RENSMA), Universidad de Huelva, Huelva, Spain
| | - Rosana Peiró
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Dirección General de Salud Pública, Fundación para el fomento de la investigación sanitaria y biomédica de la Comunidad Valenciana, FISABIO-Salud Pública, Valencia, Spain
| | - Rafael Marcos-Gragera
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Unitat d'Epidemiologia i Registre de Càncer de Girona (UERCG), Pla Director d'Oncologia, Institut Català d'Oncologia, Institut d'Investigaciò Biomèdica de Girona (IdIBGi), Universitat de Girona, Girona, Spain
| | - José M Huerta
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain
| | - Adonina Tardón
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- University of Oviedo, Oviedo, Spain
| | - Aurelio Barricarte
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Navarra Public Health Institute, Pamplona, Spain
- Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
| | - Jone-Miren Altzibar
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Osakidetza-Basque Health Service, BioDonostia Research Institute, Donostia, Spain
| | - Jessica Alonso-Molero
- Facultad de Medicina, Universidad de Cantabria - IDIVAL, Avda Herrera Oria s/n, 39011, Santander, Spain
| | | | - Nuria Aragonés
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Environmental and Cancer Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health (Instituto de Salud Carlos III-ISCIII), Avda. Monforte de Lemos, 5, 28029, Madrid, Spain
- Institute of Health Research "Puerta de Hierro", IDIPHIM, Madrid, Spain
- Epidemiology Section, Public Health Division, Department of Health of Madrid, Madrid, Spain
| | - Marina Pollán
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Environmental and Cancer Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health (Instituto de Salud Carlos III-ISCIII), Avda. Monforte de Lemos, 5, 28029, Madrid, Spain
- Institute of Health Research "Puerta de Hierro", IDIPHIM, Madrid, Spain
| | - Manolis Kogevinas
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Javier Llorca
- CIBER Epidemiología y Salud Pública, Madrid, Spain
- Facultad de Medicina, Universidad de Cantabria - IDIVAL, Avda Herrera Oria s/n, 39011, Santander, Spain
| |
Collapse
|
45
|
O'Callaghan-Gordo C, Kogevinas M, Cirach M, Castaño-Vinyals G, Aragonés N, Delfrade J, Fernández-Villa T, Amiano P, Dierssen-Sotos T, Tardon A, Capelo R, Peiró-Perez R, Moreno V, Roca-Barceló A, Perez-Gomez B, Vidan J, Molina AJ, Oribe M, Gràcia-Lavedan E, Espinosa A, Valentin A, Pollán M, Nieuwenhuijsen MJ. Residential proximity to green spaces and breast cancer risk: The multicase-control study in Spain (MCC-Spain). Int J Hyg Environ Health 2018; 221:1097-1106. [DOI: 10.1016/j.ijheh.2018.07.014] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2018] [Revised: 07/24/2018] [Accepted: 07/26/2018] [Indexed: 11/26/2022]
|
46
|
Lope V, Castelló A, Mena-Bravo A, Amiano P, Aragonés N, Fernández-Villa T, Guevara M, Dierssen-Sotos T, Fernandez-Tardón G, Castaño-Vinyals G, Marcos-Gragera R, Moreno V, Salas-Trejo D, Diaz-Santos M, Oribe M, Romieu I, Kogevinas M, Priego-Capote F, Pérez-Gómez B, Pollán M. Serum 25-hydroxyvitamin D and breast cancer risk by pathological subtype (MCC-Spain). J Steroid Biochem Mol Biol 2018; 182:4-13. [PMID: 29679754 DOI: 10.1016/j.jsbmb.2018.04.005] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/02/2018] [Accepted: 04/13/2018] [Indexed: 12/14/2022]
Abstract
Epidemiologic evidence on the association between vitamin D and breast cancer is still inconclusive. This study analyzes the association between serum 25-hydroxyvitamin D (25(OH)D) and breast cancer risk by pathologic subtype, stage at diagnosis and specific breast cancer risk factors. We conducted a population-based multicase-control study where 546 histologically-confirmed breast cancer cases and 558 population controls, frequently matched by geographic area, age and body mass index, were recruited in 12 Spanish provinces (MCC-Spain). Information was collected by a questionnaire and plasma 25(OH)D was measured by solid-phase extraction on-line coupled to liquid chromatography-tandem mass spectrometry (SPE-LC-MS/MS). Odds ratios and 95% confidence intervals were calculated using logistic and multinomial mixed regression models. We found a clear protective effect between 25(OH)D levels and breast cancer risk, with a significant dose-response trend (OR per 10 nmol/L = 0.88; 95%CI = 0.82-0.94). While no differences were observed between pre and postmenopausal women, stage at diagnosis, or across strata of the main breast cancer risk factors, the protection was more pronounced for triple negative tumors (OR per 10 nmol/L = 0.64; p-heterogeneity = 0.038). Similar results were observed when only cases sampled in the first month after diagnosis were considered. The protective effect of vitamin D on breast cancer risk may be subtype specific, being stronger for more aggressive tumors, which provides a new approach to prevent this disease.
Collapse
Affiliation(s)
- Virginia Lope
- National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain
| | - Adela Castelló
- National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain
| | - Antonio Mena-Bravo
- Department of Analytical Chemistry, University of Córdoba, Spain; Maimónides Institute of Biomedical Research (IMIBIC), Reina Sofía University Hospital, University of Córdoba, Spain
| | - Pilar Amiano
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain; Public Health Division of Gipuzkoa, BioDonostia Research institute, San Sebastian, Spain
| | - Nuria Aragonés
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain; Epidemiology Section, Public Health Division, Department of Health of Madrid, Spain
| | - Tania Fernández-Villa
- Área de Medicina Preventiva y Salud Pública, Departamento de Ciencias Biomédicas, Universidad de León, León, Spain; Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS), Universidad de León, León, Spain
| | - Marcela Guevara
- Early Detection Section, Public Health Institute of Navarra, Pamplona, Spain
| | - Trinidad Dierssen-Sotos
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain; University of Cantabria - IDIVAL, Santander, Spain
| | | | - Gemma Castaño-Vinyals
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Rafael Marcos-Gragera
- Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona Biomedical Research Institute (IdiBGi), Girona, Spain
| | - Víctor Moreno
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Campus de Bellvitge, L'Hospitalet del Llobregat, Spain; Unit of Biomarkers and Susceptibility, Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat, Spain
| | - Dolores Salas-Trejo
- Valencia Breast Cancer Screening Program, General Directorate Public Health, Valencia, Spain
| | - Marian Diaz-Santos
- Universidad de Huelva, Huelva, Spain; Centro de Investigación en Salud y Medio Ambiente (CYSMA), Huelva, Spain
| | - Madalen Oribe
- Public Health Division of Gipuzkoa, BioDonostia Research institute, San Sebastian, Spain
| | - Isabel Romieu
- Center for Research on Population Health, National Institute of Public Health, Mexico; Hubert Department of Global Health, Emory University, Atlanta, GA, USA
| | - Manolis Kogevinas
- Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain; ISGlobal, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Feliciano Priego-Capote
- Department of Analytical Chemistry, University of Córdoba, Spain; Maimónides Institute of Biomedical Research (IMIBIC), Reina Sofía University Hospital, University of Córdoba, Spain
| | - Beatriz Pérez-Gómez
- National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain
| | - Marina Pollán
- National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.
| |
Collapse
|
47
|
Gómez-Acebo I, Dierssen-Sotos T, Palazuelos C, Fernández-Navarro P, Castaño-Vinyals G, Alonso-Molero J, Urtiaga C, Fernández-Villa T, Ardanaz E, Rivas-del-Fresno M, Molina-Barceló A, Jiménez-Moleón JJ, García-Martinez L, Amiano P, Rodriguez-Cundin P, Moreno V, Pérez-Gómez B, Aragonés N, Kogevinas M, Pollán M, Llorca J. Pigmentation phototype and prostate and breast cancer in a select Spanish population-A Mendelian randomization analysis in the MCC-Spain study. PLoS One 2018; 13:e0201750. [PMID: 30106959 PMCID: PMC6091948 DOI: 10.1371/journal.pone.0201750] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2018] [Accepted: 07/20/2018] [Indexed: 12/13/2022] Open
Abstract
INTRODUCTION Phototype has been associated with an increased risk of prostate cancer, and it is yet unknown if it is related to other hormone-dependent cancers, such as breast cancer or whether this association could be considered causal. METHODS We examined the association between the phototype and breast and prostate cancers using a Mendelian randomization analysis. We studied 1,738 incident cases of breast cancer and another 817 cases of prostate cancer. To perform a Mendelian randomization analysis on the phototype-cancer relationship, a genetic pigmentation score was required that met the following criteria: (1) the genetic pigmentation score was associated with phototype in controls; (2) the genetic pigmentation score was not associated with confounders in the relationship between phototype and cancer, and (3) the genetic pigmentation score was associated with cancer only through its association with phototype. Once this genetic score is available, the association between genetic pigmentation score and cancer can be identified as the association between phototype and cancer. RESULTS The association between the genetic pigmentation score and phototype in controls showed that a higher genetic pigmentation score was associated with fair skin, blond hair, blue eyes and the presence of freckles. Applying the Mendelian randomization analysis, we verified that there was no association between the genetic pigmentation score and cancers of the breast and prostate. CONCLUSIONS Phototype is not associated with breast or prostate cancer.
Collapse
Affiliation(s)
- Inés Gómez-Acebo
- CIBER Epidemiología y Salud Pública (CIBERESP),Spain
- University of Cantabria–IDIVAL, Santander, Spain
- * E-mail:
| | - Trinidad Dierssen-Sotos
- CIBER Epidemiología y Salud Pública (CIBERESP),Spain
- University of Cantabria–IDIVAL, Santander, Spain
| | | | - Pablo Fernández-Navarro
- CIBER Epidemiología y Salud Pública (CIBERESP),Spain
- Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
- Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (IDIPHIM), Madrid, Spain
| | - Gemma Castaño-Vinyals
- CIBER Epidemiología y Salud Pública (CIBERESP),Spain
- ISGlobal Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- IMIM (Hospital Del Mar Medical Research Institute), Barcelona, Spain
| | | | - Carmen Urtiaga
- Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
| | - Tania Fernández-Villa
- Grupo de Investigación en Interacciones Gen-Ambiente y Salud, Instituto de Biomedicina (IBIOMED), Universidad de León, León, Spain
| | - Eva Ardanaz
- CIBER Epidemiología y Salud Pública (CIBERESP),Spain
- Navarra Public Health Institute, Pamplona, Spain
- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | | | - Ana Molina-Barceló
- Área de Cáncer y Salud Pública, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Salud Pública), Valencia, Spain
| | - José-Juan Jiménez-Moleón
- CIBER Epidemiología y Salud Pública (CIBERESP),Spain
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain
| | - Lidia García-Martinez
- Grupo de Investigación en Interacciones Gen-Ambiente y Salud, Instituto de Biomedicina (IBIOMED), Universidad de León, León, Spain
| | - Pilar Amiano
- CIBER Epidemiología y Salud Pública (CIBERESP),Spain
- Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
| | | | - Víctor Moreno
- CIBER Epidemiología y Salud Pública (CIBERESP),Spain
- Cancer Prevention and Control Program, Catalan Institute of Oncology-IDIBELL, L’Hospitalet de Llobregat, Spain
- Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | - Beatriz Pérez-Gómez
- CIBER Epidemiología y Salud Pública (CIBERESP),Spain
- Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
- Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (IDIPHIM), Madrid, Spain
| | - Nuria Aragonés
- CIBER Epidemiología y Salud Pública (CIBERESP),Spain
- Subdirección General de Epidemiología, Dirección General de Salud Pública, Consejería de Sanidad, Comunidad de Madrid, Spain
| | - Manolis Kogevinas
- CIBER Epidemiología y Salud Pública (CIBERESP),Spain
- ISGlobal Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- IMIM (Hospital Del Mar Medical Research Institute), Barcelona, Spain
- School of Public Health, Athens, Greece
| | - Marina Pollán
- CIBER Epidemiología y Salud Pública (CIBERESP),Spain
- Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
- Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (IDIPHIM), Madrid, Spain
| | - Javier Llorca
- CIBER Epidemiología y Salud Pública (CIBERESP),Spain
- University of Cantabria–IDIVAL, Santander, Spain
| |
Collapse
|
48
|
Solans M, Coenders G, Marcos-Gragera R, Castelló A, Gràcia-Lavedan E, Benavente Y, Moreno V, Pérez-Gómez B, Amiano P, Fernández-Villa T, Guevara M, Gómez-Acebo I, Fernández-Tardón G, Vanaclocha-Espi M, Chirlaque MD, Capelo R, Barrios R, Aragonés N, Molinuevo A, Vitelli-Storelli F, Castilla J, Dierssen-Sotos T, Castaño-Vinyals G, Kogevinas M, Pollán M, Saez M. Compositional analysis of dietary patterns. Stat Methods Med Res 2018; 28:2834-2847. [PMID: 30045678 DOI: 10.1177/0962280218790110] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Instead of looking at individual nutrients or foods, dietary pattern analysis has emerged as a promising approach to examine the relationship between diet and health outcomes. Despite dietary patterns being compositional (i.e. usually a higher intake of some foods implies that less of other foods are being consumed), compositional data analysis has not yet been applied in this setting. We describe three compositional data analysis approaches (compositional principal component analysis, balances and principal balances) that enable the extraction of dietary patterns by using control subjects from the Spanish multicase-control (MCC-Spain) study. In particular, principal balances overcome the limitations of purely data-driven or investigator-driven methods and present dietary patterns as trade-offs between eating more of some foods and less of others.
Collapse
Affiliation(s)
- M Solans
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,2 Research Group on Statistics, Econometrics and Health (GRECS), Universitat de Girona, Girona, Spain.,3 Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona, Spain
| | - G Coenders
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,2 Research Group on Statistics, Econometrics and Health (GRECS), Universitat de Girona, Girona, Spain
| | - R Marcos-Gragera
- 2 Research Group on Statistics, Econometrics and Health (GRECS), Universitat de Girona, Girona, Spain.,3 Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona, Spain
| | - A Castelló
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,4 Cancer Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain.,5 Faculty of Medicine, University of Alcalá, Alcalá de Henares, Madrid, Spain
| | - E Gràcia-Lavedan
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,6 ISGlobal, Barcelona, Spain.,7 ISGlobal, Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Y Benavente
- 8 Unit of molecular and genetic epidemiology in infections and cancer, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain
| | - V Moreno
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,9 Unit of Biomarkers and Susceptibility, Cancer Prevention and Control Program, Catalan Institute of Oncology (ICO). Hospitalet de Llobregat, Barcelona, Spain.,10 Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL). Hospitalet de Llobregat, Barcelona, Spain.,11 Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
| | - B Pérez-Gómez
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,12 Cardiovascular and Metabolic Diseases Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - P Amiano
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,13 Public Health Division of Gipuzkoa, BioDonostia Research Institute, Health Department, Basque Country, San Sebastian, Spain
| | | | - M Guevara
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,15 Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Spain
| | - I Gómez-Acebo
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,16 Universidad de Cantabria - IDIVAL, Santander, Spain
| | - G Fernández-Tardón
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,17 IUOPA, Universidad de Oviedo, Asturias, Spain
| | - M Vanaclocha-Espi
- 18 Cancer and Public Health Area, FISABIO - Public Health, Valencia, Spain
| | - M D Chirlaque
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,19 Department of Epidemiology, Regional Health Authority, IMIB-Arrixaca, Murcia University, Murcia, Spain
| | - R Capelo
- 20 Centro de Investigación en Recursos Naturales, Salud y medio Ambiente (RENSMA), Universidad de Huelva, Huelva, Spain
| | - R Barrios
- 21 Departamento de Medicina Preventiva y Salud Pública, Facultad de Medicina, Universidad de Granada, Granada, Spain
| | - N Aragonés
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,22 Epidemiology Section, Public Health Division, Department of Health of Madrid, Madrid, Spain
| | - A Molinuevo
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain
| | | | - J Castilla
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,15 Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Spain
| | - T Dierssen-Sotos
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,16 Universidad de Cantabria - IDIVAL, Santander, Spain
| | - G Castaño-Vinyals
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,6 ISGlobal, Barcelona, Spain.,7 ISGlobal, Universitat Pompeu Fabra (UPF), Barcelona, Spain.,23 IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - M Kogevinas
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,6 ISGlobal, Barcelona, Spain.,7 ISGlobal, Universitat Pompeu Fabra (UPF), Barcelona, Spain.,23 IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - M Pollán
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,4 Cancer Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - M Saez
- 1 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.,2 Research Group on Statistics, Econometrics and Health (GRECS), Universitat de Girona, Girona, Spain
| |
Collapse
|
49
|
Solans M, Castelló A, Benavente Y, Marcos-Gragera R, Amiano P, Gracia-Lavedan E, Costas L, Robles C, Gonzalez-Barca E, de la Banda E, Alonso E, Aymerich M, Campo E, Dierssen-Sotos T, Fernández-Tardón G, Olmedo-Requena R, Gimeno E, Castaño-Vinyals G, Aragonés N, Kogevinas M, de Sanjose S, Pollán M, Casabonne D. Adherence to the Western, Prudent, and Mediterranean dietary patterns and chronic lymphocytic leukemia in the MCC-Spain study. Haematologica 2018; 103:1881-1888. [PMID: 29954942 PMCID: PMC6278961 DOI: 10.3324/haematol.2018.192526] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2018] [Accepted: 06/25/2018] [Indexed: 12/12/2022] Open
Abstract
Diet is a modifiable risk factor for several neoplasms but evidence for chronic lymphocytic leukemia (CLL) is sparse. Previous studies examining the association between single-food items and CLL risk have yielded mixed results, while few studies have been conducted on overall diet, reporting inconclusive findings. This study aimed to evaluate the association between adherence to three dietary patterns and CLL in the multicase-control study (MCC-Spain) study. Anthropometric, sociodemographic, medical and dietary information was collected for 369 CLL cases and 1605 controls. Three validated dietary patterns, Western, Prudent and Mediterranean, were reconstructed in the MCC-Spain data. The association between adherence to each dietary pattern and CLL was assessed, overall and by Rai stage, using mixed logistic regression models adjusted for potential confounders. High adherence to a Western dietary pattern (i.e. high intake of high-fat dairy products, processed meat, refined grains, sweets, caloric drinks, and convenience food) was associated with CLL [ORQ4 vs. Q1=1.63 (95%CI 1.11; 2.39); P-trend=0.02; OR 1-SD increase=1.19 (95%CI: 1.03; 1.37)], independently of Rai stages. No differences in the association were observed according to sex, Body Mass Index, energy intake, tobacco, physical activity, working on a farm, or family history of hematologic malignancies. No associations were observed for Mediterranean and Prudent dietary patterns and CLL. This study provides the first evidence for an association between a Western dietary pattern and CLL, suggesting that a proportion of CLL cases could be prevented by modifying dietary habits. Further research, especially with a prospective design, is warranted to confirm these findings.
Collapse
Affiliation(s)
- Marta Solans
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, Spain.,Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Girona, Spain
| | - Adela Castelló
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Cancer Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain.,Faculty of Medicine, University of Alcalá, Alcalá de Henares, Madrid, Spain
| | - Yolanda Benavente
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Unit of Molecular Epidemiology and Genetic in Infections and Cancer (UNIC-Molecular), Cancer Epidemiology Research Programme (IDIBELL), Catalan Institute of Oncology, L' Hospitalet De Llobregat, Spain
| | - Rafael Marcos-Gragera
- Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, Spain.,Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, Girona, Spain
| | - Pilar Amiano
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain
| | - Esther Gracia-Lavedan
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,ISGlobal, Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Laura Costas
- Unit of Molecular Epidemiology and Genetic in Infections and Cancer (UNIC-Molecular), Cancer Epidemiology Research Programme (IDIBELL), Catalan Institute of Oncology, L' Hospitalet De Llobregat, Spain
| | - Claudia Robles
- Unit of Information and Interventions in Infections and Cancer (UNIC-I&I), Cancer Epidemiology Research Programme, (IDIBELL), Catalan Institute of Oncology, L' Hospitalet De Llobregat, Spain
| | - Eva Gonzalez-Barca
- Hematology, Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain
| | - Esmeralda de la Banda
- Hematology Laboratory, Department of Pathology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain
| | - Esther Alonso
- Hematology Laboratory, Department of Pathology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain
| | - Marta Aymerich
- Hospital Clinic de Barcelona, University of Barcelona, CIBERONC, Barcelona Spain
| | - Elias Campo
- Hospital Clinic de Barcelona, University of Barcelona, CIBERONC, Barcelona Spain
| | - Trinidad Dierssen-Sotos
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,University of Cantabria - Marqués de Valdecilla Research Institute (IDIVAL), Santander, Spain
| | - Guillermo Fernández-Tardón
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,University Institute of Oncology (IUOPA), University of Oviedo, Spain
| | - Rocio Olmedo-Requena
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Department of Preventive Medicine and Public Health, University of Granada, Spain.,Instituto de Investigación Biosanitaria de Granada, Hospitales Universitarios de Granada, Spain
| | - Eva Gimeno
- Hematology Department, Hospital del Mar, Barcelona, Spain
| | - Gemma Castaño-Vinyals
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,ISGlobal, Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain.,Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain
| | - Nuria Aragonés
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Epidemiology Section, Public Health Division, Department of Health of Madrid, Spain
| | - Manolis Kogevinas
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,ISGlobal, Barcelona, Spain.,Universitat Pompeu Fabra (UPF), Barcelona, Spain.,Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain
| | - Silvia de Sanjose
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Unit of Molecular Epidemiology and Genetic in Infections and Cancer (UNIC-Molecular), Cancer Epidemiology Research Programme (IDIBELL), Catalan Institute of Oncology, L' Hospitalet De Llobregat, Spain.,PATH, Reproductive Health, Seattle, WA, USA
| | - Marina Pollán
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.,Cancer Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Delphine Casabonne
- Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain .,Unit of Molecular Epidemiology and Genetic in Infections and Cancer (UNIC-Molecular), Cancer Epidemiology Research Programme (IDIBELL), Catalan Institute of Oncology, L' Hospitalet De Llobregat, Spain
| |
Collapse
|
50
|
Garcia-Saenz A, Sánchez de Miguel A, Espinosa A, Valentin A, Aragonés N, Llorca J, Amiano P, Martín Sánchez V, Guevara M, Capelo R, Tardón A, Peiró-Perez R, Jiménez-Moleón JJ, Roca-Barceló A, Pérez-Gómez B, Dierssen-Sotos T, Fernández-Villa T, Moreno-Iribas C, Moreno V, García-Pérez J, Castaño-Vinyals G, Pollán M, Aubé M, Kogevinas M. Evaluating the Association between Artificial Light-at-Night Exposure and Breast and Prostate Cancer Risk in Spain (MCC-Spain Study). Environ Health Perspect 2018; 126:047011. [PMID: 29687979 PMCID: PMC6071739 DOI: 10.1289/ehp1837] [Citation(s) in RCA: 90] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Revised: 03/13/2018] [Accepted: 03/15/2018] [Indexed: 05/26/2023]
Abstract
BACKGROUND Night shift work, exposure to light at night (ALAN) and circadian disruption may increase the risk of hormone-dependent cancers. OBJECTIVES We evaluated the association of exposure to ALAN during sleeping time with breast and prostate cancer in a population based multicase-control study (MCC-Spain), among subjects who had never worked at night. We evaluated chronotype, a characteristic that may relate to adaptation to light at night. METHODS We enrolled 1,219 breast cancer cases, 1,385 female controls, 623 prostate cancer cases, and 879 male controls from 11 Spanish regions in 2008-2013. Indoor ALAN information was obtained through questionnaires. Outdoor ALAN was analyzed using images from the International Space Station (ISS) available for Barcelona and Madrid for 2012-2013, including data of remotely sensed upward light intensity and blue light spectrum information for each geocoded longest residence of each MCC-Spain subject. RESULTS Among Barcelona and Madrid participants with information on both indoor and outdoor ALAN, exposure to outdoor ALAN in the blue light spectrum was associated with breast cancer [adjusted odds ratio (OR) for highest vs. lowest tertile, OR=1.47; 95% CI: 1.00, 2.17] and prostate cancer (OR=2.05; 95% CI: 1.38, 3.03). In contrast, those exposed to the highest versus lowest intensity of outdoor ALAN were more likely to be controls than cases, particularly for prostate cancer. Compared with those who reported sleeping in total darkness, men who slept in "quite illuminated" bedrooms had a higher risk of prostate cancer (OR=2.79; 95% CI: 1.55, 5.04), whereas women had a slightly lower risk of breast cancer (OR=0.77; 95% CI: 0.39, 1.51). CONCLUSION Both prostate and breast cancer were associated with high estimated exposure to outdoor ALAN in the blue-enriched light spectrum. https://doi.org/10.1289/EHP1837.
Collapse
Affiliation(s)
- Ariadna Garcia-Saenz
- ISGlobal (Barcelona Institute for Global Health), Barcelona, Spain
- CIBER (Consorcio de Investigación Biomédica en Red) Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Alejandro Sánchez de Miguel
- Instituto de Astrofísica de Andalucía (IAA)–Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain
- Departamento de Astrofísica y CC. de la Atmósfera, Universidad Complutense de Madrid, Madrid, Spain
- Département de physique, Cégep de Sherbrooke, Sherbrooke, Canada
- Environment and Sustainability Institute, University Exeter, Penryn, UK
| | - Ana Espinosa
- ISGlobal (Barcelona Institute for Global Health), Barcelona, Spain
- CIBER (Consorcio de Investigación Biomédica en Red) Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Antonia Valentin
- ISGlobal (Barcelona Institute for Global Health), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Núria Aragonés
- CIBER (Consorcio de Investigación Biomédica en Red) Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
- Cancer and Environmental Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Javier Llorca
- CIBER (Consorcio de Investigación Biomédica en Red) Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
- Instituto de Investigación Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain
| | - Pilar Amiano
- CIBER (Consorcio de Investigación Biomédica en Red) Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
- Public Health Division of Gipuzkoa, Health Department of Basque Region, San Sebastian, Spain
| | - Vicente Martín Sánchez
- CIBER (Consorcio de Investigación Biomédica en Red) Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
- Research Group on Gene–Environment Interactions and Health, University of León, León, Spain
| | - Marcela Guevara
- CIBER (Consorcio de Investigación Biomédica en Red) Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
- Instituto de Investigación Sanitaria de Navarra (IdiSNA), Instituto de Salud Pública de Navarra, Pamplona, Spain
| | - Rocío Capelo
- Centro de Investigación en Salud y Medio Ambiente (CYSMA), Universidad de Huelva, Huelva, Spain
| | - Adonina Tardón
- CIBER (Consorcio de Investigación Biomédica en Red) Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
- University Institute of Oncology (IUOPA), University of Oviedo, Oviedo, Spain
| | - Rosana Peiró-Perez
- CIBER (Consorcio de Investigación Biomédica en Red) Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
- Centro de Salud Pública de Dénia, Consellería de Sanidad Universal y Salud Pública, Generalitat Valenciana, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Valencia, Spain
| | - José Juan Jiménez-Moleón
- CIBER (Consorcio de Investigación Biomédica en Red) Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
- Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Complejo Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain
| | - Aina Roca-Barceló
- Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona, Spain
| | - Beatriz Pérez-Gómez
- CIBER (Consorcio de Investigación Biomédica en Red) Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
- Cancer and Environmental Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Trinidad Dierssen-Sotos
- CIBER (Consorcio de Investigación Biomédica en Red) Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
- Instituto de Investigación Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain
| | - Tania Fernández-Villa
- CIBER (Consorcio de Investigación Biomédica en Red) Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
- Research Group on Gene–Environment Interactions and Health, University of León, León, Spain
| | - Conchi Moreno-Iribas
- Instituto de Investigación Sanitaria de Navarra (IdiSNA), Instituto de Salud Pública de Navarra, Pamplona, Spain
- Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Madrid, Spain
| | - Victor Moreno
- CIBER (Consorcio de Investigación Biomédica en Red) Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
- Bellvitge Biomedical Research Institute ( IDIBELL), Catalan Institute of Oncology, L’Hospitalet de Llobregat, Spain
- Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, L’Hospitalet del Llobregat, Spain
| | - Javier García-Pérez
- CIBER (Consorcio de Investigación Biomédica en Red) Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
- Cancer and Environmental Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Gemma Castaño-Vinyals
- ISGlobal (Barcelona Institute for Global Health), Barcelona, Spain
- CIBER (Consorcio de Investigación Biomédica en Red) Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Marina Pollán
- CIBER (Consorcio de Investigación Biomédica en Red) Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
- Cancer and Environmental Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain
| | - Martin Aubé
- Département de physique, Cégep de Sherbrooke, Sherbrooke, Canada
| | - Manolis Kogevinas
- ISGlobal (Barcelona Institute for Global Health), Barcelona, Spain
- CIBER (Consorcio de Investigación Biomédica en Red) Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| |
Collapse
|